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SUMMARY
Two areas of current interest in toxicology have been studied using in vitro models.
1. Carcinogen-induced nuclear enlargement has been reported both in vitro and in vivo, 
but the mechanism, and whether it is causally related to carcinogenesis, has not yet 
been established. In order to obtain some insight into potential mechanisms, several 
cell culture systems were used to investigate the role of increased DNA content in 
induction of nuclear enlargement. N-methyl-N-nitrosourea and adriamycin were shown 
to induce nuclear enlargement in vitro following ‘pulse’ treatment. This was 
accompanied by an increase in the proportions of cells in the G2+M phase of the cell 
cycle, possibly due to G2 block. There was some evidence of polyploidy induction 
following adriamycin treatment, but not following N-methyl-N-nitrosourea treatment. 
In contrast, diethylstilboestrol increased the range of nuclear areas and DNA content, to 
both less than and greater than that of control cells, but only after a prolonged exposure 
period of 48h. These data were consistent with diethylstilboestrol inducing spindle 
damage.
2. In vitro models were also used to investigate steatogen-induced hepatotoxicity and 
hepatotoxicity induced by fibrinogen receptor antagonists. The need to include toxicity 
markers in in vitro hepatotoxicity tests which are relevant to the type of in vivo 
hepatotoxicity was investigated. In both cases, simple cytotoxicity markers were used 
in combination with more sensitive biochemical or morphological markers. In the case 
of steatogen-induced hepatotoxicity it was found that measurement of intracellular 
triglyceride levels provided more information on the in vitro toxicity of ethanol and 
valproic acid than measurement of simple cytotoxicity. However, the inclusion of 
triglyceride measurement did not provide additional information on the in vitro toxicity 
of ethionine. It was also found that in vitro examination of mitochondrial changes 
following treatment of hepatocytes with fibrinogen receptor antagonists was a more 
sensitive marker than simple cytotoxicity markers.
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1. General Introduction
Russell and Burch (1959) first put forward the ideas of refinement, reduction and 
replacement as potential ways to minimise the numbers of animals used in scientific 
experiments and to prevent unnecessary suffering to animals which are used.
A large number of animals is currently used each year in the safety testing of new 
industrial chemicals and pharmaceutical agents. For example, in 1995 654,072 animals 
were used in Great Britain for the purpose of toxicology/safety assessment (Home Office, 
1996). It has frequently been suggested that the use of cell/tissue culture {'in vitro' 
techniques) could provide an alterative to experimentation on whole animals for toxicity 
testing (Balls et al, 1995a). However, a toxic compound can potentially induce a wide 
variety of biochemical and histological changes in many different organs/cell types. It is 
clear that a simple cell culture based assay (or even battery of assays) could not, at 
present, replace the vast complexity of whole animal test systems.
This is not to imply however, that in vitro tests do not have a valuable role to play in 
toxicology. For clearly defined areas of toxicology, in vitro models are able to answer 
questions about potential mechanisms of toxicity if the in vitro models are carefully 
chosen to accurately reflect the changes which are observed in vivo. For example, in vitro 
tests for genotoxicity and for skin corrosivity can play an important role in the 
toxicological evaluation of new chemical entities (Kirkland, 1990; Botham et at, 1995). In 
such cases, in vitro models can offer distinct advantages over whole animal models in 
terms of ease of manipulation of culture conditions, reproducibility and the use of small 
amounts of test material.
The research described in this thesis examines the choice and suitability of in vitro models 
for two areas of current interest in toxicology. The first part of the thesis examines the 
role of in vitro models in defining possible mechanisms of carcinogen-induced nuclear 
enlargement. Nuclear enlargement has been reported after treatment with carcinogens 
both in vitro and in vivo, but the mechanism, and whether it is causally related to 
carcinogenesis has not been established. In the present investigations in vitro techniques
have been used to establish a model for carcinogen-induced nuclear enlargement and 
investigate the underlying mechanisms for the enlargement. The second part of the thesis 
examines the role of in vitro models for studying hepatotoxicity. The aim of these 
investigations was to attempt to model two specific types of hepatotoxicity in vitro. The 
two types of hepatotoxicity examined were steatogen-induced hepatotoxicity and a 
characteristic form of hepatotoxicity which was encountered in the dog during the 
toxicological development of a series of GlaxoWellcome drug candidates.
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PART 1 - Carcinogen-induced nuclear enlargement
11
2. INTRODUCTION
Nuclear enlargement has often been observed as one of the earliest histological changes 
associated with chemically-induced carcinogenesis in vivo, dating back to the work of 
Page (1938) who reported nuclear enlargement in the epidermis of mice following topical 
application of 3-methylcholanthrene and cholanthrene. Since this initial work in mouse 
skin, a large amount of literature has accumulated which documents the induction of 
enlarged nuclei as an early histological change associated with chemically-induced 
carcinogenesis both in in vivo and in vitro systems.
2.1 Carcinogen-induced nuclear enlargement in experimental animals in vivo
Nuclear enlargement in the skin
Carcinogen-induced nuclear enlargement in the epidermis of mice has been extensively 
studied and has been made use of in the development of a short term test for the 
identification of potential skin carcinogens. It was discovered that the nuclear enlargement 
induced by 3,4-benzpyrene (BP) could be enhanced by pretreatment of mouse skin with 
the promoter, croton oil (Ingram and Grasso, 1977). The methodology for detecting such 
carcinogen-induced nuclear enlargement in mouse skin was modified further (Ingram, 
1979) to include the use of an irritant vehicle (methylethyl ketone; MEK). Using this 
combination of BP, croton oil and MEK it was found that BP produced detectable nuclear 
enlargement in the epidermis over a comparable range of doses to those known to produce 
tumours in long-term mouse studies.
The nuclear enlargement skin test (NEST) was then used to study 27 compounds from 
several different chemical classes (Ingram and Grasso, 1985). The compounds tested 
included skin carcinogens, carcinogens which produce tumours only in internal organs 
and non-carcinogens. All but one of the skin carcinogens tested (dibenz[a,i]pyrene) 
induced significant nuclear enlargement in mouse skin when applied in MEK after croton 
oil treatment. It has since been demonstrated (Ingram and Grasso, 1987) that the NEST 
assay accurately predicted the carcinogenicity of a series of oils for which long-term
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mouse skin painting data was available. Oils can also be separated using fractionation and 
the carcinogenic components tested using the NEST assay (Ingram, 1990).
The NEST assay has proved particularly useful in the oil industry for the detection of skin 
carcinogens in complex mixtures of oils and tars (Soames et al, 1992). The availability of 
a reliable assay to test such substances is essential due to the occurrence of skin cancer in 
workers exposed to poorly refined lubricating and cutting oils (Ingram and Philips, 1993).
Nuclear enlargement in the liver
Nuclear enlargement (often termed ‘karyomegaly’) has been reported frequently in the 
liver after treatment with carcinogens. A systematic literature search for examples of such 
nuclear enlargement however, is not possible. Karyomegaly is often reported as an 
incidental histological change in carcinogenesis research and is therefore often not 
included in the title or abstract of a paper. The examples listed below are therefore from 
papers whose focus has been the study of hepatocarcinogen-induced nuclear enlargement.
Nuclear enlargement occurs in the liver of rats after treatment with dimethylnitrosamine, 
pyrrolizidine alkaloids, thioacetamide, carbon tetrachloride, azo dyes and ethionine 
(Christie and LePage, 1961; Jackson, 1974; Clawson et al, 1992). N-nitrosopyrrolidine, 
methylazoxymethanol, aflatoxin Bj and 2-acetylaminofluorene are known to induce 
tumours in the livers of rats and have all been shown to induce nuclear enlargement in rat 
liver together with other nuclear alterations (Enzmann and Bannasch, 1987; Zedeck et al, 
1970, Zedeck and Sternberg, 1975; Dobre et al, 1976; Hendy and Grasso, 1977; Neal and 
Butler 1978; Clawson et al, 1992). Nuclear enlargement in hepatocytes was also one of 
the histological changes seen in a series of experiments in mice with a carcinogenic 
polychlorinated biphenyl mixture (Aroclor 1254) administered together with iron (Madra 
et al, 1995). The majority of papers which report carcinogen-induced nuclear enlargement 
in the liver describe experiments with rodents. Diethylnitrosamine however, has also been 
demonstrated to cause a dose-dependent nuclear enlargement in turkey liver exposed in 
ovo (Enzmann et al, 1995).
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It is important to remember however, that factors other than carcinogen treatment (e.g. 
choline deficient diet, senility (Christie and LePage, 1961) can also lead to an increase in 
the volume of hepatocyte nuclei.
Nuclear enlargement in other organs
The skin and liver are by far the most widely studied organs with respect to carcinogen- 
induced nuclear enlargement. Nuclear enlargement has however also been reported in the 
kidney (Hard and Butler, 1971), subcutaneous tissue (Hooson et al, 1971) and intestine 
(Zedeck et al, 1970) following exposure to carcinogens. Nuclear enlargement was 
observed in the nasal cavity of sulphur dioxide-treated rats after exposure to a series of 
four nitrosamines (Fowlie et al, 1990). This latter example illustrates a feature which is 
often seen in carcinogen-induced nuclear enlargement; the application of an irritant at the 
same time as the test carcinogen considerably enhances the degree of nuclear enlargement 
(as seen with MEK in the NEST assay).
2.2 Carcinogen-induced nuclear enlargement in vitro
Perhaps the earliest report of carcinogen-induced nuclear enlargement in an in vitro 
system was made by Lewis (1935). Inhibition of cell growth and subsequent nuclear 
enlargement were observed in chick cell cultures after treatment with 
dibenz[a,h]anthracene, benzo[a]pyrene or 3-methylcholanthrene. Nuclear enlargement has 
since been reported in a variety of cell types after treatment with a number of different 
carcinogens. Again, as with nuclear enlargement in vivo, these reports were often 
anecdotal and used a wide number of different treatment regimens. Examples of 
carcinogens which have been demonstrated to induce nuclear enlargement in vitro include 
aflatoxin B  ^ (Hartley et al, 1969), methylnitrosourethane (Ord, 1965), mitomycin C 
(Kuroda and Furyama, 1963), p-propiolactone (Powell, 1966) and adriamycin (Lanks and 
Lehman, 1990).
In view of the possible association between nuclear enlargement in vitro and carcinogenic 
potential, a systematic investigation into this phenomenon was undertaken by Grant and 
Grasso (1978). HeLa S3 cells (an immortalised human cervical carcinoma cell line) were
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treated for 30 minutes (‘pulse’ treatment) with 12 compounds which included carcinogens 
and non-carcinogens in the presence and absence of an exogenous metabolising system 
(rat liver S9 fraction). All of the carcinogens tested were able to inhibit cell division 
which was accompanied by nuclear enlargement. The non-carcinogens were also tested up 
to concentrations which inhibited cell division but none was found to induce nuclear 
enlargement.
Following the success of this initial investigation, several other studies examined the 
relationship between nuclear enlargement in HeLa S3 cells and the carcinogenic potential 
of test compounds. A further 13 compounds were tested by Agrelo (1978). Again, a 100% 
correlation was obtained between carcinogenic potential and ability to induce nuclear 
enlargement. The methodology used in the HeLa S3 cell nuclear enlargement test was 
adapted by Finch et al (1980) to allow analysis of nuclear areas using an automated 
particle analyser. Recently, (Rizzi et al, 1991) new automated morphometric techniques 
have been applied to the HeLa S3 nuclear enlargement test to make the measurement of 
nuclear area a less time-consuming process.
The possible use of an in vitro nuclear enlargement test to detect carcinogens was 
investigated in an international study along with many other potential in vitro tests for 
carcinogens (Anon, 1978). 24 coded compounds were tested in both HeLa S3 cells and 
primary human skin fibroblast cultures. Of the carcinogens tested, 71% were correctly 
identified using the HeLa S3 test, however 50% of the non-carcinogens tested were also 
found to induce nuclear enlargement (Agrelo and Amos, 1981). As a result of this study, 
the basis of the use of nuclear enlargement in vitro as a test for carcinogenicity was 
questioned. However, the HeLa S3 system did respond to several carcinogens, such as 
diethylstilboestrol, hexamethylphosphoramide, safrole and ethylenethiourea which were 
difficult to detect in many of the genetically based assays in the international trial. It has 
therefore been suggested that the HeLa S3 nuclear enlargement test may provide a useful 
tool for investigating mechanisms of carcinogen-induced nuclear enlargement rather than 
for primary identification of carcinogens.
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2.3 Mechanisms of carcinogen-induced nuclear enlargement
Whilst the existence of carcinogen-induced nuclear enlargement is well documented, the 
mechanism(s) by which it occurs are not well understood. It has frequently been suggested 
that the increase in nuclear area which is seen may be the result of an increase in DNA 
within the nucleus (Fowlie et al, 1990; 1991; Hooson et al, 1971). In some cases, 
particularly in rodent liver (Carrière, 1969; Jackson 1974; Clawson et al, 1992) it has been 
shown that a doubling of the nuclear volume following carcinogen treatment is 
accompanied by a doubling of nuclear DNA content. However, this relationship between 
nuclear size and DNA content has not been conclusively shown for all cases of 
carcinogen-induced nuclear enlargement. This is an important point to clarify since both 
polyploidy (an increase in chromosome number by an exact multiple of the haploid 
chromosome number) and aneuploidy (a gain or loss of one or more chromosomes) are 
known to be associated with the progression and development of some tumours types.
Polyploidy
The occurrence of polyploidy in normal mammalian cells is common in organs such as 
the liver, heart, nervous system, pancreas and retina (Brodsky and Uryvaeva, 1985; 
Mitchell et al, 1995). For example, the liver of a new-born mouse is mainly diploid (2n). 
However, as the animal ages there is increased polyploidisation of the hepatocytes such 
that in an adult mouse only 25% of the cells will be 2n, the rest will be polyploid: 60% 
(4n); 12% (8n); <3% (16n) (Feldmann, 1992). The biological significance of such 
increases in ploidy in ‘normal’ cells is not clear, though it is thought that it is an 
‘economical’ way for individual cells to produce more gene product without more cells. 
Another possibility, especially in the liver, is that since the liver produces many 
potentially mutagenic metabolites, a polyploid cell would still have functioning copies of 
a gene even if one gene had been mutated (Mitchell et al, 1995).
Xenobiotics which induce polyploidy are of particular concern as many tumours are 
polyploid (Brodsky and Uryvaeva, 1985; Aziz and Peter, 1991). It is possible that 
induction of polyploidy may be particularly involved in the later stages of carcinogenesis 
in the generation of karyotypic instability (Mitchell et al, 1995).
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Aneuploidy
Components of the spindle apparatus and other factors involved with spindle function are 
the prime targets for xenobiotics which induce aneuploidy (aneugens) in either mitosis or 
meiosis. Interference with either chromosome pairing or crossing-over are important 
addition targets for meiotic aneugens. Meiotic aneuploidy is known to result in several 
clinical syndromes (e.g. Down syndrome, Patau syndrome. Turner syndrome and 
Klinefelter syndrome) and is responsible for approximately 30% of early human foetal 
wastage (Dellarco et al, 1985).
There is also increasing evidence that mitotic aneuploidy could be a major factor in the 
emergence and development of many somatic tumours (Dellarco et al, 1985). Many 
tumours contain aneuploid cells. In many cases it is impossible to determine whether the 
aneuploidy is a primary cause of carcinogenesis or a secondary change associated with 
neoplastic transformation.
2.3.1 Nuclear enlargement and increased nuclear DNA
It is widely accepted that there is a concordance between the size of the nucleus and the 
amount of genetic material which it contains i.e. when the number of chromosome sets 
increases in a polyploid series, there is a roughly proportional increase in the volume of 
the nucleus (Fawcett, 1981). For example, the increase in DNA content which is seen 
clinically during hepatocellular carcinoma correlates well with an increase in nuclear size 
in these cells (Kuo et al, 1994). The nuclear DNA content of non-small cell lung tumours 
increases with time when they are grafted onto nude mice and this is paralleled by an 
increase in nuclear area (Kruczynski et al, 1992). As mentioned above, it has also been 
shown that an increase in ploidy is associated with some cases of carcinogen-induced 
nuclear enlargement in the liver. However, it is not clear if nuclear enlargement in general 
is a specific marker for polyploidy. The increase which is seen in the nuclear size of 
cardiac myocytes of rats following myocardial infarction has been shown to be 
independent of DNA content and that in this case nuclear enlargement is a marker for 
cellular hypertrophy (Kellerman et al, 1992; Gerdes et al, 1991; 1994)
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2.3.2 Nuclear enlargement which is not associated with changes in ploidy
As mentioned above (Section 2.3.1), in the example of cellular hypertrophy in cardiac 
myocytes, nuclear enlargement is not always accompanied by an increase in nuclear DNA. 
Nuclear size may increase as a result of increased histones (Latner et al, 1973) or 
depolymerisation of DNA. It is also possible that cytotoxic agents may induce 
‘ballooning’ of cell nuclei in vitro. Crissman et al (1985) suggested that in some cases, 
synthesis of RNA and proteins associated with mitosis can continue within a cell in the 
absence of DNA synthesis.
It is important that nuclear enlargement as a result of either aneuploidy or polyploidy can 
be distinguished from other, non-specific forms of nuclear enlargement.
2.4 Aims of current research
The NEST assay used to identify skin carcinogens in the oil industry has proved both 
reliable and predictive. However, the underlying mechanism behind the test still remains 
largely unexplained. In order to further investigate possible mechanisms of carcinogen- 
induced nuclear enlargement, the in vitro HeLa S3 test was used as a model system. An in 
vitro assay can allow several experiments to be performed to define precisely optimal 
conditions for carcinogen-induced nuclear enlargement. Using these conditions, further 
experiments can then be performed to attempt to establish the mechansim of the 
carcinogen-induced nuclear enlargement.
Three methods were used to assess whether the nuclear enlargement induced by 
carcinogens in HeLa S3 cells was associated with any increases in nuclear DNA:
• Simple chromosome counting in metaphase preparations, which is a classical method 
to study aneuploidy and polyploidy. In vitro models are particularly useful for this 
purpose as it is not possible to obtain cytogenetic preparations from many tissues in 
vivo if the cell population is not rapidly dividing.
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• Flow cytometry, which is a fast method for analysing large numbers of cells and can be 
used to measure total cellular DNA. Cell based in vitro models are particularly 
appropriate for flow cytometric measurements as single cell suspensions can be 
prepared with relative ease.
• Microdensitometry, which is a quantitative method for assessing DNA in stained 
microscopic preparations. This method has the potential advantage over flow 
cytometry in that it is possible to distinguish between cells which are in interphase of 
the cell cycle and those undergoing mitosis. Thus exactly the same cell population can 
be studied using microdensitometry that is sampled during assessment of nuclear 
enlargement.
In addition to the work using HeLa S3 cells, some experiments were also performed to 
investigate the effect of carcinogens on the nuclear size of two keratinocyte cell types, 
since these may model more accurately the situation in the NEST assay.
2.5 Compounds chosen for investigations into carcinogen-induced nuclear 
enlargement
Carcinogens are usually defined on the basis of a positive rodent bioassay in the absence 
of human data. They can be broadly classified into genotoxic and non-genotoxic (or 
epigenetic) carcinogens (Williams and Wesburger, 1991). Genotoxic carcinogens are 
carcinogens which damage DNA in short term assays for mutagenicity, clastogenicity 
(chromosome damage) and DNA repair. As such, these compounds cause irreversible 
alterations in the genome. Many of these alterations have been shown to be important in 
the activation of protooncogenes and inactivation of tumour repressor genes during the 
complex, multi-stage process of carcinogenesis. For instance the protooncogene c-Ha-ras, 
which is activated in many chemically-induced rodent tumours, can be activated by a 
single point mutation in specific codons within the gene. Likewise, clastogenicity has 
been implicated in carcinogenesis in human chronic myeloid leukaemia where the 
‘Philadelphia chromosome’ forms as the result of chromosome translocation (Tweats, 
1993).
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By definition, non-genotoxic carcinogens are non-mutagenic and show no evidence of 
chemical reactivity with DNA. The mechanisms by which this diverse group of 
carcinogens cause tumours can include hormone modification, tumour promotion, 
immunosuppression and peroxisome proliferation as well as many, as yet, unclassified 
mechansims (Williams and Weisburger, 1991).
Three carcinogens were chosen for investigation into carcinogen-induced nuclear 
enlargement. These were two well-documented genotoxins: N-methyl-N-nitrosourea 
(MNU) and adriamycin hydrochloride (ADM) and one questionable genotoxin/non- 
genotoxin: diethylstilboestrol (DES). All three of these compounds had previously been 
shown to induce nuclear enlargement in vitro.
2.5.1 N-methyl-N-nitrosourea (MNU)
MNU was selected as a model agent for mechanistic studies into nuclear enlargement as it 
has previously been shown to cause nuclear enlargement in a number of in vitro and in 
vivo systems. MNU caused nuclear enlargement in HeLa S3 cells in vitro (Grant and 
Grasso, 1978; Agrelo, 1978) and when applied topically to mouse skin in the presence of 
a promoter (Ingram and Grasso, 1985). It has also been demonstrated to induce many 
nuclear changes (including enlargement) near the injection site after subcutaneous 
administration to mice, rats and guinea pigs (Hooson et al, 1971).
MNU is a member of a large group of chemicals (the N-nitroso compounds) which have 
been widely used as model agents for the investigation of carcinogenesis since N,N- 
dimethylnitrosamine (DMN) was found to be carcinogenic in rats in 1954 (Barnes and 
Magee, 1954). MNU was subsequently shown to induce a wide range of tumours in 
several experimental animal species including the mouse, rat, hamster, rabbit, guinea pig, 
dog, pig and monkey after topical, oral, subcutaneous and intravenous administration 
(Montesano and Bartsch, 1976; Lijinsky, 1992; lARC, 1978).
At alkaline and neutral pHs, MNU spontaneously decomposes to produce a cyanate ion 
and the methylating group, monomethylnitrosamine (Hecht and Kozarich, 1973). 
Monomethylnitrosamine is a highly reactive intermediate which can react covalently
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(without the need for further metabolic activation) with a wide variety of nucleophilic 
sites in cellular constituents including proteins and nucleic acids. The alkylation of bases 
within the cellular nucleic acids by carcinogenic alkylating agents has received a great 
deal of attention. Abnormal méthylation of nucleic acid bases may be responsible for the 
inhibition of protein and RNA synthesis. The presence of methylated bases may also lead 
to the incorporation of incorrect nucleosides (i.e. mutations) by nucleic acid polymerases 
during nucleic acid synthesis and stimulate DNA repair processes (Pegg, 1977; Saffhill et 
al, 1985). The primary site for MNU-induced alkylation is the N7 of guanine, though a 
number of other sites are also attacked (Montesano and Bartsch, 1976). Changes in the 
méthylation status of DNA has been proposed as one possible mechanism involved in the 
perturbed gene expression of cancer cells (Kanduc et al, 1992). MNU is therefore widely 
used as a classic example of a genotoxic carcinogen and gives positive results in most in 
vitro and in vivo genotoxicity assays (Montesano and Bartsch, 1976; lARC, 1987).
2.5.2 Adriamycin (ADM)
ADM was selected as a second example of a genotoxic agent to further investigate the 
mechanisms of nuclear enlargement. Whilst ADM has not previously been tested for its 
ability to induce nuclear enlargement in HeLa S3 cells, it has been shown to cause nuclear 
enlargement in murine L929 cells in vitro (Lanks and Leham, 1990). ADM has also been 
associated with the induction of polyploidy in vitro (Zucker et al, 1991).
ADM (also known as ‘doxorubicin’) is an antibiotic/antitumour agent isolated from 
Streptomyces peucetius var. caesius which is used in the treatment of several types of 
neoplastic disease both as a single drug and in combination therapy (lARC, 1975). ADM 
is one of the anthracycline group of antibiotics, which also includes the related drug 
daumomycin and nogalamycin, cinerubin, rhodomycins and rubomycins .
The main biochemical effects of ADM which are the basis of its use as an antitumour 
agent result in the inhibition of DNA and RNA synthesis and the arrest of cell division 
(Pratt and Rudden, 1979). It is rapidly concentrated into cell nuclei and has a high binding 
affinity for DNA in vitro. X-ray diffraction has shown that ADM intercalates with the
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major groove of the DNA double helix and that unlike other antitumour drugs such as 
actinomycin, there is no base specificity for this interaction of ADM with DNA.
ADM is an inhibitor of DNA topoisomerase n  (topo H); (D’Arpa and Liu, 1989). The 
function of topo II is to catalyse a number of reactions involving DNA conformation 
including the relaxation of superhelical twists by transiently breaking double-stranded 
DNA. Topo II may also contribute to chromosome condensation in mitosis (Liu, 1983)
There is insufficient data available from either experimental animals or from human 
epidemiology to classify it as a carcinogen (lARC, 1975). ADM is however, a potent 
genotoxin in a wide variety of in vitro and in vivo assays (IARC, 1987a) and as such is 
considered to have carcinogenic potential.
2.5.3 Diethylstilboestrol (DES)
DES has previously been reported to induce nuclear enlargement in HeLa S3 cells (Agrelo 
and Amos, 1981). It was chosen as a test compound for the current investigations as 
treatment of HeLa S3 cells has also been associated with induction of aneuploidy (Sawada 
and Ishidate, 1978). It was hoped that mechanistic studies with DES would help to further 
define any link between carcinogen-induced nuclear enlargement and carcinogen-induced 
aneuploidy/polyploidy.
DES is a synthetic oestrogen which was prescribed between 1940 and 1970 for many 
pregnancy complications including threatened abortion, habitual abortion, prior stillborn, 
prior premature labour, prior pre-eclampsia and eclampsia. The widespread use of DES to 
treat such conditions was based on the thought that the synthetic oestrogen would help by 
regulating levels of endogenous hormones (Marselos and Tomatis, 1992). It has since 
been demonstrated that exposure to DES in utero during the 12th week of pregnancy is 
causally associated with an increase in vaginal and cervical clear-cell adenocarcinoma in 
women (Marselos and Tomatis, 1992; lARC, 1979; 1987b). DES also induces tumours 
(primarily endometrial carcinoma) in humans exposed postnatally to the synthetic 
oestrogen for treatment of symptoms such as those associated with Turner’s syndrome.
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DES has also been demonstrated to be carcinogenic to many laboratory species after in 
utero and postnatal exposure (lARC, 1979). The exact mechanism by which DES causes 
its carcinogenicity however, remains unexplained. Likewise, the genotoxic potential of 
DES is still far from resolved. Consistently negative results are obtained with DES in 
microbial mutagenicity tests (Glatt et al, 1979; McCann et al, 1975; Rudiger et al, 1979) 
and the majority of mammalian cell mutation assays (Barret et al, 1983; Friedrich and 
Nass, 1983; Buenaventura et al, 1984; Drevon et al, 1981). Occasional positive test 
results have been reported when clastogenicity (Sato et al, 1992; Sakakibara et al, 1991; 
Dulout and Natarajan, 1987) and unscheduled DNA synthesis (Martin et al, 1978) have 
been measured although negative results have also been published for each of these 
endpoints.
Of importance to the current work, DES has been reported to induce polyploidy in vitro in 
a variety of cell types (Danford, 1985; Ishidate, 1988; Sato et al, 1992; Dulout and 
Natarajan, 1987; Priston and Dean, 1985; Banduhn and Obe, 1985). Hill and Wolff (1982) 
showed that DES did not induce polyploidy in vitro in lymphocytes cultured from a male 
donor whereas significant polyploidy induction was seen in cultures initiated from a 
pregnant woman. DES has also been shown to cause aneuploidy in a variety of cell types 
in vitro (Danford, 1985; Sato et al, 1992; Dulout and Natarajan, 1987; Tsutsui et al, 1983; 
Banduhn and Obe, 1985). Aneuploidy has also been reported in 8  day old mouse embryos 
after administration of DES in utero (Chrisman, 1974). In some, but not all cases, 
polyploidy/aneuploidy induction by DES has been accompanied by structural 
chromosome aberrations. It has been suggested (Sakakibura et al, 1991, Sharp and Parry, 
1985; Hartley-Asp et al, 1985) that the effect of DES on cellular chromosome 
complements may be a result of spindle damage as DES is known to inhibit the in vitro 
polymerisation of microtubule proteins.
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3. MATERIALS AND METHODS
3.1 Chemicals
Adriamycin hydrochloride (ADM), demecolcine, diethylstilboestrol (DES), 
dimethylsulphoxide (DMSG), N-methyl-N-nitrosourea (MNU) stabilised with aqueous 
acetic acid, mitomycin C, propidium iodide (PI) and Neutral Red were purchased from 
Sigma, Poole, Dorset. RNase (DNase-free from bovine pancreas) was purchased from 
Boehringer Mannheim, Lewes, Sussex. Chromium IQ potassium sulphate dodeca-hydrate, 
dibutylpolystyrene xylene (DPX), gallocyanin, Giemsa stain, Schiff s reagent and Methyl 
Green were purchased from BDH, Upminster, Essex.
All other chemicals used were obtained from either Sigma, Poole, Dorset or BDH, 
Upminster, Essex.
3.2 Tissue Culture Ingredients and Plasticware
Adenine, cholera toxin (from Vibrio cholerae), rat tail collagen type (VII), epidermal 
growth factor (EGF, from mouse submaxillary glands), hydrocortisone, insulin (from 
bovine pancreas), human transferrin and 3,3 ’ ,5-triiodo-1 -thyronine (T3) were purchased 
from Sigma, Poole, Dorset. Dulbecco’s modified minimal essential medium (DMEM, 
with non-essential amino acids and without sodium pyruvate). Eagle’s minimal essential 
medium (EMEM), Ham’s F12 nutrient mixture, heat inactivated foetal calf serum (FCS), 
L-glutamine, kanamycin, minimal essential medium (MEM) non-essential amino acids 
and trypsin-EDTA solution were purchased from Gibco, Paisley, Renfrewshire. 25 and 80 
cm^ tissue culture flasks, cryovials, 12 and 96 well plates and 22mm round Thermanox® 
coverslips were purchased from Flow Laboratories, High Wycombe, Buckinghamshire.
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3.3 Cells and Cell Maintenance
3.3.1 HeLa S3 Cells
HeLa cells were the first human tumour cells to be established as a continuous cell line. 
HeLa S3 cells are the most commonly used derivative from this initial cell line which was 
established in 1951 from a cervical carcinoma of a 31 year old woman (Henrietta Lang) 
who later died from the cancer (Gey et al, 1952).
Monolayer cultures of HeLa S3 cells were established from a liquid nitrogen stock 
obtained from Mrs D Simpson, School of Biological Sciences, University of Surrey. The 
cells were routinely maintained in 80 cm  ^ flasks in 10ml HeLa S3 DMEM [DMEM 
containing 10% (v/v) PCS, 200mM L-glutamine and 10 000 pg/ml kanamycin]. Cells 
were incubated at 37°C, 5% CO2 and allowed to achieve near-confluency prior to 
subculturing. To prevent excessive genetic drift, new cultures were established from 
frozen stocks every 2  months.
3.3.2 Rat Tongue Epithelium (RTE) Cells
Monolayer cultures of rat tongue epithelial (RTE) cells were established from a liquid 
nitrogen stock originally established by Dr L. Gajjar, Robens Institute, University of 
Surrey. Maintenance of RTE cells was essentially the same as that used for HeLa S3 cells, 
with the exception that the growth medium used was EMEM supplemented with 10% 
(v/v) PCS, 200 mM L-glutamine, 10 000 pg/ml kanamycin and MEM non essential amino 
acids as described by Gajjar and Benford (1987). Cells were incubated at 37°C, 5% CO2 
and allowed to achieve near-confluency prior to subculturing. As RTE cells have a finite 
lifespan in culture they were grown and used at a constant passage number of 25 in all 
experiments reported here. This allowed direct comparison between experiments.
3.3.3 Human Keratinocyte (HK) Cells
Monolayer cultures of primary human kératinocytes (HK) cells were established from 
cells which had previously been isolated from mastectomy discard tissue (Dr F. Dickson,
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Robens Institute, University of Surrey) and frozen in liquid nitrogen. The culture of 
human kératinocytes was adapted from the methods described by Hoh et al (1987), Green 
et al (1979) and Barlow and Pye (1990).
Cells were rapidly thawed and seeded into 25 cm^ flasks at a density ^ of 1 x 10  ^ cells/ml 
together with mitotically arrested 3T3 feeder cells (see Section 3.3.4) at a density of 0.5 x 
10  ^ cells/ml. The presence of mitotically arrested feeder cells in the culture allows the 
proliferation of kératinocytes whilst suppressing the growth of any dermal fibroblasts 
which may be present in the cell suspension (Parkinson and Yeudall, 1992). The basal 
medium used for culture of HK cells was 3:1 DMEMiHam’s F12 Nutrient mix with 10% 
(v/v) FCS, 200mM L-glutamine and 10 000 pg/ml kanamycin. On the day of use, this 
medium was supplemented with 0.4 pg/ml hydrocortisone, 5.0 pg/ml transferrin, 0.14 
ng/ml T3, 24 pg/ml adenine, 5.0 pg/ml insulin, 1 x 10‘^^M cholera toxin and 10 ng/ml 
EGF. This medium is termed “complete HK medium” for the remainder of this thesis. 
Cells were incubated at 37°C, 5% CO2 and allowed to achieve near-confluence prior to 
subculturing.
When HK cells achieved near confluence, remaining 3T3 cells were removed by repeated 
aspiration of the culture flask with 0.02% EDTA. This treatment with EDTA did not 
remove HK cells from the monolayer as HK cells attach more firmly to the culture flasks 
that the mitotically arrested 3T3 cells. HK cells were then trypsinised as described below. 
HK cells of the 2nd or 3rd passage (P2 or P3 HK cells) were used in the subsequent 
experiments and were grown in the absence of 3T3 feeder cells and EGF. For culture of 
P2 and P3 kératinocytes, culture vessels were coated with rat tail collagen using a 
modification of the method of Dougherty et al (1980). Vessels were coated with 0.5 
mg/ml rat tail collagen in 0.5% glacial acetic acid in phosphate buffered saline (PBS). 
Flasks were incubated overnight at 37°C and washed twice with PBS prior to use (or 
storage at 4°C).
3.3.4 3T3 Cells
Monolayer cultures of 3T3 Swiss albino transformed mouse embryo fibroblasts were 
established from a liquid nitrogen stock within the Robens Institute, University of Surrey
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and were maintained in an identical manner to HeLa S3 cells (see Section 3.3.1). In order 
to provide mitotically arrested 3T3 ‘feeder’ cells for use in keratinocyte culture, a 
subconfluent flask (50-70%) was treated with 0.04 pg/ml mitomycin C (in a final volume 
of 1% (v/v) methanol in culture medium) as described by Barlow and Pye (1990) for 2-4h 
at 37°C. Following treatment, cells were trypsinised, resuspended in 10 ml HeLa S3 
DMEM and stored for up to 7 days at 4°C prior to use.
3.3.5 Subculturing and cell preservation
All cell types were subcultured in a similar manner. The cells from a near-confluent (80- 
90 %) monolayer were detached by incubating with 2ml trypsin/EDTA solution at 37°C. 
Following detachment 10ml of FCS-containing medium was added, cells were 
centrifuged at 1500 rpm and resuspended in 1 0 ml of the appropriate growth medium. 
Cells were then diluted 1:10 with growth medium before addition to a new flask. For 
storage in liquid nitrogen, all cell types were trypsinised as described above and 
resuspended at a density of 2 x 10  ^ cells/ml in HeLa S3 DMEM containing 10% (v/v) 
DMSO. Cryovials containing 1ml aliquots of this cell suspension were then frozen in the 
neck of a Jencons 35HC liquid nitrogen freezer for Ih prior to indefinite storage in liquid 
nitrogen (vapour phase).
3.4 Nuclear Enlargement Tests
The methodology used for nuclear enlargement assays was a modification of that used by 
Grant and Grasso (1978).
3.4.1 Sample production
HeLa S3 and RTE cells were seeded at a density of 1 x 10  ^ cells/ml in 12 well tissue 
culture plates containing Thermanox® coverslips (1 ml/well). HeLa S3 DMEM and 
EMEM were used to culture HeLa S3 cells and RTE cells respectively. Cells were 
allowed to attach to the coverslips for 24h before treatment with the test compound. HK 
cells (P2 or P3) were seeded into 12 well plates containing collagen coated coverslips at 1
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X 10  ^ cells/ml (1 ml/well in complete HK medium) and were treated when they reached 
approximately 50% confluency.
At appropriate timepoints, the medium was removed from the wells and the cells were 
fixed with ethanol:glacial acetic acid (3:1). This is a fixation procedure which has been 
shown to maintain good nuclear morphology (Butterworth et al, 1987). 1ml of fixative 
was incubated with the cells for 30 minutes at room temperature, this was then removed 
and the coverslips were washed three times with distilled water. Coverslips were then left 
to dry overnight before mounting them (cells uppermost) onto labelled microscope slides 
using DPX.
3.4.2 Staining
For image analysis of nuclear area cells were stained with gallocyanin/chrome alum stain 
(Husain and Watts, 1983). This stains nucleic acids a deep blue/black and therefore 
provides a good contrast for image analysis. RNA was removed from the cells by 
pretreatment with 1% potassium hydroxide in 80% alcohol for one hour (Ingram, 1990). 
After washing cells were stained overnight with gallocyanin/chrome alum stain prepared 
as follows.
3g of gallocyanin was oxidised by the addition of 6 ml concentrated sulphuric acid. When 
the oxidation was complete, 52.2g chromium m  potassium dodeca-hydrate dissolved in 
300 ml distilled water was added and boiled for 5 minutes. This was allowed to cool, 
filtered and the pH adjusted to <1.0 before restoring the volume to 300ml.
Stained slides were washed with distilled water and dehydrated through graded alcohols 
before clearing in xylene. A coverslip was mounted on top of each slide to give a 
permanent preparation. Slides were coded prior to analysis to eliminate the possibility of 
observer bias during scoring.
The areas of at least 100 nuclei were measured from each of three replicate slides for each 
concentration/timepoint using a Quantimet Q920 image analyser (Cambridge Instruments, 
Cambridge, UK) by means of a microscope fitted with a x40 objective and a xl.25
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projection lens. Only interphase nuclei were measured and were selected on the basis that 
they were clearly separated from their neighbours.
3.4.3 Statistical Treatment of Data
The nuclear size data from each slide was generated in the form of a histogram, scoring 
frequency of areas in increments of 20 pm^. The data from the three replicate slides was 
then pooled for each treatment and the median and 99th percentile values calculated. The 
percentage of test cell nuclei that were larger than the 99th percentile of concurrent 
solvent controls was calculated for each treatment. As 1% of control nuclei are larger than 
the 99th percentile, an increase of 5% above the concurrent control 99th percentile was 
considered to have biological significance, as suggested by Ingram and Grasso (1985). In 
addition, the mean nuclear area from the three replicate slides was also calculated for each 
treatment and compared with the concurrent control mean using Student’s t-test.
3.5 Flow Cytometry
25 cm^ cultures were treated with test compounds in an identical manner to the nuclear 
enlargement tests. At the appropriate time after treatment, cells were trypsinised as 
described in section 3.3.5 and centrifuged (1500 rpm) to obtain a cell pellet. This pellet 
was then rapidly fixed in 10ml ice cold ethanohPBS (7:3). This procedure permeabilises 
the cell membrane and allows the cells to be stored for up to 4 weeks at 4°C (Ormerod, 
1990).
3.5.1 Staining of cells
For staining of DNA, the method of Ormerod (1990) was used. The phenanthridinium dye 
propidium iodide (PI, 3,8-diamino-5-diethylmethylaminopropy 1-6-phenyl
phenanthridinium diiodide) was used which intercalates with helical polynucleotide 
structures (Latt, 1979). This binding, which is stoichiometrical is associated with a shift in 
dye absorbance from 493 nm to 639 nm. Following at least 30 minutes at 4°C in fixative, 
the fixed cell suspensions were passed through a 25 gauge hypodermic needle to eliminate 
clumps of cells. Each sample was then centrifuged (1500 rpm, lOminutes), washed with
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PBS and re-centrifuged. Each pellet was then incubated at 37°C for 30 minutes in the 
presence of 100 pi RNase (1 mg/ml) and 100 pg/ml PI (400 pg/ml; filtered through 0.2 
pm filter prior to use).
3.5.2 Flow Cytometry and analysis of data
10 000 cells were analysed from each sample using a FACScan flow cytometer (Becton 
Dickinson, San Jose, CA, USA) equipped with a 488 nm argon-ion laser and FACScan 
research software. As each cell was drawn through the machine, the red fluorescence was 
measured (indicating the amount of bound PI). A DNA histogram was then produced for 
each sample where red fluorescence (DNA content) was plotted on the x axis against 
frequency on the y axis. The DNA histograms produced by FACScan analysis (for an 
example see Fig 1) are typically a Gaussian distribution with two peaks. The first peak 
(Gq/Gj peak) represents cells with a diploid DNA content ie. cells in G% or Gq of the cell 
cycle. The second, smaller peak (G2+M peak) represents cells with twice the diploid DNA 
content ie. cells in G2 of the cell cycle and those undergoing mitosis. All cells undergoing 
DNA synthesis (those in S phase) will have a DNA content somewhere between these two 
peaks. Therefore, the relative percentages of cells in the Gq/Gj, S and G2+M phases can 
be estimated from these histograms.
The percentage of cells in each stage of the cell cycle was estimated for each control 
sample by electronic ‘gating’of the PI histograms produced. The relative percentages of 
cells in each stage of the cell cycle in the treated samples at each timepoint were estimated 
using the electronic ‘gates’ generated for the concurrent control sample. Nuclei located in 
the region beyond the Gaussian distribution of G2 (called “>G2 ” in all tables) were also 
measured as an estimation of the percentage of polyploid cells. Whilst more accurate 
measurements of the proportion of cells in each phase of the cell cycle can be made using 
commercially available software, many of the samples analysed did not contain a Gq/Gj 
peak and could therefore not be analysed using such software. Three independent replicate 
experiments were carried out for each compound.
In addition to fluorescence, the argon-ion laser was also used to generate forward (FSC) 
and side scatter (SSC) data for each cell, which are indications of cell size and granularity 
respectively (Thompson etal, 1985).
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Fig 1. Example of PI FACScan histogram illustrating a typical Gaussian 
distribution
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The mean FSC and SSC data for each experiment and the percentage of cells at each stage 
in the cell cycle after treatment were compared to concurrent control values using 
Student’s t-test.
3.6 Microdensitometry
Coverslip cultures of HeLa S3 cells were treated and fixed with ethanol:glacial acetic acid 
(3:1) which is the recommended fixative for microdensitometric measurement of nuclei 
(Cowden, 1972) and attached to microscope slides using DPX. The DNA of these cells 
was then stained magenta using the Feulgen cold hydrolysis method. Two different 
methods (Pascoe and Stemp, 1990; Chayen and Bitensky, 1991) were used in preliminary 
experiments to determine the optimal staining protocol. The method of Chayen and 
Bitensky was found to give superior staining and was used for the main experiment.
Prior to Feulgen staining, the DNA was initially hydrolysed in 5M hydrochloric acid for 
40 minutes at room temperature to expose the aldehyde groups on the deoxyribose sugar 
moieties of the nucleotides (Cowden, 1972). The slides were then rinsed briefly in O.IM 
hydrochloric acid before staining for a further 40 minutes in buffered Schiff s reagent 
(10% Schiff s reagent, 1.5% sodium metabisulphate in glycine buffer, pH 2.3). Schiff s 
reagent is a leuco-basic fuchsin which turns magenta in the presence of aldehydes. Slides 
were then rinsed three times in rinse buffer (1.5% sodium metabisulphate in glycine 
buffer, pH 2.3), rinsed again in distilled water, dehydrated through graded alcohols, 
cleared in xylene and finally mounted in DPX (a mountant compatible with 
microdensitometry [Chayen and Bitensky, 1990]). Slides were coded prior to analysis to 
eliminate the possibility of observer bias during scoring.
3.6.1 Microdensitometry measurement
The total amount of magenta stain in 50 interphase nuclei was determined in each of three 
replicate slides from each treatment group. The amount of stain was quantified using a 
Vickers M85 scanning microdensitometer. The nuclei were viewed using a x40 objective 
through a conventional transmitted light microscope attached to the microdensitometer. A 
circular mask was selected which was superimposed onto the specimen image to indicate
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the area of the specimen to be measured. The mask size was selected such that the largest 
nucleus to be measured would fit within the mask, with a ring of unstained material 
around it. Cells were scored only if the nucleus was sufficiently far away from its 
neighbours to allow it to be the only nucleus within the masked area. A wavelength of 550 
nm was then selected (absorption peak for Feulgen stain). A large number of absorption 
measurements (125 measurements/pm^) were then rapidly made by the “flying-spot” 
scanning integrated microdensitometer across the entire masked area using a spot size of 
0.5 pm as recommended for such specimens (Vickers M85 scanning microdensitometer 
instruction manual). By summing all the individual values obtained in this measurement a 
true value for total specimen absorbance was then displayed by the machine. The 
absorbance of each nucleus was measured only once, as initial investigations using 10 
separate measurements per nucleus showed that the variation between readings was small.
3.6.2 Statistical Treatment of Data
The mean nuclear area from the three replicate slides was calculated for each treatment 
and compared with the concurrent control mean using Student’s t-test. The data for each 
treatment are also presented as a histogram for comparison to nuclear enlargement data.
3.7 Metaphase Chromosome Preparation
In some experiments, metaphase chromosome preparations were made from 10 ml 
cultures using standard techniques (Scott et al, 1990). Two hours prior to chromosome 
preparation, 200 pi of 10 pg/ml demecolcine was added to each flask. Demecolcine 
(Colcemid) is a spindle damaging agent which causes cells to accumulate in metaphase of 
the cell cycle. It is a synthetic, but less toxic, derivative of colchicine which has been used 
historically for preparation of metaphase chromosomes (Rieder, 1992). Cells were then 
trypsinised to give a single cell suspension as described in Section 3.3.5, centrifuged at 
1500 rpm and resuspended in 10ml of a freshly made hypotonic solution of potassium 
chloride (0.075M). Cells were left in this hypotonic solution at room temperature to 
expand the volume of the cells and allow distribution of the chromosomes throughout the 
cytoplasm (Dean and Danford, 1984).
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After centrifugation at 1500 rpm for 5 minutes, most of the supernatant was carefully 
removed and the cells were rapidly fixed using 10 ml glacial acetic acid:methanol (1:3). 
This procedure of centrifugation followed by resuspension in fixative was repeated twice 
more. Fixative was always made fresh and discarded after Ih (Dean and Danford, 1984).
Following a final centrifugation, most of the fixative was removed from the cell pellet and 
the cells were resuspended in a small volume of fixative. One drop of this fixed cell 
suspension was then dropped from a height of approximately 20 cm onto a precleaned 
microscope slide. Slides were cleaned by soaking for 20 minutes in industrial methylated 
spirits (IMS) following 24h in 1% hydrochloric acid in 70% IMS.
Slides were allowed to air dry, stained for 12 minutes in 10% buffered Giemsa’s stain (pH 
6.8), washed briefly in pH 6.8 buffer and allowed to dry overnight. To give permanent 
preparations, stained slides were soaked for 10 minutes in xylene and mounted with a 
coverslip using DPX.
3.8 Synchronisation of Cell Cycle in HeLa S3 Cells
Monolayer cultures of HeLa S3 cells were established at 1 x 10"^  cells/ml in 80 cm^ flasks. 
Three days later the double thymidine block technique (Prescott, 1988) was used to 
synchronise cells in culture so that all cells were at the same stage of the cell cycle. This 
technique involves growing the cells in the presence of excess thymidine (2mM) which 
inhibits the action of nucleoside diphosphate reductase.
3.8.1 Principle of double thymidine block
Nucleoside diphosphate reductase is regulated by allosteric inhibition ie. it is regulated by
its own end product (thymidine triphosphate; TTP). When levels of cellular TTP rise,
nucleoside diphosphate is inhibited thus preventing the synthesis of both TTP and
deoxycytidine triphosphate (dCTP). Therefore, if intracellular TTP levels are raised
artificially (by addition of thymidine to cells in culture which is phosphorylated to TTP in
an unregulated manner), synthesis of both TTP and dCTP will be inhibited. dCTP is an
incorporation!
essential deoxynucleoside triphosphate for I j  into replicating DNA. If synthesis
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of dCTP is inhibited by addition of thymidine to the cells in culture, they will be unable to 
replicate their DNA and will accumulate at the G /S  border of the cell cycle.
Inhibition of nucleoside diphosphate reductase by TTP however is not complete, and cells 
will continue to replicate DNA at a slow rate. To acheive a completely synchronised 
population of cells, a double thymidine block must be used.
3.8.2 Method used forsynchronisationof HeLa S3 cells in G2
Rao and Johnson (1970) determined the length of time that HeLa cells spend in each of 
the phases of the cell cycle, when growing exponentially at 37°C. The cell generation time 
is 21.8h with S phase = 7.0h, G2 = 3.5h, M = 0.9h and G^  = 10.4h. Therefore sampling of 
cells 6h after removal of the second thymidine block should produce a population of cells 
synchronised in G2 .
This technique of double thymidine block was used to produce samples of cells in both S
phase and in G2 for analysis of nuclear area in comparison to asynchronously growing
control cells. Cells were also sampled at various times throughout the synchronisation
procedure for FACScan analysis of cell cycle as a check to investigate whether the
technique for cell synchronisation had been successful.
Details of the exact rnethodology used are described in Fig 16,^p85.|
3.9 Neutral Red Uptake Assays
In some tests, concentrations of test compounds for treatment of HeLa S3 cells were 
chosen based on the results of a preliminary cytotoxicity assay. The cytotoxicity assay 
chosen was Neutral Red uptake (Borenfreund and Peurner, 1985; Babich and 
Borenfreund, 1992). Neutral Red is a supravital dye which is taken up by living cells and 
accumulates in the lysosomes of viable, uninjured cells. It is a weak, cationic dye that 
penetrates cell membranes and binds with anionic sites in the lysosomal matrix. HeLa S3 
cells were seeded into 96 well plates at a density of 1 x 10  ^ cells/ml and treated with the 
test compound after 24h as described for nuclear enlargement tests. Six wells were treated 
with each concentration of test compound (200 pl/well) dissolved in the same vehicle that 
was to be used in subsequent assays. At the appropriate sampling times, media was
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removed from the cells and replaced with media containing 50 pg/ml Neutral Red. After 
3h, the Neutral Red media was removed and replaced with 100 pi destain (1% glacial 
acetic acid; 50% ethanol in water). The Neutral Red solubilised from each well was then 
quantified spectrophotometrically at 540 nm using a Microplate Biokinetics Reader 
EL340 (Biotek Intruments, Vermont, USA). To give an indication of the cytotoxicity 
induced by the test compound, the mean absorbance for each treatment group was 
expressed as a percentage of the mean concurrent control absorbance.
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4. NUCLEAR ENLARGEMENT RESULTS
Initially, experiments were conducted with the three chosen carcinogens to determine 
conditions under which nuclear enlargement occurred. These conditions would then be 
used in subsequent experiments to determine the mechanisms of enlargement (Chapter 5).
4.1 N-methyl-N-nitrosourea (MNU)
The majority of experiments which investigated nuclear enlargement with MNU used 
HeLa S3 cells. The responses seen were then investigated further in the other 2 cell types 
(RTE and HK cells).
4.1.1 HeLa S3 Cells
Experimental details
The methodology used was a direct adaptation of that used by Grant and Grasso (1978) 
who pulse treated HeLa S3 cells for 30 minutes with direct-acting carcinogens (including 
MNU) dissolved in PBS. In all experiments with MNU, solutions were made up 
immediately before treatment as MNU is unstable in aqueous solution with a half-life of 
only l-2h at pH 7 (Lijinsky, 1992). Following treatment, cultures were washed with PBS 
and nuclear enlargement was then assessed after 24, 48 and 72h in fresh DMEM as 
described in section 3.4.2.
The concentrations of MNU chosen for the HeLa S3 cell experiments initially ranged 
from 0.1-10 pg/ml based on those used by Grant and Grasso (1978). In the subsequent 
three experiments with MNU, the concentration range was altered (covering 
concentrations from 1-5000 pg/ml) to define the optimal concentrations required to 
induce nuclear enlargement at the three timepoints used. Results of an initial Neutral Red 
cytotoxicity assay with MNU indicated that treatment for 30 minutes with concentrations 
of 0.1-500 pg/ml MNU did not affect the viability of HeLa S3 cells after treatment for 24, 
48 or 72h. However, a 30 minute treatment with 5000 pg/ml MNU caused severe 
cytotoxicity at all timepoints tested. The Neutral Red uptake in cultures treated with 5000
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pg/ml MNU was 19, 5 and 4% of concurrent control values after 24, 48 and 72h
respectively.
Results o f nuclear enlargement tests
The statistical data from the 4 nuclear enlargement experiments with MNU are shown in 
Tables 1-4. The same data represented in the form of histograms is shown in Fig 2 from a 
representative experiment.
Concentrations of 5-5000 pg/ml MNU clearly induced nuclear enlargement in HeLa S3 
cells 24, 48 and 72h after pulse treatment for 30 minutes, with the greatest increase in 
nuclear size seen after treatment with 500 pg/ml. The increases in nuclear area were 
greatest 72h after treatment at all of these concentrations. In the case of the lower 
concentrations (5-10 pg/ml MNU), no statistically significant increase in nuclear area was 
observed until 72h after treatment.
Lower concentrations of MNU (0.1-3 pg/ml) did not induce nuclear enlargement in HeLa 
S3 cells at any of the timepoints tested. The decrease in response at 5000 pg/ml MNU 
indicates that the nuclear enlargement is not associated with cytotoxicity.
4.1.2 RTE Cells
Following the observation that MNU induced nuclear enlargement in HeLa S3 cells, an 
experiment was conducted which investigated the ability of MNU to induce nuclear 
enlargement in RTE cells. The use of this keratinocyte cell line more closely resembles 
the situation in the in vivo nuclear enlargement assay in rodent skin.
Experimental details
The methodology used to assess MNU-induced nuclear enlargement in RTE cells was the 
same as that used for HeLa S3 cells with the exception of the length of treatment used. As 
RTE cells are slower growing than HeLa S3 cells, pulse treatment was for a longer period
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Nuclear enlargement in HeLa S3 cells after treatment with MNU: Results from
individual experiments
Table 1 : Initial experiment using concentrations of MNU as used by Grant and
Grasso (1978)
MNU Timepoint Nuclear area(pm^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 24 182.0 ± 14.4 181.7 364.9 1.0
0.1 221.0 + 15.1 204.2 438.3 3.6
1 206.3 ± 10.3 199.8 430.6 2.7
10 195.5 ±7.0 193.8 431.2 3.1
0 48 193.5b 189.2 536.0 1.0
0.1 192.7 ±5.9 190.0 402.1 0.0
1 195.7 ± 15.5 189.5 388.5 0.4
10 230.0b 225.8 457.7 0.0
0 72 183.3 ± 13.3 178.4 386.0 1.0
0.1 170.3 ±14.8 155.3 357.9 0.6
1 184.7 ±7.0 178.6 349.5 0.6
10 348.0 ± 23.9 *** 331.9 717.0 33.4®
Table 2: Second experiment using higher concentrations of MNU (up to cytotoxic
concentrations)
MNU Timepoint Nuclear area(pm‘^ ) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 24 182.7 ±8.2 178.1 352.3 1.0
50 250.7 ±10.5 ** 250.0 408.4 5.3®
500 326.3 ±21.2 *** 317.2 552.1 36.1®
5000 169.0 ±6.5 162.8 352.0 1.0
0 48 169.0 ±10.1 161.1 298.4 1.0
50 240.0 ±11.4 ** 235.2 427.2 21.3®
500 396.7 ±15.4 *** 396.8 597.1 87.6®
5000 329.7 ± 10.0 *** 327.9 518.8 64.0®
0 72 236.0 ± 47.9 219.2 470.3 1.0
50 369.7 ± 54.4 346.8 728.3 18.7®
500 472.3 ± 52.3 ** 461.0 907.9 45.5®
5000 438.0 ± 6.4 ** 436.3 717.4 34.1®
Mean nuclear areas (n=3; >100 nuclei measured /  sample) compared to concurrent control using Student’s t- 
test. Significantly different from control ** p<0.01; *** p<0.001.
^Significance is attached to this value if > 5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 3.4.3)
^Only two replicate slides counted
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Nuclear enlargement in HeLa S3 cells after treatment with MNU: Results from
individual experiments (continued)
Table 3: Third experiment with MNU to define optimal concentrations of MNU
which induce nuclear enlargement in HeLa S3 cells
MNU
(pg/ml)
Timepoint
(h)
Nuclear area(pm* )^
Mean ± SE Median 99th percentile
Percentage of cells 
> control 99th percentile
0 24 151.7 ±5.0 151.0 266.3 1.0
12.5 191.0 ±3.5 *** 189.1 318.5 7.3®
25 205.3 ± 33.8 193.9 417.7 22.7®
50 250.7 ±20.1 ** 246.5 496.8 40.6®
0 48 127.7 ±0.9 125.7 235.7 1.0
12.5 212.0 ± 18.9 ** 198.1 396.9 30.8®
25 194.3 ±7.7 *** 184.0 372.0 21.0®
50 250.7 ±20.1 *** 223.9 394.1 42.4®
0 72 139.0 ± 10.2 132.9 278.0 1.0
12.5 345.0 ±11.1 *** 342.9 587.9 78.6®
25 358.3 ±7.2 *** 362.7 556.8 87.3®
50 328.5b 321.8 619.7 69.3®
Table 4: Fourth experiment with MNU investigating a range of concentrations (721
timepoint only)
MNU Timepoint Nuclear area(pm'^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 72 164.0 ±7.2 154.6 338.6 1.0
1 187.7 ± 13.9 184.5 355.8 2.5
2 181.3 ±9.8 169.9 534.2 3.3
3 174.3 ±5.8 164.2 436.0 1.7
4 238.3 ± 24.7 * 223.2 494.6 8.8®
5 225.0 ± 14.7 ** 204.5 577.2 9.0®
6 267.7 ± 34.8 * 240.5 676.6 24.2®
7 289.7 ± 14.5 *** 274.1 656.0 24.1 ®
8 297.7 ± 4.8 *** 271.8 656.2 22.0®
9 256.3 ± 24.2 ** 238.4 557.3 15.0®
10 307.0 ±15.5 *** 279.7 737.0 32.7®
Mean nuclear areas (n=3; >100 nuclei measured /  sample) compared to concurrent control using Student’s t- 
test. Significantly different from control * p<0.05; ** p<0.01; *** p<0.001.
^Significance is attached to this value if > 5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 3.4.3)
^Only two replicate slides counted
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(3 hours) as used by Fowlie et al (1991) with rat tracheal epithelial cells. Due to the 
longer treatment period involved, MNU was not dissolved in PBS, but in EMEM to allow 
cells access to nutrients during the treatment period. As with the HeLa S3 experiments 
nuclear enlargement was measured 24, 48 and 72h after treatment. In this case all 
treatment times are expressed as time after the start of dosing.
The concentrations of MNU chosen for the nuclear enlargement test in RTE cells were 5, 
50 and 500 pg/ml as these concentrations had induced significant nuclear enlargement in 
the HeLa S3 experiments.
Results o f nuclear enlargement test
The histograms showing the results of the experiment with in RTE cells MNU are shown 
in Fig 3. The statistical data associated with these histograms are shown in Table 5.
A concentration of 500 pg/ml MNU caused a significant increase in nuclear area of RTE 
cells 48 and 72h after a 3h pulse treatment. Treatment with 5 and 50 pg/ml MNU did not 
result in any nuclear enlargement at any of the timepoints tested. 72h after treatment with 
5 pg/ml MNU a slight increase (7.0 %) was seen in the percentage of cells with a nuclear 
area greater than the 99th percentile of the concurrent control. However, this increase was 
small and not reflected in the other measurements of nuclear enlargement (mean and 
modal nuclear areas). It was concluded therefore that this result at 5 pg/ml was not of 
biological significance.
42
Nuclear enlargement in RTE cells after treatment with MNU: Results from
individual experiments
Table 5. Nuclear enlargement in RTE cells after treatment with MNU
MNU Timepoint Nuclear area(ijm^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th
0 24 147.7 ±14.5 146.5 278.3 1.0
5 147.3 ±14.5 145.1 268.2 0.6
50 164.3 ±9.0 157.5 289.5 1.6
500 150.0 ±2.5 143.8 325.4 3.6
0 48 148.0 ±17.4 135.8 314.0 1.0
5 148.7 ± 17.6 136.3 297.5 0.8
50 140.0 ±24.5 127.7 344.2 1.1
500 241.3 ±7.1 ** 226.9 486.4 20.5
0 72 109.0 ±4.6 103.9 219.8 1.0
5 131.3 ±12.4 122.4 373.9 7.0
50 96.4 ± 3.3 * 92.2 232.9 1.3
500 269.3 ± 26.3 ** 247.4 558.3 60.6
Mean nuclear areas (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s t- 
test. Significantly different from control * p<0.05; ** p<0.01
^Significance is attached to this value if > 5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 3.4.3)
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4.1.3 HK Cells
As MNU induced nuclear enlargement in both HeLa S3 and RTE cells in vitro, three 
experiments were conducted which examined the ability of MNU to induce nuclear 
enlargement in HK cells. The use of human tissue is of particular interest in in vitro 
toxicity assays, as it can give an indication as to whether an effect seen in vivo and in vitro 
in experimental animals may translate to a similar effect in humans.
Experimental details
Several different treatment regimens were used in the investigation of the ability of MNU 
to induce nuclear enlargement in HK cells. Three independent experiments were 
conducted with variations in: 1. Treatment time, 2. Concentration of MNU, 3. Sampling 
time and 4. HK cell type (ie. different tissue donors and different passage numbers).
Results o f nuclear enlargement tests
The statistical data from the 3 nuclear enlargement experiments with MNU in HK cells 
are shown in Tables 6-8. The same data represented in the form of histograms is shown in 
Fig 4 from a representative experiment.
In the first experiment with MNU in HK cells (Table 6), 2nd passage (P2) cells were 
treated for 30 minutes with MNU dissolved in PBS (as in HeLa S3 experiments). As HK 
cells are much slower growing than HeLa S3 cells, an extra sampling time of 144h was 
also introduced to allow for any delayed effects. MNU did not induce nuclear enlargement 
in HK cells at any of the concentrations tested.
MNU was then retested in HK cells derived from a different individual and using the 
longer treatment time of 3h as used when MNU was tested in RTE cells. In this 
experiment (Table 7) a small, statistically significant increase in mean nuclear area was 
seen after 24h (1000 pg/ml) and after 72h (1 pg/ml). However, in both cases, this was not 
accompanied by any increase in the percentage of cells with a nuclear area greater than the 
99th percentile of the concurrent control, nor was the effect time- or concentration-related.
45
Nuclear enlargement in HK ceils after treatment with MNU: Results from individual
experiments
Table 6. Initial experiment: Cell Type: HK28P2 (ie. Donor No 28, 2nd passage)
Treatment: 30 minutes (MNU dissolved in PBS)
MNU Timepoint Nuclear area(pm^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th |
0 24 196.7 ±8.4 182.8 394.3 1.0
5 175.3 ±4.7 * 167.4 368.6 0.8
50 172.0 ±6.4 * 160.0 379.6 0.6
500 166.3 ±40.4 157.9 369.4 1.0
0 48 224.7 ± 23.8 203.6 542.2 1.0
5 180.7 ±22.6 159.7 428.4 0.5
50 211.7 ±5.5 190.9 477.6 0.9
500 241.7 ±13.7 224.8 555.0 1.2
0 72 185.3 ±8.4 172.4 485.6 1.0
5 200.3 ± 43.5 168.4 732.4 2.4
50 213.3 ± 18.0 195.6 549.4 1.8
500 215.7 ± 15.6 191.0 577.2 2.2
0 144 222.3 ±31.2 187.8 650.8 1.0
5 196.5^ 175.9 514.0 0.5
50 187.0 ± 15.4 163.1 470.7 0.0
500 161.7 ±9.4 146.8 557.0 0.5
Mean nuclear areas (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s 
t-test. Significantly different from control * p<0.05.
^Only two replicate slides counted.
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Nuclear enlargement in HK cells after treatment with MNU: Results from individual
experiments (continued)
Table 7. Second experiment: Cell Type: HK33P2 (ie. Donor No 33, 2nd passage)
Treatment: 3h (MNU dissolved in HK media - EGF)
MNU
(pg/ml)
Timepoint
(h)
Nuclear area(pm'^)
Mean ± SE Median 99th percentile
Percentage of cells 
> control 99th percentile
0 24 141.0 ±10.0 133.0 350.6 1.0
1 163.5 173.4 338.2 0.7
100 151.3 ±7.3 139.0 295.2 1.2
1000 163.7 ±2.4 * 152.0 356.6 1.1
0 48 209.3 ±19.2 191.3 495.2 1.0
1 207.0 ±9.5 186.7 516.0 1.0
100 207.0 ±0.6 191.4 512.6 1.2
1000 209.3 ±17.3 194.9 426.8 0.0
0 72 221.7 ±6.5 194.3 659.1 1.0
1 241.0 ±5.5 * 210.8 674.6 10.2
100 209.0 ±16.1 190.0 516.2 0.3
1000 228.3 ± 5.8 202.1 635.6 0.9
Table 8. Third experiment: Cell Type: HK33P3 (ie. Donor No 33, 3rd passage)
Treatment: 3h (MNU dissolved in HK media - EGF)
MNU Timepoint Nuclear area(pm^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 24 185.7 ±14.0 167.4 471.4 1.0
5 212.0 ±17.7 174.9 628.3 3.9
50 217.3 ±17.1 195.4 675.2 3.6
500 215.0 ±21.4 188.6 656.4 2.0
0 48 203.3 ±25.7 168.4 592.4 1.0
5 198.3 ±11.7 172.1 573.2 0.7
50 178.0 ± 2.0 144.9 645.2 1.6
500 266.7 ±15.5 * 234.7 678.8 2.0
0 72 203.0 ±24.2 159.0 644.4 1.0
5 183.0 ±17.0 138.5 648.8 1.1
50 177.0 ±9.3 147.3 440.8 0.0
500 247.0 ± 9.9 225.8 654.2 1.1
Mean nuclear areas (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s 
t-test. Significantly different from control * p<0.05.
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For these reasons it was assumed that the statistical significance achieved with these two 
concentrations was not of any biological relevance.
The first two experiments with HK cells both used 2nd passage cultures. A much wider 
spread in control nuclear areas (particularly large nuclei) was seen than had been observed 
previously for either HeLa S3 of RTE cells. This can clearly be seen in the control 
histograms (Figs 2-4) Such a wide variation in control cell nuclear area may mask any 
small increases in MNU-induced nuclear enlargement.
It was thought that the large variation in control nuclear areas seen for HK cells may have 
been due to the early passage number of the cells used ie. a more heterogeneous 
population of cells had been used than for the other 2 cell types. A third experiment was 
therefore carried out using 3rd passage HK cells to investigate whether the use of HK 
cells at a later passage may give more uniform control nuclei (Table 8). A small increase 
was seen in mean nuclear area after 48 and 72h treatment with 500 pg/ml. This increase in 
nuclear size only achieved statistical significance at 48h due to the large variation seen in 
control nuclear sizes at 72h. Again, as with the previous two experiments, no increase was 
seen in nuclear area when the percentage of cells with a nuclear area greater than the 99th 
percentile of concurrent controls was taken in to account.
In conclusion MNU did not induce a reproducible increase in the nuclear size of cultured 
HK cells using any of the conditions examined in these experiments. A slight increase in 
nuclear area was seen 48 and 72h after treatment of P3 HK cells with 500 pg/ml MNU, 
but this was not uniformly significant and is therefore difficult to interpret. Whilst the 
large variation in control nuclear size of HK cells does make statistical analysis of the data 
difficult, it is clear from the graphical presentation of the data that MNU did not induce 
the large increase in nuclear area that was seen in RTE and HeLa S3 cells. It is possible 
that primary cultures of human cells may be less susceptible than other cell types to 
carcinogen-induced nuclear enlargement. Previously, Agrelo and Amos (1981) showed 
that primary cultures of human skin fibroblasts were less sensitive than HeLa S3 cells to 
carcinogen-induced nuclear enlargement.
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4.1.4 Summary of nuclear enlargement results with MNU
The results described above show that MNU induced nuclear enlargement in HeLa S3 
cells after a 30 minute treatment with concentrations of 5-5000 pg/ml and in RTE cells 
after a 3 hour treatment with 500 |ig/ml MNU. MNU did not cause any consistent increase 
in the nuclear area of HK cells after treatment for 30 minutes or 3b with concentrations 
ranging from 1-1000 ng/ml. As the MNU-induced nuclear enlargement was best observed 
in HeLa S3 cells, this cell type was used for the majority of the subsequent investigations 
into the nature of MNU-induced nuclear enlargement (see Section 5).
4.2 Adriamycin (ADM)
Following the work with MNU where HeLa S3 cells were shown to be the most sensitive 
cell type for studying nuclear enlargement, all work with ADM was carried out in HeLa 
S3 cells.
4.2.1 HeLa S3 cells
Three independent experiments examining the ability of ADM to induce nuclear 
enlargement in HeLa S3 cells were carried out.
Experimental details
The methodology used to study ADM in HeLa S3 cells was exactly the same as that used 
to study MNU, i.e. measurement of nuclear area 24, 48 and 72h after a 30 minute pulse 
treatment. As ADM is not soluble in water at the concentrations tested, it was first 
dissolved in neat DMSO at lOOx the required concentration and then diluted with PBS to 
obtain the final treatment solutions (i.e. all treatment and control solutions contained 1% 
DMSO).
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Nuclear enlargement in HeLa S3 cells after treatment with ADM: Results from
individual experiments
Table 9: Initial experiment using concentrations of ADM based on those used by
Lanks and Leham (1990)
ADM
(pg/ml)
Timepoint
(h) Mean ± SE
Nuclear area(pm^)
Median 99th percentile
Percentage of cells 
> control 99th percentile
0 24 161.3 ±13.0 154.0 317.4 1.0
2.5 223.7 ± 16.6 206.7 498.0 16.1"
5 242.7 ± 27.8 * 235.2 452.5 15.5"
10 351.7 ±19.1 349.0 575.1 64.7"
0 48 182.7 ±17.9 185.4 332.0 1.0
2.5 305.0 ± 37.5 303.7 518.2 38.9"
5 352.0 ± 34.6 338.3 646.4 52.3"
10 404.0 ± 27.7 395.0 652.4 69.7"
0 72 169Tf 165.8 345.1 1.0
2.5 418.5" 412.3 798.8 68.2"
5 375.0 ± 54.1 365.8 757.3 54.9"
10 331.3 ± 14.7 318.9 697.2 43.1"
Table 10: Second experiment using lower concentrations of ADM
ADM Timepoint Nuclear area(pm^) Percentage of cells
(Mg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 24 105.5 ±3.1 102.9 206.3 1.0
1.25 209.7 ±18.8 197.1 423.3 45.6"
2.5 275.0 ± 57.9 276.1 535.4 66.4"
5 292.7 ± 9.5 293.3 453.1 89.5"
0 48 152.7 ±11.9 146.3 296.5 1.0
1.25 358.7 ± 19.0 350.4 631.1 67.0"
2.5 384.3 ±31.3 375.5 624.7 81.8"
5 323.7 ± 25.2 318.6 544.7 60.9"
Mean nuclear area (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s t- 
test. Significantly different from control * p<0.05; ** p<0.01; *** p<0.001.
 ^Significance is attached to this value if > 5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 2.4.3).
 ^Only two replicate slides counted.
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Nuclear enlargement in HeLa S3 cells after treatment with ADM: Results from
individual experiments (continued)
Table 11 : Third experiment with lower concentrations of ADM: Attempt to establish
a no effect level.
ADM Timepoint Nuclear area(pm^) Percentage of cells
(pg/ml) (h) Mean ± SE Median 99th percentile > control 99th percentile
0 24 182.0 ±8.9 175.2 310.1 1.0
0.1 221.7 ±7.7 ** 222.2 433.4 9.3"
1 255.3 ±13.0 * 242.3 445.8 18.3"
10 305.7 ± 34.1 ** 302.9 522.9 47.2"
0 48 184.0 ±22.1 179.4 363.3 1.0
0.1 202.0 ±41.0 195.4 492.0 4.0
1 210.0 ±25.0 194.4 431.8 3.2
10 403.7 ±18.2 *** 403.9 708.2 62.5"
0 72 150.7 ±10.4 145.6 283.4 1.0
0.1 152.3 ±10.8 139.7 361.2 4.4
1 148.0 ±13.2 142.3 303.8 1.4
10 332.7 ±17.0 *** 318.6 759.1 55.5"
Mean nuclear area (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s t- 
test. Significantly different from control * p<0.05; ** p<0.01; *** p<0.001.
 ^Significance is attached to this value if > 5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 2.4.3).
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Results o f nuclear enlargement tests
The results of nuclear enlargement tests with ADM after pulse treatment with 
concentrations of 0.1 - 10 pg/ml are shown in Tables 9-11. Fig 5 shows a representative 
set of nuclear area histograms from one experiment with ADM.
Nuclear enlargement was observed after pulse treatment with concentrations of ADM 
ranging from 1.25 to 10 pg/ml. After treatment with 1 and 0.1 pg/ml ADM a small 
increase in nuclear area was observed 24h after treatment; however, this effect was 
reversed and no nuclear enlargement was seen 48 and 72h after treatment.
4.3 Diethylstilboestrol (DES)
As with ADM, only HeLa S3 cells were used for nuclear enlargement tests.
4.3.1 HeLa S3 cells
Experimental details
Initially, the methodology used to study DES in HeLa S3 cells was exactly the same as 
that used to study MNU and ADM in HeLa S3 cells, i.e. measurement of nuclear area 24, 
48 and 72h after a 30 minute pulse treatment. As DES is not soluble in water, it was first 
dissolved in neat DMSO at lOOx the required concentration and then diluted with PBS to 
obtain the final treatment solutions (i.e. all treatment and control solutions contained 1% 
DMSO). As the literature available on DES-induced nuclear enlargement did not state the 
concentrations used, an initial Neutral Red cytotoxicity assay was carried out using 
concentrations of 0.05-500 pg/ml DES. The results of the Neutral Red cytotoxicity assay 
carried out 24h after a 30 minute treatment indicated that 10 pg/ml DES caused a 
reduction in viability to 73.5% of concurrent control levels. The next highest 
concentration tested (50 pg/ml) precipitated out of solution. A maximum, non­
precipitating concentration of 30 pg/ml DES was therefore selected for nuclear 
enlargement tests.
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Results o f nuclear enlargement tests
HeLa S3 cells were pulse treated with 0.3, 3 and 30 pg/ml DES for 30 minutes. The 
results of nuclear enlargement measurements after 24, 48 and 72h are shown in Table 12. 
DES did not induce nuclear enlargement at any of the concentrations tested or at any of 
the timepoints used. Statistical significance was achieved by the mean increase in nuclear 
size seen 72h after treatment with 3 and 30 pg/ml DES, however the 72h control group in 
this experiment had an unusually small mean nuclear area and all treated nuclei were 
within the usual control distribution for HeLa S3 cells.
As DES had previously been shown to induce both nuclear enlargement and aneuploidy in 
HeLa S3 cells, the results of this initial nuclear enlargement test were unexpected. The 
experiment was therefore repeated with an altered treatment regimen. In all subsequent 
experiments, only a 48h timepoint was used as this is the timepoint at which DES had 
previously been shown to increase chromosome numbers (Sawada and Ishidate, 1978). 
The treatment time with DES was increased to either a 3h pulse treatment (Agrelo and 
Amos, 1981 had previously used a Ih pulse treatment) or continuous treatment for the 
entire 48h as used by Sawada and Ishidate (1978). All treatments were carried out in 
DMEM containing 1% DMSO.
The results of nuclear enlargement tests with DES using these altered treatment regimens 
are shown in Table 13. A slight increase in nuclear area was seen 48h after a 3h treatment 
with 3 pg/ml DES. This increase was statistically significant, but not concentration- 
related or associated with an increase in nuclei larger than the 99th percentile of the 
concurrent control. Treatment for 48h continuously with DES did not induce nuclear 
enlargement in HeLa S3 cells, but did cause a decrease in the mean nuclear area at the 
lowest two concentrations tested (0.3 and 3 pg/ml).
As there had been no convincing evidence of an effect on nuclear area in the previous 
experiments, a final nuclear enlargement test was carried out using DES in HeLa S3 cells. 
The conditions used for this experiment were exactly the same as those used by Sawada 
and Ishidate (1978). Concentrations of 2.7, 4.0 and 5.4 pg/ml DES (corresponding to 10,
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Nuclear enlargement in HeLa S3 cells after treatment with DES; Results from
individual experiments
Table 12: 30 minute pulse treatment with 0.3, 3 and 30 pg/ml DES
DES
(pg/ml)
Timepoint
(h) Mean ± SD
Nuclear area(pm^)
Median 99th percentile
Percentage of cells 
> control 99th percentile
0 24 230.0 ± 15.4 219.8 378.8 1.0
0.3 228.3 ± 13.0 224.1 553.8 1.9
3 208.3 ± 5.9 208.6 357.7 0.1
30 223.0 ± 22.2 207.7 434.2 3.7
0 48 204.7 ± 5.8 202.9 341.5 1.0
0.3 201.0 ± 1.7 199.1 342.5 1.0
3 174.7 ±21.3 189.1 299.7 0.9
30 197.7 ±24.7 189.3 378.6 2.7
0 72 152.7 ±6.8 149.2 274.7 1.0
0.3 170.3 ±10.2 157.8 356.4 1.0
3 184.0 ±2.9 174.6 446.0 1.4
30 177.3 ±6.0 170.2 329.0 0.6
Table 13: 3h pulse treatment and 48h continuous treatment of HeLa S3 cells with DES
DES Timepoint 
(pg/ml) (h) Mean ± SE
Nuclear area(pm^)
Median 99th percentile
Percentage of cells 
> control 99th percentile
3h pulse treatment
0 48 170.0 ±6.4 160.5 358.0 1.0
0.3 185.7 ± 19.1 173.0 355.6 0.9
3 203.0 ± 14.0 * 193.1 377.9 1.5
30 165.0 ± 19.9 155.3 377.0 1.6
48h continuous treatment
0 48 189.3 ± 12.2 335.6 335.6 1.0
0.3 147.0 ± 11.0 * 286.5 286.5 0.0
3 139.7 ±16.1 * 323.9 323.9 0.7
30® 192.3 ±14.4 423.8 423.8 0.6
Mean nuclear areas (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s 
t-test. Significantly different from control * p<0.05; ** p<0.01
$ Treatment with 30 pg/ml DES for 48h continuously was visibly cytotoxic to HeLa S3 cells. Only 262 
nuclei were measured.
56
Nuclear enlargement in HeLa S3 cells after treatment with DES: Results from
individual experiments (continued)
Table 14: Treatment of HeLa S3 cells for 48h continuously with the concentrations
used by Sawada and Ishidate (1978)
DES Timepoint Nuclear area(pm'^)
(pg/ml) (h) Mean ± SE Median 99th percentile
Percentage of cells 
> control 99th percentile
48h continuous treatment
0 48 193.3 ±9.1 186.5 363.2 1.0
2.7 131.3 ±17.3* 127.6 456.4 3.2
4.0 173.7 ±19.6 143.9 570.8 8.63
5.4 209.0 ±13.5 176.7 778.3 14.73
Mean nuclear areas (n=3; >100 nuclei measured / sample) compared to concurrent control using Student’s 
t-test. Significantly different from control * p< 0.05
^Significance is attached to this value if >5% of cells have a nuclear area greater than the 99th percentile of 
the concurrent control (See section 2.4.3).
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Fig 6 Nuclear area distributions of HeLa S3 cells treated with DES
(DÜ
2.68 ng/ml DES
4.03 ng/ml DES
5.37 jig/ml DES
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Nuclear Area (pm^) ^
HeLa S3 cells were treated with DES for 48h continuously. The areas of at least 100 nuclei on each of 3 
slides was assessed for each treatment group.
The histograms show treated cell data; the concurrent control distribution is represented by the continuous 
line
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15 and 20 pM respectively) were used to treat HeLa S3 cells for 48h continuously. The 
final concentration of DMSO in all treatment and control solutions was 1% v/v.
The results of this final nuclear enlargement test with DES in HeLa S3 cells are shown in 
Table 14 and in Fig 6 . Whilst little effect was seen on the mean nuclear area of the treated 
cells there was a marked effect on the distribution of nuclear areas in the treated groups 
compared to the control. Ingram and Grasso (1985) suggested that if more than 5% of 
cells have a nuclear area greater than the control 99th percentile value, this is evidence of 
nuclear enlargement. In cells treated with DBS there was a concentration-related increase 
in the 99th percentile with greater than 5% having nuclear areas greater than this value at
4.0 and 5.4 pg/ml. Whether this effect should be termed ‘nuclear enlargement’ is 
debatable since there was also a treatment-related increase in cells with small nuclei. As 
in the previous experiment with 48h continuous treatment, a significant decrease was seen 
in mean nuclear area. From the paper of Agrelo and Amos (1981) it is not possible to tell 
whether a similar DES-induced change in nuclear area distribution was seen in their 
experiments which led them to classify DES as positive in the nuclear enlargement assay.
Following the observation that DES induced changes in the nuclear area distribution of 
HeLa S3 cells under very defined conditions, these same treatment conditions were used 
to investigate the effect of DES on chromosome number and DNA content of the cells 
(see Section 5).
4.4 Overall summary of nuclear enlargement with the three test carcinogens
The results of nuclear enlargement tests in HeLa S3 cells with MNU, ADM and DES 
confirmed the results of others (Agrelo, 1978; Agrelo and Amos, 1981; Grant and Grasso, 
1978; Lanks and Lehman, 1990), that treatment with all three carcinogens markedly 
affected the nuclear area distribution.
A marked difference in response was seen between the two potent genotoxins (MNU and 
ADM) and the questionable/non-genotoxin (DES). After treatment with MNU and ADM, 
in both cases a 30 minute ‘pulse’ treatment was sufficient to induce significantly enlarged 
HeLa S3 nuclei as originally observed by Grant and Grasso (1978) with the original series
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of genotoxic carcinogens tested. In the current investigations, this enlargement resulted in 
a shift in the nuclear size histogram for the entire cell population and was observed over a 
relatively wide concentration range (5-5000 pg/ml MNU; 0.1-10 pg/ml ADM) at several 
different timepoints after treatment. A slight difference was seen in the responses at low 
concentrations of these two compounds. Low concentrations of MNU (0.1-3 pg/ml) did 
not induce nuclear enlargement at any of the timepoints tested, whereas low 
concentrations of ADM (0.1-1 pg/ml) caused a slight increase in nuclear area 24h after 
treatment which was reversed by the later timepoints. Whether this difference in the 
response of HeLa S3 cells to these two genotoxins is of any significance can not be 
determined from this data.
The alterations in nuclear size caused by DES were markedly different from those caused 
by the two genotoxic agents. A significant change in the nuclear area distribution was 
observed over a very defined concentration range (2.7-5.4 pg/ml) and only under a very 
specific treatment regimen (48h continuous treatment). This change in nuclear area was 
unlike that seen with MNU and ADM in that the mean nuclear area for the entire 
population was not significantly affected, but a greater spread of nuclear areas was 
observed.
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5. Investigations into the mechanism of carcinogen-induced nuclear 
enlargement
Using the concentrations and treatment regimens determined in Chapter 4 for optimal 
nuclear enlargement with the 3 test carcinogens, several techniques were employed to 
investigate whether this nuclear enlargement was associated with any increase in nuclear 
DNA.
5.1 CHROMOSOME PREPARATION
As increased nuclear size has often been linked to increase ploidy (see Section 2.3), the 
first experiments into the nature of MNU and DES-induced nuclear enlargement in HeLa 
S3 cells were conventional cytogenetic assays. Simple counting of chromosome number 
can give a good indication of whether a compound is inducing polyploidy (and in some 
cases aneuploidy). HeLa S3 cells have been used for cytogenetic analysis (e.g. Sawada 
and Ishidate, 1978) and were chosen for these investigations due to the large amount of 
background information on both its cell cycle properties and nuclear enlargement tests. 
HeLa S3 cells were originally derived from human tumour tissue and the karyotype of the 
cells after many years of continuous culture is now far from the normal human diploid 
karyotype. Such a karyotypically unstable cell type would not be recommended for routine 
cytogenetic investigations.
5.1.1 MNU
Experimental details
Cultures of HeLa S3 cells were treated for 30 minutes with concentrations of MNU 
ranging from 0.1-5000 pg/ml (i.e. low concentrations of MNU that did not cause nuclear 
enlargement in initial experiments and higher concentrations that did). Chromosome 
preparations were made from cultures after 24,48 and 72h as described in Section 3.7.
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Results o f chromosome preparations from MNU-treated HeLa S3 cells
Control HeLa S3 cells gave good preparations of chromosomes, though the chromosome 
number varied markedly between metaphases as expected (see explanation above. Section 
5.1). Most metaphases contained 41-72 chromosomes with occasional cells containing 
more than 100 chromosomes (presumably polyploid cells). Counts given for cells with 
such large numbers of chromosomes are obviously estimations since accurate counting 
becomes difficult. The mean chromosome number was 60.9 with a modal value of 64/cell. 
This compares well with the data from Sawada and Ishidate (1978) who quote a modal 
chromosome number for HeLa S3 cells of 62-63. Fig 7 is a representative photograph 
taken of a “diploid” HeLa S3 metaphase and Fig 8  is a representative photograph taken of 
a “polyploid” HeLa S3 metaphase from the same culture. Fig 9 shows a metaphase from a 
control culture which is polyploid as a result of endoreduplication (formation of 
diplochromosomes as a result of two successive DNA syntheses without an intervening 
separation of chromosomes).
Karyotype analysis from cultures of HeLa S3 cells treated with concentrations of MNU 
which induced nuclear enlargement showed only metaphases with large numbers of 
condensed and badly damaged chromosomes. The extent of this damage as shown in Figs 
1 0  & 11 made it impossible to discover the chromosome number per metaphase, though 
subjectively, many of the damaged metaphases appeared to contain more Giemsa-stained 
material than control metaphases.
The mitotic index of each of the slides made for chromosome analysis was also 
determined in a random sample of >1000 cells/slide as shown in Table 15. The mitotic 
index is expressed as the number of cells undergoing mitosis per 1000 cells. This analysis 
of mitotic index in MNU-treated cultures shows that the mitotic index in control cultures 
and cultures treated with 0.1 and 1 pg/ml MNU (concentrations which do not induce 
nuclear enlargement) remained essentially the same throughout the 72h experimental 
period. After treatment with concentrations of MNU which did induce nuclear 
enlargement (10-500 pg/ml), however the mitotic index of the culture was affected in 
each case. At the earlier timepoints, an MNU-induced decrease in mitotic index was 
observed, whereas at the later timepoints (particularly 72h after treatment) there was a 
noticeable accumulation of metaphases. Interestingly, after treatment with 10 pg/ml where
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Fig 7 Photograph of control HeLa S3 cell metaphase chromosomes - “Diploid” cell
Fig 8  Photograph of control HeLa S3 cell metaphase chromosomes - “Polyploid’ 
cell
*  A
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Fig 9 Photograph of control HeLa S3 cell metaphase chromosomes 
Endoreduplicated chromosomes (-^)
Fig 10 Photograph of HeLa S3 cell metaphase chromosomes - 72h after treatment 
with 10 pg/ml MNU
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Fig 11 Photograph of HeLa S3 cell metaphase chromosomes - 72h after treatment 
with 10 pg/ml MNU
Chromosomes were prepared and stained from cultures of HeLa S3 cells as described in Section 3.7
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Table 15. Mitotic indices of HeLa S3 cell cultures 24,48 and 72h after a 30 
minute pulse treatment with MNU
Mitotic Index (Mitoses/1000 cells) 
Concentration MNU (pg/ml) 24h 48h 72h
0 3.33 3.81 2.43
0 .1 4.32 3.53 2.89
1 2.76 3.59 3.15
1 0 2.79 1.77 6.04
50 0.77 16.99 27.25
500 0.56 0.92 6.27
5000 0 .0 0 0 .0 0 0 .0 0
Cells were pulse treated with MNU for 30 mins then grown in control media until the timepoints shown. The 
mitotic index of at least 1000 cells was assessed on each of 3 slides for each treatment group. The data is 
expressed as the number of mitoses observed /  1000 cells,
66
nuclear enlargement was not observed until 72h post-treatment (Table 1), the increase in 
mitotic index was also not apparent until this timepoint. The highest concentration of 
MNU tested in HeLa S3 cells (5000 pg/ml) was cytotoxic to the cells resulting in no 
mitotic activity at any of the timepoints tested. This confirmed the results of the initial 
Neutral Red uptake test (see Section 4.1.1) which indicated that 5000 pg/ml MNU was a 
cytotoxic concentration.
5.1.2 DES
Experimental details
DES has previously been reported to cause an increase in cell chromosome number, using 
the concentrations used in the nuclear enlargement tests (Sawada and Ishidate, 1978). To 
confirm the aneuploidy-inducing capability of DES, chromosomes were counted in 
metaphases prepared from cultures of HeLa S3 cells treated for 48h with the 
concentrations of DES previously shown to induce nuclear enlargement (2.7, 4.0 and 5.4 
pg/ml).
Results o f chromosome preparations from DES-treated HeLa S3 cells
An increase in chromosome numbers per metaphase was seen after treatment with 2.7, 4.0 
and 5.4 pg/ml DES when 100 metaphases were analysed from each treatment group (see 
Fig 11). This increase in chromosome number was also reflected in the mean chromosome 
number per metaphase as shown in Table 16.
It can also be seen that DES induced an apparent increase in polyploidy as indicated by 
the increase in the percentage of cells with >100 chromosomes/nucleus. This however, 
cannot be definitely concluded from this data due to the small sample size. It has been 
suggested (Mitchell et al, 1995) that even for a karyotypically stable cell type, such as 
primary human lymphocyte cultures, at least 2000-4000 metaphases must be analysed for 
an accurate assessment of polyploidy induction.
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Table 16. Mean chromosome number per metaphase after 48h continuous 
treatment of HeLa S3 cells with DES.
Treatment Chromosome number/metaphase
Mean ± SE
1% DMSO 71.31 ±2.02
2.7 pg/ml DES 83.20 ± 2.92
4.0 pg/ml DES 90.82 ± 2.53
5.4 pg/ml DES 98.97 ± 2.85
HeLa S3 cells were treated with DES for 48h continuously. The number of chromosomes per metaphase 
nuclei on each of 5 slides (20 metaphases/slide) was assessed for each treatment group. All slides were 
coded prior to analysis. For calculation of mean values, cells containing >150 chromosomes were assumed 
to contain 150 chromosomes.
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5.1.3 Summary of chromosome preparation experiments
The results of chromosome preparation experiments after treatment of HeLa S3 cells with 
two carcinogens which cause nuclear enlargement in these cells gave markedly different 
results for the two carcinogens tested. DES, the non-genotoxic carcinogen induced 
aneuploidy (and possibly polyploidy) at concentrations which have been shown to cause 
nuclear enlargement. In this case therefore, the possibility still exists that the changes in 
nuclear area caused by DES were caused by alterations in DNA content within these 
nuclei.
MNU however, a potent genotoxin, caused a concentration-related increase in mitotic 
index at concentrations shown to induce nuclear enlargement. The accumulated mitoses 
which MNU induced in HeLa S3 cells, contained only badly damaged chromsomes. The 
results of the experiments with MNU therefore did not give any information on the DNA 
content of these cells.
At 10 pg/ml this increase in mitotic index was seen only at 72h and at 50 pg/ml, only at 48 and! 
j 72h. At earlier timepoints, nuclear enlargement was seen but the mitotic index was deereased. j
5.2 FLOW CYTOMETRY
As conventional chromosome counting was not possible for MNU-treated cultures, flow 
cytometry was used as an alternative method for assessing DNA content. This method has 
the advantage over cytogenetic assessment in that it allows the measurement of DNA in 
both interphase and mitotic cell nuclei.
5.2.1 MNU
5.2.1.1 HeLa S3 cells
Experimental details
Cultures of HeLa S3 were pulse treated with MNU for 30 minutes as in previous 
experiments and the DNA content of 10 000 cells from each culture was then analysed by 
PI fluorescence 24,48 and 72h later.
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Results o f flow cytometry tests
Figure 12 shows a set of histograms obtained from the FACScan analysis for one of the 
three replicate experiments. Essentially similar histograms were obtained in the other two 
experiments. The histograms of DNA content were gated electronically as outlined in 
section 3.5.2 to give approximate values for the percentage of cells in each stage of the 
cell cycle as well as the percentage of cells with a DNA content located beyond the 
Gaussian distribution of G2 (>G2). The percentages from each of the three replicate 
experiments were meaned and are shown in Table 17. Table 17 also shows the mean 
forward scatter (ESC) and side scatter (SSC) of the argon-ion laser from each treatment 
group which give an indication of cell size and granularity respectively.
Neither 0.1 nor 1 pg/ml MNU (concentrations which did not induce nuclear enlargement) 
caused any alterations in the percentages of HeLa S3 cells in the different stages of the 
cell cycle at any of the timepoints tested. However, those concentrations which caused 
nuclear enlargement in HeLa S3 cells (10-500 pg/ml MNU) caused marked alterations in 
the distribution of cells around the cell cycle. Again, as with alterations in mitotic index, 
the alterations seen in cell cycle analysis were most pronounced at the later timepoints of 
48 and 72h after treatment. A concentration-related decrease was seen in the percentage of 
cells in G/Gg of the cell cycle and a concurrent increase in the percentage of cells in 
G2+M. Little effect was seen on the percentage of cells in S phase of the cell cycle until 
72h after treatment, when concentrations of 10-500 pg/ml MNU caused a significant 
decrease in S phase cells. Concentrations of up to 500 pg/ml MNU had no statistically 
significant effect on the percentage of cells with a DNA content >G2 i.e. MNU did not 
induce significant polyploidy in HeLa S3 cells, though in some experiments a small peak 
did appear corresponding to 4n cells. This effect was neither time-related nor 
reproducible.
Measurement of FSC and SSC also indicate that treatment with 0.1 and 1 pg/ml have no 
effect on HeLa S3 cells whereas those concentrations which cause nuclear enlargement
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(10-500 pg/ml MNU) cause the cells to become progressively larger (as measured by 
FSC) and the cellular contents to become more granular (as measured by SSC). This 
increase in granularity in the cells with enlarged nuclei may well be, in part, a reflection of 
the condensed and badly damaged DNA in these cells described in Section 5.1.1.
Treatment of HeLa S3 cells with 5000 pg/ml MNU (a concentration which has been 
shown to be cytotoxic by both Neutral Red uptake and mitotic index measurement) 
caused very little changes in the distribution of cells around the cell cycle. It appears that 
(with the exception of a decrease in polyploid cells) the cells are ‘trapped’ in the stage of 
the cell cycle which they were in during treatment and that the cells then slowly die. The 
large amount of debris in the flow cytometry samples (resulting in total cell percentages 
far less than 1 0 0 ) and the significant decrease in relative cell size (as indicated by the 
reduction in FSC) indicate that cultures treated with 5000 pg/ml are probably dying.
5.2.1.2 RTE Cells
Experimental details
Cultures of RTE cells were pulse treated with MNU for 3 hours as in previous 
experiments and the DNA content of 10 000 cells from each culture was then analysed by 
PI fluorescence 24,48 and 72h later.
Results o f flow cytometry tests
Figure 13 shows a set of histograms obtained from the FACScan analysis for one of the 
three replicate experiments. Essentially similar histograms were obtained in the other two 
experiments. The histograms of DNA content were gated electronically as outlined in 
section 3 .5 .2  to give approximate values for the percentage of cells in each stage of the 
cell cycle as well as the percentage of cells with a DNA content located beyond the 
Gaussian distribution of G2 (>G2). The percentages from each of the three replicate 
experiments were meaned and are shown in Table 18. Table 18 also shows the mean 
forward scatter (FSC) and side scatter (SSC) for each sample.
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Fig 13 FACS can PI fluorescence analysis of RTF cells 48h after 3h pulse
treatment with MNU
5 M-g/ml MNU
La- ________ _
• • • I ■ > I I I I I I I 1 "I I I I I I I I I '
B  2 B B  4 B B  E B B  E B B  IB B B
CDÜ
2 B B 4 8 8 E B B B B B
500 pg/ml MNU
4 0 8 E B B B B B I B B B
Red Fluorescence 
 ^
Treated cell population 
Concurrent control cell population
RTE cells were pulse treated for 3h with with MNU, then grown in control media for 48h. 10 000 cells per 
sample were analysed on the FACScan. DNA content was determined by the fluorescence of PI.
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As with HeLa S3 cells, treatment of RTE cells with 500 pg/ml MNU caused both a 
decrease in the percentage of cells in Gg/Gj as well as an increase in the percentage of 
cells in G2+M. This change in distribution occurred after a treatment which caused a 
significant increase in nuclear area (Section 4.1.2). Unlike the situation with HeLa S3 
cells however, 500 pg/ml MNU also induced a significant increase in cells with a DNA 
content >G2 i.e. there was some evidence that MNU induced polyploidy in a small 
population of RTE cells.
Unlike the situation with HeLa S3 cells, the DNA profiles from cultures of RTE cells 
treated with concentrations of MNU which did not cause nuclear enlargement were not 
uniformly unaffected. The lowest concentration (5 pg/ml) did not cause either nuclear 
enlargement or alterations in the DNA profiles of the cultures. However, the intermediate 
concentration of 50 pg/ml MNU did not cause any nuclear enlargement (Section 4.1.2) 
but did cause significant increases in the percentage of cells in G2+M. The reason for this 
discrepancy is not clear. However, it is possible that the nuclear enlargement in RTE cells 
may be more variable than in HeLa S3 cells. Since the nuclear enlargement test was only 
carried out once in RTE cells, it is possible that on other occasions (including the 
experiments used for flow cytometry) MNU may have induced nuclear enlargement in 
RTE cells at 50 pg/ml.
5.2.2 ADM
5.2.2.1 HeLa S3 Cells
As with the nuclear enlargement tests with ADM, only HeLa S3 cells were used for flow 
cytometry tests.
Experimental details
Cultures of HeLa S3 cells were pulse treated with ADM for 30 minutes as in previous 
experiments and the DNA content of 10 000 cells from each culture was then analysed by 
PI fluorescence 24,48 and 72h later.
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Results o f flow cytometry tests
Fig 14 shows a set of histograms obtained from the FACScan analysis for one of the three 
replicate experiments. Table 19 shows the mean results from the three replicate 
experiments. A similar accumulation of cells in the G2+M phase of the cell cycle was seen 
after treatment with 2.5, 5 or 10 pg/ml ADM as was seen previously in experiments with 
MNU. In most samples treated with ADM the G] peak of the DNA histogram was 
essentially absent. Unlike the DNA histograms after treatment with MNU however, ADM 
induced a significant increase in the percentage of cells with a DNA content >G2 (i.e. 
polyploid cells). The maximum induction of polyploidy occurred 72h after pulse 
treatment with the lowest concentration of ADM (2.5 pg/ml).
5.2.3 DES
5.2.3.1 HeLa S3 cells
Experimental details
HeLa S3 cells were treated continously for 48h with the concentrations of DES found to 
induce nuclear enlargement (Section 4.3) and alterations in chromosome number (Section 
5.1.2).
Results o f flow cytometry tests
When HeLa S3 cells were treated for 48h with concentrations of 2.68, 4.03 and 5.37 
pg/ml DES dramatic effects were observed on the PI profiles of the treated cells (see Fig 
15). Both the G^/Gg and the G2+M peaks were greatly reduced with a simultaneous 
increase in the percentage of cells with a DNA content >G2 and with a DNA content <Gj 
(i.e. DNA content less than 2n). This data is shown in Table 20.
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5.2.4 Summary of flow cytometry experiments
The flow cytometry experiments with the three test carcinogens in HeLa S3 cells showed 
that the DNA profile of the cells was different after treatment with each compound.
The DNA profile of cells after 48h continuous treatment with DES bore a close 
resemblance to the changes which were seen in the nuclear area profile of these cells (and 
to some extent to the chromosome counts in these cells). DES induced both small and 
large nuclei at the same concentrations as it induced nuclei with a DNA content >G2 and 
<Gj. For this compound it appears therefore, that the changes seen in nuclear area may 
well be a result of changes in nuclear DNA content/chromosome number.
MNU and ADM both induced a shift in the DNA profile of the cells at concentrations 
which induced nuclear enlargement. In both cases, the major response was a G2 block in 
the cell cycle which is a response seen in other cell types after treatment with DNA- 
damaging agents such as x-rays and alkylating agents (Rao and Rao, 1976). ADM also 
induced a polyploid population of cells, but there was no evidence of this after MNU 
treatment. It appeared therefore that, if nuclear enlargement induced by MNU and ADM 
was due to increased DNA, this increase was primarily due to an increased proportion of 
cells in G2 cells rather than to polyploid/aneuploid cells. If a G2 block was the major 
cause of nuclear enlargement after treatment with these genotoxic carcinogens, the
question still remains I- what was actually causing the increase in nuclear size? It would
be expected that nuclei in G2 would be larger than those in Gj since they contain double 
the amount of DNA, however, it seemed unlikely that this alone would account for the 
large increase in size beyond the concurrent control population.
5.3 CELL SYNCHRONISATION
It was therefore decided to examine the nuclear area of untreated HeLa S3 cells as they 
progressed through G2 of the cell cycle. Would a population of untreated HeLa S3 cells 
which had been synchronised in G2 of the cell cycle show a similar increase in nuclear 
area to those blocked in G2 of the cell cycle as a result of DNA damage caused by MNU 
or ADM ?
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Fig 16. The ‘Double thymidine block’ technique to produce HeLa S3 cells in G2 of 
the cell cycle
25 cm  ^culture of HeLa S3 cells 
2mM Thymidine added
17h
Thymidine removed
I 9.5h
2mM thymidine added
I  14.5h
Thymidine removed (“S phase” synchronised)
6h
(“G2 phase” synchronised)
% of cells in *;
G , / G o  S G 2+ M
46.4 26.7 26.8
27.7 56.1 16.2
24.8 30.3 44.9
33.4 60.0 6.6
89.07.53.4
* All percentages were calculated using electronic gates generated from the non-synchronised control 
culture and have been ‘normalised’ so that each sample adds up to 100% (i.e. Cells <Gj and >G2 have been 
excluded).
asynchronous controls 
‘double thymidine blocked’ cells
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Experimental Details
The double thymidine block technique was used to produce a population of HeLa S3 cells 
in 25 cm  ^flasks which were synchronised in G2 of the cell cycle as described in Section 
3.8. In order to assess whether the thymidine block technique had worked as described in 
the literature, samples (one flask per timepoint) were taken throughout the 
synchronisation process for FACScan analysis of DNA content.
Coverslip cultures of HeLa S3 cells were treated alongside the flasks used to monitor the 
synchronisation process. The nuclear area in three replicate coverslip cultures was 
assessed as described in Section 3.4.2. This was done for non-synchronised control 
cultures, “S phase” synchronised cells and “G2 phase” synchronised cells.
Results o f cell synchronisation
The treatment schedule for synchronisation, together with the FACScan results used to 
verify whether the process had worked are shown in Fig 16.
After removal from the second thymidine block, HeLa S3 cells had been synchronised and 
had a DNA content which formed a single peak in the flow cytometry histogram which 
corresponded to the end of G^/early S phase in the unsynchronised control sample. 6h 
later (S phase lasts 7h in HeLa S3 cells [Rao and Johnson, 1970]) all cells had progressed 
through the cell cycle and were still synchronised in a single population now 
corresponding to G2+M of the unsynchronised control sample (89.0% of cells in G2+M).
The nuclear area of these cells which were synchronised in G2+M was compared to the 
unsynchronised population and also to the cells as they were released from the second 
thymidine block. The result from these measurements of nuclear area are shown in Table 
21.
The data show that HeLa S3 cells which had been synchronised in G2 clearly had a larger 
mean nuclear area than those from an asynchronous culture. However, the nuclear size of 
synchronised (untreated) G2 cells is restricted to the upper range of the control histogram.
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The nuclei of cells blocked in G2 by MNU or ADM were larger than nuclei of cells 
sunchronised in G2 and were enlarged well beyond the concurrent control distribution. 
This implies that factors other than DNA content contribute to the enlarged nuclei blocked 
in G2 by ADM or MNU.
5.4 MICRODENSITOMETRY
As an alternative to flow cytometry, microdensitometric analysis of DNA content was 
also investigated. This technique has the potential advantage over flow cytometry that 
cells can be viewed at the same time as measurement so that the investigator can ensure 
the same population of cells is being measured for DNA content as was measured for 
nuclear enlargement. However, microdensitometry is a very time-consuming procedure 
and therefore, only one experiment with MNU was conducted in HeLa S3 cells.
Experimental details
Cells were pulse treated for 30 min with concentrations of 0.1-5000 pg/ml. The total 
absorption at 550 nm was then measured in 150 nuclei from each treatment group after 
24, 48 and 72h as described in section 3.6.1.
Results o f microdensitometry
The results of the microdensitometry experiment with MNU in HeLa S3 cells are shown 
in Table 22.
No increase in the interphase nuclear DNA content was seen at any of the 
concentrations/timepoints tested. However, at concentrations where enlarged nuclei and 
abnormal mitoses were seen (i.e. 10-500 pg/ml MNU), the Feulgen staining was very 
faint (see Figs 16-17) and the microdensitometric measurements therefore showed an 
apparent decrease in nuclear DNA content.
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Feulgen Staining of MNU-treated HeLa S3 cells 
Fig 16 Photograph of HeLa S3 cell nuclei 48h after seeding
Fig 17 Photograph of HeLa S3 nuclei 72h after a 30 minute ‘pulse’
treatment with 10 pg/ml MNU
V
HeLa S3 cells were grown on Thermanox coverslips and stained with S ch iff s reagent as described in 
Section 3.6.
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Table 22 Microdensitometry data from HeLa S3 cells pulse-treated for 30 
minutes with MNU
MNU Timepoint Absorption / nucleus @ 550 nm Percentage of cells
(pg/ml) (h) Mean ± SE^ Median 99th percentile > control 99th percentile
0 24 4.56 ± 0.89 4.14 9.76 1.0
0.1 3.38 ±0.18 3.14 9.76 1.0
1 3.70 ± 0.28 3.63 11.26 2.0
10 4.37 ±0.18 4.57 9.26 0.7
50 4.76 ± 0.22 4.80 11.76 1.7
500 3.91 ± 0.92 4.19 7.76 0.0
5000 4.54 ± 0.74 3.94 10.76 1.7
0 48 4.35 ± 0.09 2.01 10.76 1.0
0.1 4.08 ± 0.92 2.51 12.76 2.7
1 4.54 ± 0.68 2.36 13.26 1.3
10 2.71 ± 0.38 ** 1.25 6.93 0.0
50 2.32 ± 0.87 * 1.71 7.76 0.0
500 3.43 ± 0.89 2.09 9.39 0.7
5000 4.40 ±1.04 2.44 10.26 0.7
0 72 4.43" 3.76 16.26 1.0
0.1 4.49 ± 0.40 3.87 16.26 1.0
1 4.18 ±0.55 4.29 10.39 0.0
10 3.51 ± 0.25 3.44 6.76 0.0
50 1.91 ±0.43 1.42 7.39 0.0
500 2.94 ± 0.90 2.07 11.26 0.0
5000 4.49 ± 0.27 4.14 9.76 0.0
HeLaS3 cells were pulse treated for 30 minutes with MNU, then grown in control media until the timepoints 
shown. The absorption at 550 nm was measured in 50 nuclei from each of three replicate slides, 
a All values are the mean from three replicate slides ± SD. Means were compared to the concurrent
control values using Student’s t-test. Significantly different from control * p<0.05; ** p<0.01.
b A t-test could not be performed on the 72h data, due to the loss of one of the control slides.
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The reasons for the faint Feulgen staining in the MNU-induced large nuclei are not clear,
however, there are several possibilities. As stated in Section 3.6 an optimal hydrolysis
time (as defined on control cultures) of 40 minutes in 5M hydrochloric acid was used for
all samples. It has been reported previously (Millet et al, 1982) that the hydrolysis profile
of DNA can be altered under different physiological conditions. For instance the
hydrolysis profile can be affected when cells are transcriptionally active such as
1 (IS^llet et al, 1982) |
embryonic cells, virally infected cells and malignant'cell^ It is possible that the DNA in 
the MNU-induced large nuclei may be more labile than that in control nuclei and that a 40 
minute hydrolysis time may cleave the DNA backbone rather than just unmasking the 
aldehyde groups in the DNA.
To investigate this possibility, a repeat experiment was performed using only a 72h 
sampling time and only one concentration of MNU (50 pg/ml). For comparative purposes, 
nuclear area was analysed on one slide from both treatment groups stained with 
gallocyanin-chrome alum. As expected, 50 pg/ml MNU induced a large increase in 
nuclear area (Control: 163 ± 42 pm^; 50 pg/ml MNU: 498 ± 140 pm^ ;100 cells/slide). 
The remaining slides were stained with Schiff s reagent for microdensitometric analysis 
after they were subjected to graded hydrolysis times in 5M hydrochloric acid. The 
hydrolysis times used were 5, 10, 20, 30, 40 or 50 minutes. 20 cells were chosen at 
random from each slide for microdensitometry measurement.
Fig 18 shows the hydrolysis profile of the HeLa S3 cell DNA of control cells and of the 
cells 72h after treatment with 50 pg/ml MNU for 30 minutes. The profiles are clearly 
different for the 2 cell populations. The control cells had an optimal DNA hydrolysis time 
of 40 minutes as expected from initial experiments. However, after treatment with 50 
pg/ml MNU the optimal hydrolysis time was 20 minutes. Despite this difference in 
hydrolysis profiles however, the optimal maximum absorbance per nucleus was still 
considerably less in the treated group (1.73 ± 0.90 at 20 minutes) than in the concurrent 
controls (4.90 ± 2.17 at 40 minutes).
It is also possible that the stoichiometry of the Feulgen reaction may be compromised in 
cells where the DNA has been extensively methylated as would be the case after treatment 
with MNU. To investigate this possibility, alternative stains for DNA could be assessed.
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Pilot experiments using Methyl Green as an alternative stain were not quantified due to 
poor staining of control cultures.
In conclusion, Feulgen microdensitometry did not appear to be an appropriate method for 
studying MNU-induced nuclear enlargement in HeLa S3 cells.
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6 . DISCUSSION
The results from the previous sections show that all three of the carcinogens tested had a 
marked effect on both the nuclear size and DNA content distribution of treated cells. The 
changes seen in these distributions were different for the three compounds. These results 
indicate that whilst measurement of nuclear enlargement can give an initial indication as 
to which concentrations and treatment regimens affect the cell nucleus, more in depth 
studies are necessary to determine whether or not the carcinogen in question does actually 
affect cell ploidy.
MNU, which is a classic genotoxic alkylating agent (lARC, 1987; Lijinsky, 1992), 
induced nuclear enlargement in HeLaS3 cells over a wide range of concentrations and at 
sample times of up to 72h after a 30 minute treatment. These results compare well to 
those of Grant (1978), Grant and Grasso (1978) and Agrelo (1978) who reported that 
MNU induced nuclear enlargement in HeLa S3 cells after treatment with MNU (10 pg/ml 
and above).
Analysis of the DNA content of these cells using flow cytometry indicated that the 
increase in nuclear size was accompanied by a shift in the DNA content per cell from the 
control Gaussian distribution towards an increasing proportion of cells with 4n DNA 
content. The increase in nuclear area correlates well with the increasing percentage of 
cells in G2 + M. This is indicative of an MNU-induced accumulation of cells in G2 of the 
cell cycle or in mitosis. MNU caused a marked increase in the mitotic index of HeLa S3 
cells at concentrations which induced nuclear enlargement (Table 15). The chromosomes 
in these cultures were badly damaged.
MNU also induced nuclear enlargement in RTE cells 48 and 72h after a 3h treatment. 
Again, as with HeLa S3 cells, an accumulation of cells in G2+M was also seen in RTE 
cells at concentrations which induced nuclear enlargement.
This shift in DNA profile can be explained to some extent by the increased mitotic index 
in some of the MNU-treated cultures, however this accumulation of aberrant mitoses 
clearly cannot explain all the results. The most likely explanation is that MNU induces a
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G2 block in the cell cycle, a phenomenon which has been reported in other cell types after 
treatment with alkylating agents (Rao and Rao, 1976). This association of MNU-induced 
nuclear enlargement and G2 block in vitro may well reflect the situation seen with MNU 
in the NEST assay in vivo. MNU was tested in the NEST assay and was found to induce 
significant nuclear enlargement in the epidermis of mice after treatment with 1 0  and 50 
mM (Ingram and Grasso, 1985). MNU has also been shown to induce G2 block in the 
epidermis of hairless mice after skin painting tests using 5 and 50 mg/ml (Kirkhus et al, 
1987).
Like MNU, ADM induced a concentration-dependent increase in the nuclear size of HeLa 
S3 cells which confirmed a similar finding by Lanks and Lehman (1990) in murine L929 
cells. As with MNU, the increase in nuclear area was accompanied by an increase in the 
percentage of cells in G2+M of the cell cycle. The DNA damage induced by ADM and 
other DNA-intercalating agents is known to induce a G2 block (Barlogie et al, 1976; 
Kinder et al, 1978; Konopa, 1988). Kinder et al (1978) reported that low concentrations 
of DNA intercalating agents produce an incomplete G2 block with some cells continuing 
to progress through the cell cycle. This may explain why low concentrations of ADM (0.1 
and 1 pg/ml) induced nuclear enlargement in HeLa S3 cells 24h after a 30 minute 
treatment, but had no significant effect on nuclear area at the later timepoints of 48 and 
72h.
G2 block is a response seen in many cell types which is often irreversible when caused by 
antineoplastic agents such as x- and y-irradiation, actinomycin D, bleomycin, 1,3 bis (2- 
chloroethyl)-nitrosourea, chlorozotocin, cyclohexindde, etoposide, neocarzinostatin, 
nitrogen mustard, streptozotocin, l-trans-(2-chloroethyl)-3-(4-methylcyclohexyl)-l- 
nitrosourea^ podophyllotoxin and puromycin (Tobey, 1975; Rao and Rao, 1976; Rao, 
1980; Dewey and Highfield, 1976; Maity et al, 1994). This irreversible G2 block is 
usually accompanied by extensive chromosome damage as seen in the current 
experiments with MNU in HeLa S3 cells. Other chendcal agents can also arrest cells in 
G2 in vitro such as inhibitors of RNA/protein synthesis, amino acid analogues and levels 
of intracellular cAMP. However, in most of these latter cases the G2 block is reversible.
* Whilst the cells which are irreversibly blocked in G2 of the cell cycle do not 
directly contribute to the development of carcinogenesis themselves, their presence 
indicates that the test chemical has the potential to damage DNA.
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It was hypothesised by Tobey (1975) that the G2 phase of the cell cycle serves as a 
surveillance period to eliminate and modify cells with damaged DNA. This phase is then 
extended (G2 block) if the cells contain very badly damaged DNA as is the case after 
MNU treatment. This delay in the cell cycle can, in some cases, be indefinite resulting in 
cell death or cells which are permanently converted to a non-viable state (Tsao et al,
1992). If the purpose of the G2 block is to repair damaged DNA, this may explain the 
reversal seen in the nuclear enlargement observed with low concentrations of ADM. It is 
possible that treatment with these low concentrations of ADM may cause DNA damage 
which results in a G2 block after 24h, but which has been repaired by 48h allowing the 
block to be removed and the size of the cell nuclei to return to control levels. Indeed it has 
been shown by flow cytometric analysis that HeLa S3 cells exposed to 0.1 pg/ml ADM 
for Ih accumulate in G2 of the cell cycle by 24h after treatment and that this G2 block is 
completely reversed when the cells are examined 10 days later (Kokuma, 1994).
When this hypothesis of a surveillance period was originally suggested in 1975, there was 
no direct evidence to support it. Recently, with advances in the understanding of cell cycle 
control mechanisms, more circumstantial evidence now exists to support this idea.
The mechanism which regulates the passage of cells from S phase into G2 of the cell cycle 
appears to be highly conserved amongst eukaryotes and has been extensively studied in a 
variety of organisms including Physarum, starfish, Xenopus, sea urchin, mammalian cells 
and \Schizosaccharomyces pombe\ (Nurse, 1990). The main intracellular factor required to 
induce mitosis in eukaryotic cells was first identified in early Xenopus embryos and was 
called Maturation Promoting Factor (MPF; Lohka et al, 1988). One component of MPF 
has since been shown to be a stable protein kinase (p34^^^^), the levels of which do not 
appear to vary according to the stage of the cell cycle (Murray, 1992). The other universal 
component of MPF is cyclin B which accumulates within the cell from the onset of S 
phase and binds to p34^ ^^ ^^  to form preMPF.
PreMPF is inactive and will not induce mitosis as the tyrosine 15 on p3 4 cdc2 ATP 
binding site) is phosphorylated. Subsequent removal of the phosphorylated tyrosine 
residue leads to the induction of mitosis. This post-translational modification of p3 4 cdc2 jg
I
* i.e. cells which do not die and detach from the monolayer, but which remain| 
attached and do not synthesise DNA or proteins or undergo cell division. |
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under complex physiological regulation involving many enzymes including the 
phosphatase cdc25 and the kinases weel and mikl (Maity et al, 1994).
Once the MPF is activated it brings about the various events associated with M phase by 
phosphorylation of a number of proteins. Several proteins have been shown to have been 
phosphorylated in vitro including HI histone, p40, pôO®'’^ , RNA polymerase ü, T antigen, 
elongation factor, cyclin and lamins. Phosphorylation of HI histone may be important for 
chromosome condensation, and lamin phosphorylation is thought to cause disassembly of 
the nuclear lamina which leads to nuclear envelope breakdown (Nurse, 1990; Weinert and 
Lydall, 1993). Exit from mitosis is accompanied by inactivation of the p34‘^‘^ ^^/cyclin 
complex and cyclin proteolysis.
More recently, cell-cycle checkpoints have been implicated in the control of cell division 
and may help to further explain chemically-induced G2 block (Murray, 1992; Weinert and 
Lydall, 1993). Such checkpoints detect the failure to complete DNA replication, repair or 
spindle formation and arrest the progress of the cell cycle. These checkpoints prevent 
initiation of a late event until an earlier event is complete and essentially error free. Three 
checkpoints are known to exist in eukaryotic cells. Two of these checkpoints are activated 
by DNA damage either in Gj prior to DNA replication or in G2 prior to mitosis. A third 
checkpoint can arrest cells in metaphase when microtubule function/assembly is defective 
(a checkpoint which has been made use of with demecolchine in the chromosome 
experiments with MNU and DES). It is thought that checkpoints detect e.g. DNA damage 
and then block cell cycle progression by inactivating positive controls. The molecular 
mechanisms of checkpoint control in mammalian cells remain obscure at present, though 
they have been extensively studied in yeasts where it is thought that checkpoints may 
inhibit the cell cycle by inactivating gene product(s) essential for cell cycle transitions 
(MPF and its regulators). Such a system in mammalian cells provides the basis of a 
mechanism of the “surveillance period” in G2 first proposed by Tobey (1975). If cells are 
treated with a DNA damaging agent once they have passed the G2/M “checkpoint”, cells 
continue into mitosis unabated by drug-induced damage.
The majority of work looking into molecular mechanisms of G2 block has been carried 
out with ionising radiation (Maity et al, 1994). For instance, exposure of HeLa cells to x-
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irradiation is known to induce G2 block and results in aberrant expression of cyclin B in 
these cells. The authors concluded that ionising radiation induces a division delay, at least 
in part, through down regulation of cyclin B levels at either the mRNA or protein level 
(Muschel et al, 1991).
Whilst it is known that chemical agents do not affect cells in precisely the same way as 
ionising radiation, there is also evidence that chemically-induced G2 block can be the 
result of inactivated MPF. MPF activity was monitored by measurement of 
phosphorylation of histone HI in Chinese hamster ovary (CHO) cells exposed to 
etoposide. The cells undergo a G2 arrest which is associated with inhibition of p3 4 ^^ ^^  
activity (Lock and Ross, 1990). This lack of activity was associated with a persistent 
tyrosine phosphorylation of p34^ ^^ ^^ . A similar, chemically induced G2 delay and 
persistent tyrosine phosphorylation of p34^^^2 j^ s^ been reported after camptothecin 
treatment of HeLa cells (Tsao et al, 1992) and nitrogen mustard treatment of CA46 cells 
(a human lymphoma cell line) (O’Connor et al, 1992).
In all these cases, DNA damage is associated with an inactivation of MPF and a 
subsequent block in the cell cycle at G2 . It has been suggested that this inactivation is 
achieved as a result of down regulation of the process which activates MPF (possibly at 
the level of cdc25; O’Connor et al, 1994). Whether or not cells do actually undergo DNA 
repair during this block remains to be proven. It appears likely however, that this 
mechanism of DNA damage-induced G2 block is the explanation for the change in DNA 
profile seen after pulse treatment of HeLa S3 and RTE cells with MNU. The 
accompanying extensive chromosome damage seen in the experiments with MNU has 
also been reported in other cell types following chemically-induced G2 block (Rao and 
Rao, 1976).
Recently, the role of the tumour supressor gene p53 has also been implicated in the cell 
death following G2 block caused by some antitumour agents such as Taxol (Wahl et al, 
1996) and Cisplatin (Chu, 1994). p53 is active at| jthe spindle “checkpoint” which 
ensures correct DNA replication before mitosis and has also been linked to the arrest of 
cells in Gj and induction of apoptosis (programmed cell death) after DNA damage. The 
p53 gene is the most frequently mutated gene in human cancers.
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Whilst a G2 block induced by MNU in HeLa S3 and RTE cells appears to be an 
explanation for the changes seen in the DNA profiles and chromosome abnormalities in 
these cells, this does not explain fully the increase in nuclear size seen. These experiments 
show that the enlarged nuclei are not caused by aneuploidy or polyploidy in treated HeLa 
S3 or RTE cells. The increased DNA content of cells blocked in G2 of the cell cycle was 
not an adequate explanation for the increase in nuclear size as demonstrated by the 
experiments where the nuclei of HeLa S3 cells synchronised in G2 of the cell cycle were 
measured. It therefore seems likely that some factor in the nuclei other than DNA may 
contribute to the increased nuclear size in these cells blocked in G2 following MNU 
treatment. A possible explanation for these enlarged nuclei is the ‘unbalanced’ growth 
that has been reported after treatment with several carcinogens in vitro, which leads to 
cellular enlargement (Crissman et al, 1988). In these cases, cellular proteins and RNA 
levels continue to increase in readiness for cell division in the absence of DNA replication 
and cell division. In some way, the different metabolic pathways involved become 
uncoupled resulting in this ‘unbalanced’ growth. Crissman et al (1985, 1988) have shown 
that such ‘unbalanced’ growth occurs following treatment of CHO cells with ADM and 1- 
P-D-arabinofuranosylcytosine. It may be possible to identify whether there is an increase 
in particular nuclear proteins (e.g. histones) during this unbalanced growth which leads to 
the nuclear enlargement measured in these tests.
Unlike the nuclear enlargement induced by MNU in HeLa S3 cells, ADM induced a 
significant increase in the percentage of cells with >G2 DNA content as well as inducing 
G2 block. This second peak in the DNA histograms indicates the presence of a polyploid 
cell population. It is possible that some of the cells which become blocked in G2 are 
released from this block to undergo further DNA replication without cell division. ADM 
has previously been reported to induce polyploidy in L929 cells (Lanks and Lehman, 
1990). Zucker et al (1991) showed that several different topo II inhibitors (including 
ADM, teniposide and amsacrine) induced both G2 block and >G2 polyploidy in murine 
erythroleukemic cells.
Zucker et al {\99\) hypothesised that the induction of polyploidy by these drugs may be 
due to an uncoupling of the chromosome condensation process from mitotic regulation.
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As topo n  activity correlates with a number of normal chromosome functions (e.g. 
condensation and separation at anaphase), inhibition of topo II by ADM may prevent 
chromosome condensation. It is also possible however, that this effect may be more 
indirect i.e. MPF activity may be inhibited (as discussed earlier as a possible mechanism 
of G2 block) reducing the ability of p34‘^ ^^  ^ to phosphorylate many of the proteins 
(including topo II) which need to be phosphorylated to be active in mitosis.
If ADM-treated cells were incapable of undergoing mitosis as described above, but could 
continue to synthesise DNA, this would result in the induction of polyploidy seen in the 
experiments with HeLa S3 cells. Zucker et al (1991) suggested if a cell was incapable of 
condensing chromatin but was capable of degrading cyclin B, DNA synthesis could occur 
once cyclin B levels have risen to initiate another cell cycle in the absence of chromosome 
condensation. If this hypothesis is correct it is not clear why ADM-treated cells are 
capable of DNA synthesis during a G2 block, but MNU-treated cells are not. A possible 
explanation could be that MNU treatment of HeLa S3 cells results in inhibition of both 
chromosome condensation and cyclin synthesis/degradation. It is also possible that MNU 
may cause more extensive cellular damage than ADM as it it capable of méthylation of 
cell macromolecules other than DNA.
The responses seen with DES in both nuclear enlargement and DNA measurement assays 
were unlike those seen with MNU and ADM. This is perhaps not surprising if the major 
cause of the MNU- and ADM-induced nuclear enlargement was a block in G2 of the cell 
cycle. As mentioned earlier (Section 2.5), ADM and MNU were both selected as 
examples of genotoxic agents which are known to induce mutagenic and clastogenic 
effects in cells. As such, both would cause substantial DNA damage to the treated cells 
resulting in the chain of events described above. DES however, is not a potent genotoxin 
and the effects of this compound on nuclear area and DNA profiles appear to be more 
related to the aneugenic properties of this compound.
DES induced a concentration-dependent increase in chromosome number per HeLa S3 
cell after 48h continuous treatment as reported by Sawada and Ishidate (1978). A number 
of oestrogens have been shown to cause aneuploidy in HeLa cells dating back to the initial 
work of Rao and Engelberg (1967). It has been suggested (Sakakibura et al, 1991; Sharp
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and Parry, 1985; Hartley-Asp et al, 1985) that the effect of DES on cellular chromosome 
complements may be a result of spindle damage as DBS is known to inhibit the in vitro 
polymerisation of microtubule proteins. Wheeler et al (1986) demonstrated that a number 
of other naturally occurring and synthetic oestrogens also induce aneuploidy in vitro and 
inhibit the polymerisation of tubulin.
Whilst the aneuploidy/polyploidy-inducing ability of DES is firmly established, whether 
this is causally related to its carcinogenic potential in humans and experimental animals 
remains uncertain. The most widely discussed mechanisms for DES-induced tumours 
have concentrated on the oestrogenic properties of DES as the tumours seen in humans 
occur in target tissues with high levels of oestrogen receptor (Tsutsui et al, 1983). 
Hormone-induced cell proliferation would point towards a non-genotoxic mechanism for 
the tumorigenicity of DES. The exact link however, between the oestrogenic properties of 
DES and its tumorigenicity is far from clear and several other factors (including genotoxic 
factors) have also been implicated in its mode of action. Such factors include the ability of 
DES (and its metabolites) to induce DNA adducts, sister chromatid exchange, 
unscheduled DNA synthesis and aneuploidy (Gladek and Liehr 1989; Tsutsui et al, 1983; 
Hill and Wolff, 1982; 1983)
There is little direct in vivo evidence to implicate DES-induced aneuploidy in its 
tumorigenicity though aneuploidy has been associated with premalignant alterations seen 
in DES-induced vaginal tumours observed in humans (Barrett et al, 1981). Whether such 
aneugenic events are causally-related to DES-induced tumourigenesis cannot be 
determined at present.
The concentrations of DES which caused aneuploidy in HeLa S3 cells also induced a 
marked change in the spread of nuclear areas in these cells, inducing an increase in the 
number of both small and large nuclei. These changes in nuclear area distribution 
compared very well with the changes in cellular DNA content as measured by flow 
cytometry. A similar spreading of flow cytometry DNA histograms has been shown after 
treatment of Chinese hamster V79 cells with the known aneugen nocodazole (Maier et al, 
1993). However, in the present investigations there is a discrepancy between nuclear area, 
DNA measurements and chromosome counts. In both nuclear area and flow cytometry
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graphs, although there is an increase in enlarged nuclei and > 6 2  cells there is also an 
accompanying increase in smaller nuclei and nuclei with <2n DNA content. This would 
be expected if DES was causing spindle disruption resulting in chromosome non­
disjunction. An unbalanced nuclear division resulting in a large hyperdiploid nucleus 
should also produce a small hypodiploid nucleus.
The chromosome count data from HeLa S3 cells however, appear to indicate only an 
increase in hyperdiploid, but not in hypodiploid metaphases. This is probably the result of 
the technical procedures used to make the cytogenetic preparations. The technique 
involves treating the cells with a hypotonic solution and dropping them onto microscope 
slides. This technique can result in excessive scattering and loss of some chromosomes. 
These scattered chromosomes are not usually taken into account for the analysis of 
chromosome aberrations or sister chromatid exchanges (Dulout and Natarajan, 1987). The 
technique of metaphase analysis can therefore only detect hyperdiploid cells as a 
measurement of hypodiploidy would be extremely unreliable. Danford (1984) attempted 
to overcome this problem with the use of a modified hypotonic treatment which reduces 
the frequency of scattered chromosomes. However, with the large numbers of 
chromosomes contained within HeLa S3 nuclei this technique was not suitable for the 
current work as chromosomes need to be well spread to allow counting.
Analysis of hyperdiploidy however (and possibly polyploidy) in DES-treated HeLa S3 
cells clearly shows that all three of the measured parameters (nuclear area, DNA content 
and chromosome number) are closely related for this compound.
In conclusion, the changes in nuclear area induced by treatment of HeLa S3 cells with 
DES were paralleled by changes in both chromosome number and DNA content 
(aneuploidy and possible polyploidy). In this respect, the results obtained with DES (a 
carcinogen of questionable genotoxicity) were unlike those obtained with MNU (a potent 
genotoxic carcinogen) where nuclear enlargement appeared to be the result of a block in 
the cell cycle. The conditions under which these DES-induced changes occurred were 
very specific (i.e. 48h continuous treatment with a narrow concentration range of DES), a 
feature that was not present in the MNU-induced nuclear changes, but has been reported 
previously when studying aneugenic compounds in vitro (Maier et al, 1993)
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6.1 Summary of in vitro investigations into carcinogen-induced nuclear
enlargement
Carcinogen-induced nuclear enlargement has been reported both in vitro and in vivo, but 
the mechanism, and whether it is causally related to carcinogenesis, has not yet been 
established. In order to obtain some insight into potential mechanisms of carcinogen- 
induced nuclear enlargement, several in vitro models were investigated (HeLa S3 cells, 
RTE cells and HK cells). Of the cell types used, culture of HeLa S3 cells produced the 
most consistent model for carcinogen-induced nuclear enlargement and was therefore 
used to investigate potential mechanisms for this enlargement.
Induction of nuclear enlargement and increased DNA content in HeLa S3 cells by the two 
genotoxic carcinogens, MNU and ADM, was compared with the effects induced by DES, 
which is arguably a non-genotoxic carcinogen, but is known to induce polyploidy. MNU 
and ADM both induced a concentration-related increase in nuclear size 24 to 72h after a 
30 minute pulse treatment. This was accompanied by an increase in the proportions of 
cells in the G2+M stage of the cell cycle, possibly due to G2 block which is a well- 
documented cellular response to DNA damage. There was some evidence of polyploidy 
induction with ADM, but not with MNU. The distributions of nuclear areas indicated that 
increases in ploidy contributed to, but did not totally account for, the nuclear enlargement. 
In contrast, DES increased the range of nuclear areas and DNA content, to both less than 
and greater than that of control cells, but only after a prolonged exposure period of 48h. 
These data were consistent with DES inducing spindle damage.
These results demonstrate that carcinogen-induced nuclear enlargement is only partially 
explained by increased nuclear DNA content, and that the underlying mechanism of 
nuclear enlargement can differ between chemicals.
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PART II - The use of in vitro models to study hepatotoxicity
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7. INTRODUCTION
7.1 The susceptibility of the liver to toxic insult
The liver is one of the most commonly affected target organs in the toxicity testing of 
xenobiotics (Timbrell, 1986). After oral or intraperitoneal administration of a test 
compound to an animal, the liver is exposed to high concentrations of the xenobiotic prior 
to its dilution in the systemic circulation, due to its complex blood supply. 75% of the 
blood received by the liver is poorly oxygenated blood from the hepatic portal vein which 
contains high levels of nutrients and potentially toxic compounds absorbed from the 
gastrointestinal tract (Fry and Bridges, 1979). The remaining 25% of the blood received 
by the liver is well oxygenated blood from the hepatic artery.
The liver is particularly susceptible to damage due to the very high levels of metabolising 
enzyme activity within the organ. Many organic xenobiotics are lipid soluble. To allow 
these agents to be excreted in the urine, the metabolising systems within the liver make 
such molecules more polar and hence water soluble. The metabolism of a compound in 
this way can have a marked effect on its toxicity: it can become less toxic, it can be made 
into a more toxic intermediate which is then subsequently detoxified or the metabolism in 
the liver may in fact create a more toxic metabolite of the parent compound (Douidar et 
al, 1992). Much of the pathology associated with hepatotoxins reflects this central role of 
the liver in xenobiotic metabolism.
The metabolism of xenobiotics in the liver can be divided into phase I and phase II 
reactions. Phase I reactions involve making compounds more polar by oxidation, 
reduction or hydrolysis and involve a variety of enzymes. Amongst these 
biotransformation enzymes are the cytochromes P450 (P450; also known as mixed 
function oxidase) which are located in the endoplasmic reticulum. Many different 
isoforms of these enzymes exist. CYPl-3 represent P450 families which metabolise 
exogenous compounds, show overlapping substrate specificity and are often inducible by 
exogenous compounds. CYP4 and higher P450 families are involved in the metabolism of 
endogenous compounds, are often highly specific for their substrates and are usually non­
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inducible (DeLeve and Klapowitz, 1995). Other liver enzymes involved in Phase I 
metabolism include flavin-containing monooygenases, epoxide hydrolase, esterases and 
amidases, alcohol-, aldehyde-, ketone- oxidation and reduction systems.
Phase n  reactions add groups which increase molecular weight, increase water-solubility 
and in many cases inactivate toxic intermediates formed during phase I reactions. Major 
phase n  reactions include glutathione conjugation, glucuronidation, sulphation, 
acétylation and amino acid conjugation.
Chemically-induced liver injury reflects both the function and the structure of the liver 
(Timbrell, 1986). Several different systems exist for describing the complex structure of 
the liver based on either the functional unit within the liver (the hepatic acinus), or on the 
histological unit (the hepatic lobule). As most pathologists examining histological 
sections of liver tend to use the second of these two nomenclatures this will be used for 
the rest of this report. The liver can be divided into three main “regions”:
1. Centrilobular (i.e. those cells surrounding branches of the terminal hepatic vein).
2. Periportal (i.e. those cells surrounding portal triads which contain branches of the 
hepatic artery, hepatic portal vein and bile duct).
3. Midzonal (i.e. cells between the centrilobular and periportal regions).
The use of this nomenclature to define regions of the liver can be useful in helping to 
understand mechanisms of hepatotoxicity. The periportal regions of the liver contain the 
highest concentrations of nutrients, oxygen, hormones and unmetabolised chemicals. 
These regions also have high levels of glycogen synthesis, mitochondrial activity and 
protein synthesis. Conversely, centrilobular regions of the liver have lower levels of 
glycogen and protein synthesis and receive lower concentrations of oxygen and nutrients. 
However, most important to toxicology, centrilobular regions of the liver contain the 
highest levels of biotransformation (and in particular cytochrome P450) enzymes. Many 
compounds which exert their toxicity after metabolic activation will tend to cause toxicity 
in centrilobular regions of the liver.
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7.2 Hepatotoxicity observed in vivo
The major cells in the liver are parenchymal cells known as hepatocytes. In the rat, 
hepatocytes account for approximately 60% of the cells in the liver, however, this 
percentage increases to over 90% when calculated as percentage volume. In man, the 
percentage is still higher (84% by number) (Fry and Bridges, 1979). Hepatocytes are 
usually the primary t^get cells for hepatotoxins in vivo (with the exceptions of bile duct 
lesions and necrosis of the reticulo-endothelial cells). Any damage caused is usually the 
result of alterations in hepatocyte biochemistry or in the secretion of bile (Timbrell, 1986).
A number of distinct pathological processes are involved in what is called, in general 
terms, “hepatotoxicity” (Plaa, 1986). The final lesion observed in histological sections of 
the liver at the end of in vivo toxicology studies depends not only on the compound under 
test, but also on the route and length of exposure. Table 23 is a summary of the major 
lesions which are commonly observed after treatment of experimental animals with 
hepatotoxins.
The cellular and organ effects listed in Table 23 can be described as tertiary toxic effects 
(Timbrell, 1986) which are the end result of the xenobiotic-induced biochemical and
functional alterations which have occurred earlier on in the toxic process. Initially, a
hepatotoxic compound (or hepatotoxic metabolite formed in the liver) can cause several 
types of direct (primary) cellular damage. These primary effects include lipid
peroxidation, covalent binding to macromolecules, changes in thiol status, enzyme 
inhibition and ischaemia. In turn, these primary effects are followed by structural and/or 
biochemical changes in the liver. These secondary effects are a consequence rather than a 
cause of the initial liver damage and can include changes in membrane 
structure/permeability, changes in the cytoskeleton, mitochondrial changes, depletion of 
ATP and other cofactors, DNA-damage, lysosome destabilisation, damage to the
endoplasmic reticulum and alterations in intracellular ion concentrations. The eventual 
tertiary consequences of the structural and biochemical lesions in the liver are then 
observed in the histopathological examination of the tissue.
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7.3 Studying hepatotoxicity in vitro
7.3.1 Models available for hepatotoxicity testing in vitro
Several in vitro systems exist for studying chemically-induced hepatotoxicity. The most 
frequently reported (Guillouzo, 1992, Balls et al, 1991) are listed below in order of 
decreasing structural complexity:
a. Isolated perfused liver.
b. Precision cut liver slices.
c. Primary hepatocyte cultures (monolayer cultures; cocultures with other, 
non-parenchymal cell types; collagen ‘sandwich’ cultures; multicellular 
spheroids).
d. Suspensions of freshly isolated hepatocytes.
e. Immortalised cell lines (e.g. hepatoma cell lines; cell lines transfected with 
cytochrome P450 cDNAs).
f. Subcellular fractions (e.g. microsomes).
The application of several of these systems to in vitro hepatotoxicity testing will be 
discussed in more detail later (Section 7.3.2). The systems used during the practical work 
reported here were primary cultures of hepatocytes and cultured liver slices. Primary 
culture of hepatocytes is probably the most widely used in vitro system for studying 
hepatotoxicity (Blaauboer et al, 1994). Cultured liver slices have become increasingly 
popular in in vitro testing since the introduction of mechanical tissue sheers in the late 
1980 s (Bach et al, 1996). These two in vitro systems are discussed in further depth 
below.
7.3.1.1 Hepatocyte cultures
As hepatocytes are the most commonly affected cell type in the liver in toxicology studies 
(See section 7.2), the most frequently used in vitro systems for investigating 
hepatotoxicity have involved hepatocytes. These can be isolated from the livers of both 
experimental animals and humans using perfusion with collagenase (Seglen 1973). 
Freshly isolated hepatocytes have several advantages over other in vitro liver models (e.g. 
liver cell lines) since they have a close functional similarity to the in vivo state. The drug 
metabolising capacity (both phase I and phase II) is similar to that of the intact liver 
(McQueen et al, 1990). The fact that a homogeneous suspension of hepatocytes can be 
used and that several different endpoints can be measured from one suspension makes
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their use attractive for in vitro hepatotoxicity testing (Guillouzo, 1992). However, the 
major drawback of using freshly isolated hepatocyte suspensions is that they are viable for 
no longer than 5-6h and are therefore of practical use for only short term, acute toxicity 
studies (Guguen-Guillouzo et al, 1988).
The longevity of isolated hepatocytes can be greatly increased by allowing the cells to 
attach to tissue culture plastic to form monolayer cultures. Attachment and cell functions 
are greatly improved if the cells are cultured on a coated substratum, e.g. collagen, 
fibronectin or Matrigel®-coating. Fresh monolayer cultures of hepatocytes combine the 
advantages of an in vitro system with many of the properties of the intact liver in terms of 
both phase I and phase II reactions (Moldeus, 1978; Guguen-Guillouzo et al, 1988). As 
adult rat hepatocytes can survive for up to 2  weeks when cultured in this way, they 
therefore provide an excellent in vitro model system for longer-term studies. The major 
limitation of such cultures however, is that they dedifferentiate with time in culture and 
lose Imany of their liver-specific functions. For example, the P450 content of monolayer 
cultures declines rapidly during the first 24h of culture with levels falling to 
approximately 50% of the in vivo levels during the first 24-48h, though different 
cytochrome P450 isoenzymes are affected at different rates (Paine and Hockin, 1982; 
Guillouzo, 1992). A large amount of research has focussed on possible ways of 
overcoming the problem of dedifferentiation of hepatocytes in vitro (e.g. Davilla et al, 
1991; Guillouzo et al, 1990; * LeCluyse et al, 1996). Much of this research has 
concentrated on the composition of the culture medium and the substrata used for cell 
attachment. Most recently the influence of cell shape, cell-cell interactions, extracellular 
matrix and polarity have been suggested as critical for the maintenance of liver-specific 
functions (LeCluyse et al, 1996).
7.3.1.2 Liver Slice Cultures
The second model for testing hepatotoxicity in vitro that has gained popularity over recent 
years uses precision cut slices of whole liver. Tissue explants such as liver slices have 
several potential advantages over cell culture (Bach et al, 1996). A major advantage over 
conventional cell culture is the maintenance of a higher level of tissue architecture which 
may better reflect the response of the target organ. In the case of the liver, the
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microarchitecture of the liver lobules is maintained in liver slices, whereas hepatocyte 
cultures contain a homogenous mix of periportal, midzonal and centrilobular hepatocytes. 
Liver slices also contain not only hepatocytes, but all other cell types which are present in 
the liver in vivo (Kupffer cells, Ito cells, bile duct epithelial cells etc.). This may be of 
importance in studying the toxicity of some hepatotoxins in vitro. For instance, it has been 
suggested that the hepatotoxicity caused by diethyl dithiocarbamate may involve both the 
hepatocyte and the Kupffer cell (Ishiyama et al, 1995). Preparation of liver slices, unlike 
hepatocyte cultures does not require the use of a proteolytic enzyme (collagenase) which 
may help to maintain near-to-normal cell/cell and cell/matrix interactions.
A critical factor in the preparation and use of liver slices is the reproducible production of 
slices which are sufficiently thin to allow oxygen, nutrients and test chemicals to penetrate 
to all cells in the slice. Hand cut tissue slices vary considerably in thickness, so that results 
are not always reproducible. A major advance in the preparation of liver slices occurred 
with the invention of the Krumdieck tissue slicer, a motor-driven automated tissue slicer 
which can generate tissue slices of consistent dimensions, with minimal traumatic effects 
on the tissue (Krumdieck et al, 1983). Cylindrical cores are taken from fresh liver tissue 
and are placed into the tissue slicer where the weighted liver core is pulled across a 
rapidly oscillating razor blade. The whole system is kept in cold buffer and, once 
produced, the slices are swept away by a channelled stream of buffer for collection.
The method used to culture liver slices also has a marked influence on their viability 
during subsequent experiments. To prevent clumping of liver slices and mechanical 
damage, it has been recommended that a “dynamic culture system” is used which also 
optimises gas exposure during incubation (Smith et al, 1986; Brendel et al, 1987, 1990, 
Wright and Paine, 1992a). Slices are floated onto a wire mesh and placed into vials 
containing culture medium. These vials are then slowly rotated in a CO2 incubator to 
allow both surfaces on the slice to be exposed alternately to the gaseous and medium 
environments.
It has been reported that liver slices can be kept viable under the conditions described 
above for up to 72h (e.g. Smith et al, 1987; Brendel et al, 1987, 1990; Beamand et al,
1993). However, the levels of cytochrome P450 appear to suffer the same fate in liver
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slices as they do in cultured hepatocytes. Total levels of cellular cytochrome P450 
decrease in slices with time in culture, with different authors describing different rates of 
decline. In general, after 24h in culture, levels of total cytochrome P450 are reported not 
to exceed 50% of in vivo values (Wright and Paine, 1992b; Sipes et al, 1987).
7.3.2 The application of in vitro models to study hepatotoxins
It has been recognised that tests using hepatocyte and liver slice cultures as general pre­
screens for assessing the potential of novel, untested compounds to cause toxicity are of 
limited value if the target organ is unknown (George et al, 1996). However, once the liver 
has been identified as the target organ through conventional in vivo studies, in vitro 
techniques can provide extremely useful information for the following three main 
purposes:
1. To rank several structurally related compounds, at least one of which is associated with 
hepatotoxicity, to give an indication of which compound is likely to be the least 
hepatotoxic in vivo. This approach has been successfully used in cultured hepatocytes 
to rank the in vitro toxicity of some antihypertensive drugs (Takagi et al, 1991), 
diuretic drugs (Tolman et al, 1989) and anthracycline antibiotics (Lebot et al, 1988). 
Hoogenbaum (1991) used cultured pig hepatocytes to rank the relative toxicities of five 
antimicrobial/antiprotozoal veterinary drugs.
2. To use hepatocytes/liver slices from different toxicological species (and man) to 
investigate any potential species-specific hepatotoxicity which is common in pre- 
clinical toxicity studies. The most widely quoted example of this use for in vitro 
hepatotoxicity assays is with peroxisome proliferators. Peroxisome proliferators are a 
chemically heterogeneous class of compounds including hypolipidaemic drugs, 
plasticisers and some chlorinated hydrocarbons which are hepatocarcinogenic in 
rodents. This hepatocarcinogenicity is thought to be linked to the compounds’ ability to 
induce proliferation of peroxisomes in the livers of test animals. Using in vitro 
techniques, it was demonstrated that peroxisome proliferation is restricted to rodent 
species and does not occur in the hepatocytes of primates or humans (Lock et al, 1989, 
Elcombe 1985, Mitchell etal, 1985).
I l l
3. To determine the mechanisms of action of a known/suspect in vivo hepatotoxin using 
hepatocytes isolated from the relevant species. As individual components of a culture 
system can be subtly changed to investigate the effects on the toxicity of a compound, 
in vitro systems provide an excellent tool for mechanistic studies of hepatotoxicity 
without the confounding, extrahepatic factors e.g. Casini et al (1982) investigated 
potential mechanisms of bromobenzene-induced hepatotoxicity using cultured rat 
hepatocytes.
7.3.3 Measuring Toxicity in vitro
When an in vitro liver model has been treated with a test compound a vast number of 
indicators are available to measure the in vitro toxicity of the compound (see Table 24). 
Clearly the marker chosen will greatly affect the outcome of the tests. As mentioned in 
Section 7.2, the hepatotoxicity of most compounds in vivo is defined on the basis of 
histopathological changes in the tissue. In general, these tertiary toxicological changes 
will take days, if not weeks/months, to develop. As mentioned in Sections 7.3.1.1 and 
7.3.1.2, both hepatocyte cultures and liver slices have a finite lifespan in vitro and both 
de-differentiate with time in culture. In vitro toxicity markers therefore, must rely on the 
earlier (primary and secondary) changes (See section 7.2) which occur in the toxic 
pathway. Many of the in vitro markers which are routinely used in toxicity testing 
measure events which lead up to, or result from cell death (e.g. leakage of intracellular 
enzymes, depletion of intracellular levels of adenosine triphosphate etc.). Such 
cytotoxicity endpoints may be useful when testing compounds which are known, or are 
suspected, to cause cell death in vivo. Several authors (e.g. Guillouzo, 1992; Tyson and 
Green, 1987) have suggested that the use of markers of metabolic competence (such as 
levels of albumin secretion, gluconeogenesis, ureogenesis etc.) may be more sensitive 
indicators of hepatotoxic damage in vitro than markers of basic cytotoxicity. This belief is 
based on the assumption that many of these functional toxicity markers (often liver- 
specific markers) involve several biochemical pathways and several organelles. Damage 
to any of these would cause a measurable decrease in the chosen functional marker.
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Some authors suggest that a battery of preselected in vitro hepatotoxicity markers should 
be used to study hepatotoxins (e.g. Blaauboer et al, 1994; Walum et al, 1992). Other 
authors have chosen in vitro toxicity endpoints which are associated with the particular 
liver lesion observed in in vivo studies. For example:
1. In vitro measurement of peroxisomal palmitoyl Co A oxidation to study peroxisome 
proliferator-induced hepatotoxicity (Bieri et al, 1990).
2. In vitro measurement of bile uptake/conjugation/secretion to study agents known to 
induce cholestasis in vivo (Boelsterli et al, 1988).
3. In vitro measurement of ferrochelatase activity/porphyrin production to study 
hepatotoxins known to induce porphyrias in vivo (Brady and Lock, 1992).
7.4 Aims of current research
The current research was aimed at further investigating the relationship between in vivo 
hepatotoxicity and the choice of relevant markers for in vitro hepatotoxicity testing. Two 
separate types of hepatotoxicity were examined using in vitro models:
1. Three compounds which are well known to cause fat accumulation (steatosis) in the 
liver of experimental animals after in vivo dosing (ethionine, ethanol and valproic acid) 
were studied in rat hepatocyte cultures in vitro. Markers of cytotoxicity were measured 
together with two potential markers specifically aimed to measure intracellular 
accumulation of fat (Oil Red O staining and biochemical measurement of triglyceride).
2. Several fibrinogen receptor antagonists which have been developed by GlaxoWellcome 
Research and Development for treatment of arterial thrombosis caused a specific type 
of hepatotoxicity in the dog during in vivo preclinical toxicity tests. This hepatotoxicity 
was characterised by the occurrence of eosinophilic inclusions in the histological 
sections of liver. Liver slices and hepatocyte cultures isolated from dog liver were used 
to investigate this hepatotoxicity in vitro.
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* The chemical names of the fibrinogen receptor antagonists used were:
GR144053F : {4- [4-(4-Carbamimidoyl-phenyl)-piperazin-1 -yl] -piperidin-1 -yl} -acetic 
acid trihydrate monohydrochloride
GRl 35528C: cis-{4-[4-(4-Carbamimidoyl-phenyl)-piperazin-1 -yl]-1 -hydroxy- 
cyclohexyl}-acetic acid dihydrochloride
GR160709B: [r-(4-Carbamimidoyl-phenyl)-4'-hydroxy-[4,4']bipiperidinyl-l-yl] 
-acetic acid trihydrochloride
GR199759B: {4-[4-(2-Piperidin-4-yl-ethyl)-benzoyl]-piperidin-1 -y 1}-acetic acid 
dihydrochloride
GRl65500A: 2S-(Butane-1 -sulfonylamino)-3-[4-(4-piperidin-4-yl-butoxy)-phenyl]- 
propionic acid trifluoroacetate
GR233548C: {4-[6-(2-Piperidin-4-yl-(E)-vinyl)-1 H-indazol-3-yl]-piperidin-1 -yl} - 
acetic acid hydrochloride
8 MATERIALS AND METHODS
8.1 Chemicals
Adenosine triphosphate (disodium salt), 4-aminobenzamidine, benzamidine, bovine 
serum albumin^fraction V), carbonate/bicarbonate buffer capsules, dexamethasone, DL- 
ethionine, firefly lantern extract, glucagon, insulin from bovine pancreas, MTT (3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), neutral red solution, palmitic 
acid (sodium salt),|o-phthaldialdehydCj, reduced glutathione, valproic acid (sodium salt), 
and 2,6-xylidine were purchased from Sigma, Poole, Dorset. GR144053F, GR135528C, 
GR160709B, GR199759B, GR165500A and GR233548(f were obtained from 
GlaxoWellcome Research and Development, Ware, Herts. The Bio-Rad protein assay kit 
and bovine plasma gamma globulin standards were purchased from Bio-Rad, Hemel 
Hempstead, Herts. Williams’ E (WE) medium, heat inactivated foetal calf serum (FCS), 
Earles balanced salt solution (EBSS), gentamycin, L-glutamine and 96 well immunoplates 
were purchased from Life Technologies, Paisley, Renfrewshire. Absolute ethanol was 
obtained from Hayman Ltd, Witham, Essex and ORO from Chroma-Gesellschaft, 
Stuttgart. Collagenase A, rat tail collagen and the BCC triglyceride assay kit were 
purchased from Boehringer Mannheim, Lewis, Sussex. Peroxidase labelled anti-rat and 
anti-dog albumin antibodies were purchased from Binding Site Ltd, Birmingham. All 
Falcon® tissue culture plastic and Thermanox® coverslips were purchased from Fahrenheit, 
Milton Keynes.
All other chemicals used were obtained from either Sigma, Poole, Dorset or BDH, 
Upminster, Essex.
8.2 Hepatocyte Isolation
Livers were taken from female Charles River Wistar rats (10-12 weeks old. University of 
Hertfordshire) which had been fed and watered ad libitum. Spare liver tissue from control 
beagle dogs was taken at the end of regulatory toxicology studies (GlaxoWellcome, Ware, 
Herts).
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Hepatocytes were isolated using a two step collagenase perfusion. The two step perfusion 
technique described by Seglen (1973) for perfusion of rat liver in situ was adapted to 
allow perfusion of individual lobes of rat liver/small encapsulated pieces of dog liver. It 
has previously been reported that in situ perfusion and perfusion of isolated liver lobes 
give similar results in terms of viability and metabolic function (Green et al, 1983). The 
lobes were perfused at a constant flow rate of 1 0  ml/minute through cannulae inserted into 
vessels on the cut surface of either rat or dog liver. Initial perfusion was for 15 minutes 
with a chelating buffer [EBSS (Ca^+ and Mg^+ free) containing 0.5 mM EGTA] to 
remove the Ca^ "^  which maintains the protein structure of intercellular filaments between 
desmosomes of the tight junctions between cells. This chelating buffer was washed from 
the liver by perfusion with EBSS. Finally, the liver was perfused with EBSS containing 
2mM CaCl2 and collagenase A (0.12 U/ml for rat liver; 0.24U/ml for dog liver). After 
digestion, (20-30 minutes for rat liver; 30-40 minutes for dog liver) hepatocytes were 
suspended in WE media supplemented with 10% FCS, 2mM L-glutamine and 50 pg/ml 
gentamycin. Clumps of cells were eliminated by passing the cell suspension through 
nylon bolting cloth (Lockertex, Warrington, Cheshire; pore size 64 pm). Membrane 
integrity of freshly isolated hepatocytes was assessed using trypan blue exclusion and was 
>75%.
8.3 Hepatocyte culture and treatment
Hepatocytes were plated out at a density of 1000 viable cells/mm^ into tissue culture 
vessels (25 cm^ flasks, 6  well plates or 96 well plates dependent on the experiment) which 
had been pre-coated with rat tail collagen (50 pg/ml in PBS). Cells were allowed to attach 
at 37°C for 2h in a humidified CO2 incubator (5% C0 2 :9 5 % air) and then washed once 
with PBS to remove any dead cells. The cells were then treated with the test compound 
dissolved in WE (without FCS). One column (8  wells) in 96 well plates (200 pl/well) or 3 
flasks (5 ml/flask) were treated per data point. When cells were cultured in 6  well plates 
containing Thermanox® coverslips for microscopy, 2 ml treatment media was added to 
each well.
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8.4 Liver slice culture
10 mm cores were taken from dog liver and placed into the tissue holder of a Krumdieck 
Tissue Slicer (Alabama Research, Munford, Alabama). Slices were prepared that were in 
the region of 20-30 mg wet weight which had previously been shown to correspond to 
200-250 pm in thickness. The optimal thickness of a liver slice suitable for culture lies 
between 50-100 pm and 400-500 pm. At 50-100 pm, a large percentage of the overall 
cells are destroyed in or near the cut surface. At 400-500 pm, the cells in the centre of the 
slice become deprived of oxygen and nutrient supply, resulting in the appearance of a 
band of necrotic cells in the centre of the slice. Thus an ideal thickness where both 
architecture and oxygenation status of the cells are maintained was defined as 200-250 
pm (Brendel et al, 1987).
Each slice was floated on to a wire mesh (Locker Wire Weavers, Barnet, Hertfordshire) 
and placed into a small plastic tube containing 1.25 ml WE medium (without FCS). The 
lid of each tube contained a small hole to allow gas exchange. The tubes were then placed 
on a roller machine and rotated at 9 rpm at 37°C in a humidified CO2 incubator (5% CO2) 
for 2h to allow dead and damaged cells on the cut surfaces to be sloughed off. The wire 
meshes and slices were then washed once with PBS and transferred to new plastic tubes 
containing 1.25 ml of control or treatment media and returned to the rolling incubator. At 
the end of treatment, slices were fixed in 1 0 % neutral buffered formalin and processed 
into paraffin wax for histological sections to be made.
8.5 Neutral Red uptake tests
The methodology used for Neutral Red uptake tests was as described in section 3.9.
8.6 MTT tests
Treatment medium was removed from 96 well plates and 100 pi of WE containing 500 
pg/ml MTT was added to each well. Plates were then incubated at 37°C during which 
time the yellow, soluble MTT was converted to a blue/black insoluble formazan product 
within the hepatocytes (Supino, 1995). After 2h, medium was removed from all wells and
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the formazan product in each well was solubilised using 100 pi propan-2-ol. The 
formazan product destained from each well was then quantified spectrophotometrically at 
550 nm using a Titerteck Plus M212 plate reader (ICN Flow, Thame, Oxfordshire). To 
give an indication of the cytotoxicity induced by the test compound, the mean absorbance 
for each treatment group was expressed as a percentage of the mean concurrent control 
absorbance.
8.7 Extraction of total lipid fraction from cultured hepatocytes
Medium was removed from cells cultured in 25 cm^ flasks and the monolayer was washed 
with PBS to remove any dead cells. Cells were then scraped from the bottom of the flask 
into a final volume of 10ml ice-cold PBS. A cell pellet was then produced by 
centrifugation at 3000 rpm for 10 minutes at 4°C. The pellet was then weighed and stored 
at -70°C until extraction of lipids.
Several methods are available for extraction of lipids from tissues (Christie, 1993) 
involving a variety of solvents. The most commonly used procedure is that originally 
described by Folch et al (1957) which employs a 2:1 chloroform:methanol mixture. This 
method was adapted and refined to produce a method for extraction of total lipid from the 
hepatocyte cell pellets. Initial assessment of this technique on several replicate samples 
taken from the same control culture indicated that the method produced reproducible 
levels of triglyceride in the subsequent extract.
2 :1  chloroform:methanol (v/v) was added to the thawed cell pellet ( 2 0  pi/ mg cells), 
mixed and allowed to stand for a minimum of 30 minutes. To allow centrifugation of the 
sample, methanol was then added to the sample (20% of original volume, Folch et al, 
1957) and the sample centrifuged at 3000 rpm for 10 minutes. The solvent was then 
removed from the pellet and the chloroform:methanol ratio restored to 2:1. The pellet was 
dissolved in IM NaOH and used to determine the total protein levels in the sample (see 
section 8.10). The solvent extract was washed by addition of salt solution (0.04% MgCl2 ,
0.73% NaCl, 0.88% KCl) followed by vortex mixing and allowed to separate. The 
resulting mixture separates into two phases. The lower phase (total pure lipid; Folch et al, 
1957) was then evaporated to dryness.
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8.8 Measurement of triglyceride levels in lipid extracts
50 pi of chloroform (or in later experiments propan-2-ol, as used by Freneaux et al, 1988) 
was added to each dry lipid extract. Triglyceride levels in each sample were then 
measured using a colorimetric enzymatic assay which produces a red/pink colouration in 
the presence of triglyceride using the following reactions:
lipase
Triglyceride + HgO ^  Glycerol + Free fatty acid
glyceroklnase
Glycerol + ATP ^  Glycerol-3-phosphate (G3P) + ADP
glycerol phosphate oxidase 
G3P + Og  ^  Dihydroxyacetone phosphate + H^Og
peroxidase
HgOg + 4-chorophenol  ^  4-(p-benzoquinone-monoimmino)-phenazone
+ 4-aminophenazone + HgO + HCI
Initially this assay was performed manually as follows. 10 pi of sample was added to 1 ml 
of triglyceride assay buffer which had been pre-warmed to 37°C. Each sample was then 
incubated in duplicate at 37°C for exactly 10 minutes, mixed and the absorbance read at 
505 nm using a UV-1200 spectrophotometer. In later experiments this analysis was 
performed on a Monarch 2000 autoanalyser (Instrumentation Laboratories). All readings 
were related to a standard curve of known triglyceride concentrations (Seronorm 
standards, Nycomed, UK). All values were expressed as pmol triglyceride/mg protein.
8.9 ORO staining of hepatocytes
Staining of hepatocyte cultures with ORO was adapted from the method of Bancroft and 
Cook (1984) which is routinely used for histological specimens. Media was removed from 
the 25 cm^ flasks and cultures were washed briefly with 60% propan-2-ol. Cultures were 
then stained with filtered ORO stain (0.6 mg/ml in 60% propan-2-ol) for 10 minutes at 
room temperature followed by a brief rinse in 60% propan-2-ol and two washes in PBS. 
At this point, cultures were examined microscopically to check for the presence of red- 
stained lipid droplets. Cultures were destained at room temperature using 2 ml 60%
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propan-2-ol and the absorbance of each culture was measured at 520 nm (peak 
absorbance) using a Shimadzu UV-1200 spectrophotometer. The amount of ORO 
destained from each culture was quantified using a standard curve of ORO (5-50 pg/ml). 
The protein from each culture was dissolved in IM sodium hydroxide and measured as 
described in section 8.10. All values were then expressed as pg ORO/mg protein.
8.10 Measurement of total protein levels
All samples for protein analysis were measured using the Coomassie Blue assay 
(Bradford, 1976). This procedure is based upon staining protein with Coomassie Brilliant 
Blue G-250 where there is a shift in absorbance from 465 to 595 nm when binding to 
protein occurs in the presence of dilute acid. All samples for protein analysis were 
dissolved in IM sodium hydroxide. 10 pi of sample was added to 200 pi filtered Bio-Rad 
reagent (Bio-Rad, protein assay kit) which had been diluted 1 in 4 with distilled water. 
Absorbance at 595 nm was measured using a Titerteck Plus M212 plate reader. All 
readings were related to a protein standard curve (0 -0 .6  mg/ml bovine plasma y globulin).
8.11 Measurement of intracellular ATP and GSH levels
In some experiments, intracellular levels of adenosine triphosphate (ATP) and reduced 
glutathione (GSH) were measured in tricholoroacetic acid (TCA) extracts.
For monolayer cultures of hepatocytes, 833 pi 6.5% TCA was added to each 25 cm^ flask 
and shaken at 4°C for 30 minutes. The TCA extract was then frozen at -80°C prior to 
analysis and the monolayer dissolved in IM sodium hydroxide for analysis of protein 
content (see Section 8.10). Liver slices were homogenised in 1 ml ice cold 6.5% TCA 
using an UltraTurrax homogeniser (Sartorius Ltd, Epsom, Surrey). Following 
centrifugation (1000 rpm, 10 min, 4°C) the supernatant (TCA extract) was frozen at - 
80°C prior to analysis and the remaining pellet dissolved in IM sodium hydroxide for 
analysis of protein content (see Section 8.10).
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8.11.1 Measurement of ATP
A luminometric assay was used in which ATP is measured by the intensity of light 
emitted from the firefly luciferin-luciferase system after adding a small quantity of cell 
extract (Kimmich et al, 1975). Light is emitted as a consequence of the oxidative 
decarboxylation of luciferin (Lundin et al, 1976). 10 pi of TCA extract (see Section 8.11) 
was added to 2 ml buffer (90 mM MgS0 .^7 H2 0 ; 10 mM KH2PO4 ; 100 mM 
Na2HAsS0 4 .7 H2 0 ). Following addition of lOOpl luciferase-firefly latem extract, the 
bioluminescence produced was measured using a Luminoskan luminometer (Labsystems, 
Basingstoke, Hampshire). All readings were related to an ATP standard curve (0 - 40 
nmol/ml). All values were expressed as nmol ATP/mg cellular protein.
8.11.2 Measurement of GSH
GSH was measured using a fluorimetric method first described by Hissin and Hilf (1976). 
75 pi of TCA extract (see Section 8.11) was added to 2775 pi buffer (13.6mg KH2PO4 ; 
1.86mg EDTA/ml in water). 150 pi of 1 mg/ml o-pthaldialdehyde was then added to give a 
final volume of 3 ml, the solution was vortex mixed and allowed to stand and room 
temperature, protected from light for 20 minutes. Each sample was analysed in duplicate. 
The fluorescence of each sample was measured using an LS30 flourimeter (Perkin Elmer, 
Beaconsfield, Buckinghamshire) with an excitation wavelength of 350 nm and an 
emission wavelength of 420 nm. All readings were related to a GSH standard curve (0 - 
32 nmol/ml). All values were expressed as nmol GSH/mg cellular protein.
8.12 Measurement of albumin secretion
In some experiments, the amount of albumin secreted by cultured hepatocytes into the 
culture medium was quantified using an enzyme linked immunosorbent assay (Dunn et al, 
1991). 120 pi of the sampled culture medium was added to 120 pi peroxidase-labelled 
anti-rat (or anti-dog) albumin antibody (diluted 1: 3500 with 0.5% v/v Tween 20:PBS). 
Samples were mixed thoroughly and 100 pi of the sample/antibody mix was added to 
duplicate wells of a 96 well immunoplate which had been pre-coated overnight at 4°C 
with rat (or dog) albumin (0.5 mg/ml in carbonate/bicarbonate buffer; pH 9.6). Plates
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were then sealed and incubated at 4°C overnight. Following thorough washing with 0.5% 
v/v Tween 20:PBS, 100 pi of substrate solution (0.4 mg/ml o-phenylenediamine; 0.12% 
v/v hydrogen peroxide; 5.25 mg/ml citric acid.H2 0 ; 7.10 mg/ml Na2HP0 4  in water) was 
added to each well. After incubation at room temperature for exactly 10 minutes, the 
reaction was stopped by addition of 50 pi 2M H2SO4 to each well. Absorbance at 492 nm 
was measured using a Titerteck Plus M212 plate reader. All readings were related to a rat 
(or dog) albumin standard curve (0-100 pg/ml). All values were expressed as pg albumin 
secreted /mg cellular protein.
8.13 Microscopy of treated hepatocyte cultures
In some experiments, in depth morphological studies were carried out on cultured 
hepatocytes. This consisted of microscopic analysis on three levels:
8.13.1 Phase contrast microscopy
Living cultures in 25 cm^ flasks were examined daily for alterations in morphology using 
phase contrast microscopy (Televal 31 inverted microscope; Zeiss, Welwyn Garden City, 
Hertfordshire).
8.13.2 Light microscopy of fixed specimens
Hepatocytes were cultured and treated on collagen-coated Thermanox ® coverslips and 
fixed in 10% neutral buffered formalin (NBF) at various timepoints during the treatment. 
Fixed monolayers were then mounted onto microscope slides and stained using 
haematoxylin and eosin. In initial experiments, some coverslips were fixed using 
ethanohacetic acid (3:1) as described in section 3.4.1. This was discontinued due to poor 
cytoplasmic preservation. To compare the morphology of hepatocytes with changes seen 
in previous in vivo experiments, slides were examined by Dr. Ruth Lightfoot, 
GlaxoWellcome, Pathology.
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8.13.3 Transmission electron microscopy (TEM)
Heaptocytes were cultured and treated on collagen-coated Thermanox ® coverslips and 
fixed in 4% formalin/1 % glutaraldehyde at various timepoints during treatment. 
Processing and analysis of these samples was carried out by Mr. John Bowles, Glaxo 
Wellcome, Electron Microscopy. Small areas were selected from each coverslip and 
processed into epon resin. Ultrathin sections (60-90 nm) of the monolayers oriented en 
face were then stained with uranyl acetate and lead citrate and examined in a Philips 
CM 10 TEM. All sections were coded to eliminate the possibility of observer bias during 
analysis.
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9. The use of in vitro models to study hepatotoxins which induce steatosis in vivo
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9.1 INTRODUCTION
9.1.1 Experimental occurrence of steatosis
The most common histological manifestation of liver toxicity seen in in vivo toxicity 
studies is steatosis (Zimmerman, 1978). Also termed “fatty change”, steatosis is a visible 
accumulation of fat in the hepatocellular cytoplasm which can be seen as soon as 3-4h 
after acute treatment. A fatty liver is defined as one that contains more than 5% lipid by 
weight (Lu, 1991). Steatosis can exhibit a zonal distribution within the liver lobule. 
Ethionine and elemental phosphorous lead to an initial accumulation of fat in the 
periportal region (Zimmerman, 1978; Waterfield et al, 1993), whereas tetracycline and 
ethanol cause centrilobular fat accumulation (Combes et at, 1972; Edmonson and Schiff, 
1975).
Steatosis can be further classified based on the appearance of the fat droplets within the 
cell. Some agents (e.g. methotrexate and ethanol) cause macrovesicular steatosis (where 
most of the fatty cells contain a large droplet of fat which displaces the nucleus). Others, 
(e.g. tetracycline and ethionine) cause microvesicular steatosis (where the hepatocyte is 
full of many tiny fat droplets that do not displace the nucleus).
There is also often an overlap between compounds which induce necrosis and those which 
induce steatosis. Whilst some compounds cause only steatosis (e.g. ethionine, orotic acid 
and hydrazine [Mori, 1983; Farber, 1967; Scales et al, 1982]), others also induce necrosis 
to a small extent (e.g. amanitine, elemental phosphorus) whilst others induce mainly 
necrosis with some associated steatosis (e.g. carbon tetrachloride, tannic acid 
[Zimmerman, 1978]).
Also, as with many other toxicological endpoints, different species can often react 
differently to steatogens. Some agents (e.g. ethionine) which produce steatosis only in 
some species (rat) can produce both necrosis and steatosis in other species (dog and rabbit 
[Farber, 1967; Wang et al, 1958]). Orotic acid on the other hand causes steatosis in only 
one species (rat) whereas other species (mouse, hamster, rabbit, guinea pig, chicken.
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monkey and man) are resistant to the effects of orotic acid (Valli et al, 1968; Kelley et al, 
1970).
9.1.2 Biological significance of steatosis
Whilst some authors regard steatosis as “amongst the most common signs of acute 
hepatotoxicity” (Hinton and Grasso, 1993) there are several problems with the 
interpretation of the relevance of steatosis in toxicology studies, as stated by Plaa (1986) 
“Can one say that excessive fat accumulation in itself is damaging ?”.
• A fatty liver does not necessarily lead to death of hepatocytes; ethionine, puromycin 
and cycloheximide all cause fat accumulation without causing necrosis.
• In most cases, the accumulation of fat in hepatocytes is a reversible lesion.
This is not to say that steatosis is of no consequence to the animal. For instance, the 
steatosis associated with a choline deficient diet eventually leads to cell death, fibrosis and 
nodular hyperplasia (Gopinath, 1991) and, after chronic exposure to ethionine, rats will 
develop coarse, nodular cirrhosis, bile duct proliferation and hepatocellular carcinomas 
(Farber, 1963).
Another problem with the interpretation of steatosis in experimental animals is that 
several factors, other than xenobiotics, can cause accumulation of fat in hepatocytes. 
These include dietary changes, deficiency of lipotropic factors, humoral mobilisation of 
fat and disturbed metabolism (Gopinath, 1991). Fat accumulation as a result of dietary 
changes tends to be periportal and microvesicular. An increase in fat in the liver following 
starvation is a particular problem in toxicity studies if treatment with the test compound 
leads to a reduction in food intake. Therefore, if a fatty liver is seen in an animal which is 
showing many signs of toxicity, it is often assumed that the steatosis is as a consequence 
of the general ill-health of the animal rather than an intrinsic property of the test 
compound.
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As with experimental animals, several disease states in humans can also lead to steatosis 
These include kwashiorkor where severe fatty change (>40%) is associated with a high 
mortality rate, though the steatosis is reversible at any stage in its progression. Severe 
obesity, diabetes mellitus and Reye’s syndrome (Heubi et al, 1987) are also associated 
with fat accumulation in the liver. Also, as would be predicted, inherited disorders of lipid 
metabolism (Tangier disease, Wolman’s disease and abetalipoproteinaemia) are 
associated with inherent steatosis (Hoyumpa et al, 1975; Illingworth et al, 1980). A rare 
disorder of unknown cause can lead to a very severe form of fatty liver during the third 
trimester of pregnancy (idiopathic fatty liver of pregnancy) which can lead to death of 
both mother and child (Grimbert et al, 1993).
Steatosis is also induced by xenobiotics in man. The most common cause of fatty liver in 
the United States is chronic alcohol consumption (Hoyumpa et al, 1975). Several 
pharmaceutical agents are also associated with steatosis which, in some cases of severe 
illness, can be one of the only histological abnormalities seen. In other cases, fat 
accumulation is one of several changes observed in the patients’ liver. Documented 
human steatogens include tetracycline (Strieker and Spoelstra, 1985), the antianginal 
agent amiodarone (Fromenty et al, 1990), methotrexate (Deboyser et al, 1992) calcium 
hopantenate (Noda et al, 1991) and valproic acid (Olson et al, 1986). More recently, 
(FDA, 1993) drug-induced microvesicular steatosis was found amongst patients with 
chronic hepatitis B infection after participation in a clinical study with the anti-viral agent 
fialuridine (FIAU).
9.1.3 Mechanisms of steatosis induction
To understand the pathogenesis of steatosis, a brief description of the passage of fat 
through the healthy liver is needed.
9.1.3.1 p-Oxidation of fatty acids
Hepatocytes can use fatty acids as a source of energy. In essence, p-oxidation of fatty 
acids involves the splitting of 2C fragments of acetyl-CoA from the end of the fatty acyl- 
CoA thioester. Each of these fragments can then enter the tricarboxylic acid cycle to be
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oxidised to CO2 and water or form ketone bodies (acetoacetate, D-p-hydroxybutyrate) 
which are then transported via the blood to the peripheral tissues.
9.1.3.2 Synthesis of triglyceride
As well as a source of energy, hepatocytes use fatty acids (and glycerol-3 -phosphate 
[G3P]) for the synthesis of triglyceride within the smooth endoplasmic reticulum. 
Formation of triglycerides removes the potentially toxic effects of excess fatty acids (e.g. 
membrane damage and enzyme inhibition). It is therefore essential that all of the enzymes 
involved in triglyceride synthesis should have a high level of activity within the cell.
The fatty acids may themselves be synthesised in the hepatocyte de novo or delivered to 
the cell from the adipose fat depots or the gut. G3P is formed in the cell during glycolysis 
and also by the phosphorylation of glycerol. The pathway by which three acyl-CoA esters 
are added to the G3P backbone is summarised in Fig 19 with the major enzymes involved 
in this pathway.
The specific long chain fatty acids (Cj^ or greater) which are incorporated into the 
triglycerides depend largely on which fatty acids are available within the cell. Some of the 
enzymes involved in the acylation process do have a degree of selectivity for fatty acid 
type. For instance, monoacyl glycerol phosphate acyl transferase is relatively selective for 
unsaturated fatty acids. However, this specificity is by no means absolute (Brindley, 
1991).
9.1.3.3 Secretion of triglyceride
Triglycerides and phospholipids are combined with apoprotein B-lOO (ApoB) in the 
hepatocyte to create very low density lipoproteins (VLDLs). ApoB behaves as an integral 
membrane protein which consists of 4536 amino acids with 13 separate lipid binding 
domains (Davis, 1991). VLDLs are globular particles of 25-75 nm which carry the 
triglycerides from the hepatocyte to the blood.
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Fig 19 Synthesis of triglyceride within the hepatocyte
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9.1.3.4 Potential mechanisms for fat accumulation in the hepatocyte
A fatty liver occurs if there is an imbalance between the rate of synthesis and the rate of 
release of triglyceride within the hepatocytes (Plaa, 1986). During steatosis, one (or 
several) of the steps involved in the processing of fat within the liver may be disturbed to 
lead to a build up of fat. At a very basic level, triglyceride can accumulate in the liver as a 
result either of an increase in the fat arriving/being produced in the liver or as a result of 
defective secretion from the cell.
9.1.4 Compounds chosen for investigations into steatosis in vitro
For studying steatosis in vitro, 3 examples of steatogens with different proposed 
mechanisms of action were investigated.
9.1.4.1 Ethionine
Ethionine is an analogue of the amino acid methionine and was first synthesised in 1938 
during investigations into methionine metabolism. Both the L and D isomers of ethionine 
cause steatosis in experimental animals, though L-ethionine is the more potent isomer. 
Many species are sensitive to ethionine-induced steatosis including the mouse, rat, guinea 
pig, pigeon, rabbit, chicken, dog, cat, monkey and human (Wang et al, 1958; Farber, 
1967; Mori, 1983). 3-4h after administration of large doses of ethionine to female rats 
( 1 0 0 0  mg/kg), fat accumulation can be seen under the electron microscope as lipid 
droplets in the smooth and rough endoplasmic reticulum of the hepatocytes. After 6-7h, 
the fat accumulation in periportal hepatocytes is visible at the light microscope level.
There is a marked sex difference in the response of rats to ethionine-induced steatosis 
(Katoh et al, 1991; Farber, 1967). In many strains, including the Wistar, jFischerj and 
Sprague-Dawley, the female is sensitive to compound-induced steatosis whilst the male is 
effectively resistant. Female rats can be rendered resistant to ethionine-induced steatosis 
by administration of androgens or by adrenalectomy.
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The mechanism by which ethionine induces steatosis in vivo has been extensively studied 
and is believed to result from impaired secretion of VLDL from the hepatocytes. 
Ethionine combines with adenosine in exactly the same way as methionine to produce 5- 
adenosylethionine. 5-adenosylmethionine then releases its methyl group by methylating 
another substrate. However, 5-adenosylethionine is unable to release its ethyl group and 
the ATP is trapped (see Fig 20). Treatment with ethionine therefore induces a reduction in 
levels of ATP within the liver. There is then a reduction in levels of protein synthesis. It 
has been suggested (Lyon and Kisilevsky, 1990) that ethionine-induced decreases in 
hepatic protein synthesis following ATP depletion may be as a result of modification to 
ribosomal subunits. Following a reduction in protein synthesis there is a consequent 
reduction in the production of the apoprotein complex which is necessary to transport 
lipid out of the liver. The result of this block is an accumulation of triglyceride within the 
hepatocytes and a decrease in plasma levels of triglyceride, cholesterol and lipoprotein 
(Timbrell, 1986; Farber, 1971). The movement of lipid from the endoplasmic reticulum to 
the golgi is also an ATP-dependent process, which explains the absence of lipid in the 
golgi of hepatocytes from rats treated with ethionine (Mori, 1983). It has been shown that 
administration of adenine to ethionine-treated rats will restore levels of protein synthesis 
(Lyon and Kilsilevsky, 1990) and that administration of ATP or adenine will prevent the 
formation of fatty liver (Farber et al, 1964).
Regarding the sex-specific effects of ethionine, it has been suggested (Katoh et al, 1991) 
that the liver oestradiol (E2) receptor is involved in the pathogenesis of ethionine-induced 
fatty liver in the rat, since the synthesis of lipoprotein is correlated with the levels of liver 
oestradiol receptors. The concentration of these receptors is greatly reduced in female rats 
by a single intraperitoneal (i.p.) injection of ethionine. This decrease in number of 
oestradiol receptors is also closely correlated with the decrease in triglyceride and VLDL 
levels in the plasma.
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Fig 20 Comparison of metabolism of methionine and ethionine in hepatocytes
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9.1.4.2 Ethanol
Ethanol is rapidly absorbed through the gut and oxidised principally in the liver. As 
mentioned earlier, ethanol is the major causative agent of steatosis in humans. The 
hepatocellular injury which chronic ethanol abuse causes in humans is multifactorial. The 
extent of liver fibrosis and consequent cirrhosis which are characteristic of alcoholic liver 
disease is dependent on factors such as nutritional status, immune injury and hepatitis C 
infection (French, 1996). A single dose of ethanol given to rats results in moderate 
accumulation of fat in the hepatocellular cytoplasm. Chronic administration to rats results 
in pronounced steatosis and in alterations to hepatic mitochondrial structure and function 
(Lieber, 1973a; 1973b).
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Although the steatosis caused by ethanol has been known for many years, the precise 
mechanism of its action is still far from clear. The major route of ethanol metabolism in 
hepatocytes is by several isozymes of the cytosolic enzyme alcohol dehydrogenase 
(ADH). Human ADH exists as at least 20 different isoforms which are encoded by at least 
7 genes. Two other enzymes involved in ethanol metabolism are catalase in peroxisomes 
(minor importance) and the microsome ethanol oxidising system (MEOS) in the 
endoplasmic reticulum. The MEOS collectively refers to the cytochromes involved in 
ethanol oxidation and in particular to cytochrome P450 2E1 which is ethanol-inducible. In 
all cases the oxidation of ethanol results in the formation of acetaldehyde, 90% of which 
is subsequently oxidised to acetate by acetaldehyde dehydrogenase (Weiner et al, 1994).
During the conversion of acetaldehyde to acetate in the liver there is an increase in the 
NADH/NAD ratio within hepatocytes. The mitochondria of hepatocytes then use these 
hydrogen equivalents resulting from the oxidation of ethanol rather than oxidising fatty 
acids. Therefore, the fatty acids which are usually the primary source of energy in the liver 
are supplanted by ethanol. This ethanol-induced depression of p-oxidation has been 
demonstrated in isolated hepatocytes, liver slices, perfused liver and in vivo. It has been 
suggested that the decrease in p-oxidation is the mechanism by which ethanol induces 
steatosis (Lieber, 1983). It has also been shown that ethanol induces an increase in the rate 
of triglyceride synthesis in cultured rat hepatocytes (as determined by thin layer 
chromatography) after treatment for 6-9h (Grunnet et al, 1985).
9.1.4.3 Valproic Acid
Valproic acid is an anticonvulsive agent which was introduced in Europe in 1968 and in 
the United States in 1978 (Kesterson et al, 1984) and is therapeutically active only at high 
plasma concentrations (>200 pM) (Olson et al, 1986). A small subpopulation of those 
patients treated with valproic acid develop severe, treatment-related steatosis, which in 
many cases can lead to death due to liver failure (Zimmerman and Ishak, 1982). The 
frequency of fatal liver injury among patients taking valproic acid has been estimated as 
high as 1 in 500 depending on factors such as age and concomitant drug therapy (Farrell, 
1994). The primary visible change in the livers of patients who die from valproic acid
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toxicity is microvesicular, periportal steatosis, occasionally with some associated necrosis. 
The steatosis is histologically very similar to that seen in Reye’s syndrome, a disease 
characterised by encephalopathy and fatty degeneration of the viscera, but the 
pathogenesis of which remains unclear (Heubi et al, 1987). The same effect can also be 
modeled in rats after a single i.p. or subcutaneous injection of valproic acid (Olson et al, 
1986; Kesterson et al, 1984; Lewis et al, 1982).
The precise mechanism by which valproic acid induces steatosis is still unresolved. 
Valproic acid is extensively metabolised in the liver. The major pathways are 
glucuronidation, mitochondrial P-oxidation and cytochrome P450-catalysed oxidation 
(Jurima-Romet et al, 1996). It has also been suggested (Rogiers et al, 1992; 1995) that 
valproic acid may also act as an inducer of cytochromes P4502B1 and P4502B2 in rat 
liver in vitro and in vivo as well as inducing a decrease in glutathione S-transferase 
activity. Kesterson et al (1984) studied the effects of valproic acid and some of its 
unsaturated metabolites in young rats and concluded that different metabolites are 
responsible for necrosis and steatosis. As with ethanol, reduced levels of p-oxidation has 
been suggested as a possible mechanism for the fat build up caused by valproic acid as 
valproate inhibits ketogenesis from palmitate (Olson et al, 1986). In the normal liver in 
the presence of fatty acids, ketogenesis from p-oxidation is 30% higher in centrilobular 
than in periportal regions of the liver lobule. This has been suggested as a possible reason 
for the periportal specificity of valproic acid-induced steatosis.
Further circumstantial evidence for this mechanism of valproate-induced steatosis comes 
from the pathological similarities to the steatosis seen in Reye’s syndrome (Strieker and 
Spoelstra, 1985). Reye’s syndrome is caused by a toxic metabolite of hypoglycin A which 
resembles 4-pentanoic acid, a powerful inhibitor of p-oxidation. A structurally similar 
compound, (2-propyl-4-pentanoic acid) is also produced as a minor metabolite during 
P450-mediated metabolism of valproic acid (See Fig 21). Kesterson et al (1984) showed 
that both 2-propyl-4-pentanoic acid and its p-oxidation product (2-propyl-(E)-2,4- 
pentadeinoic acid) induce microvesicular steatosis in rats and inhibit fatty acid P- 
oxidation. It is thought that the reactive intermediates in the metabolism of valproic acid 
are also capable of depleting mitochondrial glutathione in rat hepatocytes both in vivo and 
in vitro (Tang et al, 1995, Jurima-Romet et al, 1996).
134
Fig 21 Structure of 4-pentanoic acid and related compounds
4-Pentanoic acid
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9.1.5 Aims of current research
The most widespread approach for the investigation of steatogens in vitro has been to
study triglyceride synthesis and secretion in | hepatocyte suspensions using scintillation 
counting after exposure to ^"^C-plamitate (Deboyser et al, 1989; 1992; Gravela et al, 1977; 
1979). The same technique has also been used to study the effects of culture media 
composition (Dich et al, 1983) and species differences in fat usage by hepatocytes 
(Kleppe etal, 1988).
Whilst the measurement of triglyceride synthesis and secretion can help considerably in 
clarifying a mechanism of action of a known steatogen, a more empirical measurement of 
a compound’s steatogenic potential is to demonstrate an accumulation of fat within the 
cell as seen in vivo. For this, cultures can be stained for fat using similar histological 
techniques to those used to identify a fatty liver in vivo. The aim of the current 
investigations was therefore to examine the use of Oil Red O (ORO) staining and 
biochemical measurement of intracellular triglyceride to identify lipid accumulation in 
hepatocytes after treatment with the three test steatogens in vitro.
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ORO is a commonly used histological stain which is used to confirm the presence of 
lipids within tissues. ORO stains pnsaturatedhydrophobic lipids red and phospholipids 
pink (Bancroft and Cook, 1984).
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9.2 RESULTS
9.2.1 Cytotoxicity Tests
MTT and Neutral Red uptake tests were carried out with the three reference steatogens, 
ethanol, ethionine and valproic acid in female rat hepatocytes.
Experimental details
Monolayer cultures of hepatocytes in 96 well plates were treated for 20h with increasing 
concentrations of test compound. The top concentration selected in each case was 5000 
pg/ml as recommended in many in vitro toxicity testing protocols (e.g. Cole et al, 1990). 
Neutral Red uptake and MTT tests were carried out at the end of treatment. Two replicate 
plates were used in each experiment and each experiment was conducted on three separate 
occasions. The results of the individual experiments were pooled.
Results o f cytotoxicity tests
The results of Neutral Red uptake and MTT tests in female rat hepatocytes are shown in 
Fig 2 2 .
Hepatocytes cultured in 96 well plates were treated for 20h with 100-5000 pg/ml ethanol. 
No ethanol-induced decrease in absorbance was seen at any of the concentrations tested in 
either Neutral Red uptake, or MTT tests. When hepatocytes were treated with 100-5000 
pg/ml valproic acid however, a concentration-related decrease in absorbance was seen in 
both the Neutral Red and MTT tests. Corresponding IC50 values (the calculated 
concentration of test compound required to reduce the absorbance to 50% of the 
concurrent control value) of approximately 2850 and 3520 pg/ml valproic acid were 
obtained for the Neutral Red uptake and MTT tests respectively
After treatment for 20h with 100-5000 pg/ml ethionine, a concentration-related decrease 
in absorbance was observed in the Neutral Red uptake assay with a corresponding IC50
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Figure 22 MTT and Neutral Red test results after treatment of rat hepatocytes 
with ethanol, valproic acid or ethionine
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Hepatocytes isolated from female rats were treated for 20h with 0-5000 pg/ml of either ethionine, ethanol or 
valproic acid. At the end of the treatment period, MTT and Neutral Red tests were performed as described 
in Sections 8.6 and 3.9 respectively. In each experiment, two 96 well plates were used for each treatment (8 
wells/treatment). All results were expressed as % of concurrent control absorbances. The results shown are 
the mean ± SE of three independent experiments. Treated groups were compared to concurrent control using 
Student’s t-test. Significantly different from control *p<0.05.
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value of 2280 pg ethionine/ml. However, with the MTT test, no significant decrease in 
absorbance was observed even after treatment with 5000 pg ethionine/ml.
9.2.2 Biochemical Measurement of Triglyceride content
Intracellular triglyceride levels were measured biochemically after treatment of rat 
hepatocytes with ethanol, ethionine and valproic acid.
Experimental details
Monolayer cultures of hepatocytes in 25 cm^ flasks were treated for 20h with increasing 
concentrations of test compound. In some experiments, additional timepoints were 
included to further investigate some of the effects seen. Three concentrations of each 
compound were tested initially based on the results from the initial cytotoxicity tests. In 
some cases, further tests were conducted using different concentrations following the 
results from initial tests. Total lipid was extracted from the cultures at the end of treatment 
and the triglyceride content measured as described in Section 8 .8 . Three independent 
experiments were performed for each compound.
Results o f Biochemical Measurement o f Triglyceride content
Whilst control levels of intracellular triglyceride varied little between individual cultures 
from a particular animal, control levels of intracellular triglyceride varied markedly 
between experiments. Control levels ranged from 6.5-55.8 nmol triglyceride/mg cellular 
protein (22.6 ± 12.2, mean ± SD, n=14). Due to this inter-animal variability in control 
levels. Tables 25-27 show the results of individual experiments as well as pooled data. 
The reason for this inter-animal variability is not known, but may well be related to the 
nutritional status of the animals at the time the livers were taken.
9.2.2.1 Ethionine
When hepatocytes were treated for 20h with concentrations of 500-5000 pg/ml ethionine, 
no significant increases were seen in levels of intracellular triglyceride. In fact, a
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significant decrease in triglyceride levels was seen in some tests (See Table 25). This was 
an unexpected finding as ethionine is well documented to cause fat accumulation in 
female rat hepatocytes in vivo. To investigate whether an increase in intracellular 
triglycerides would be seen after in vitro treatment with ethionine for a longer time period, 
cultures were treated with fresh, ethionine-containing media for 4 consecutive days and 
triglyceride levels measured after 48, 72 and 96h (See Table 25). No significant increase 
was seen in levels of triglyceride at any of these timepoints, though a significant decrease 
in levels of intracellular triglyceride was seen in one experiment after treatment for 72h. 
In one of the three replicate experiments, an apparent increase in triglyceride was seen. 
However, due to the small number of replicate cultures in this experiment this data could 
not be analysed statistically. It was therefore assumed that, as this effect was not 
reproducible, it was not of biological significance.
9,22.1 Ethanol
Two series of experiments were performed with ethanol (see Table 26). Initially 
concentrations of 500, 3000 and 5000 pg/ml were used based on the findings that ethanol 
was not cytotoxic to hepatocytes (MTT and Neutral Red tests) over this concentration 
range. Measurement of levels of intracellular triglyceride showed that all three 
concentrations of ethanol induced a significant increase in triglyceride levels in each of 
three independent experiments. A further series of experiments was therefore conducted 
using lower concentrations of ethanol (5, 50 and 500 pg/ml) to define a no effect level. 
Again, in these experiments 500 pg/ml ethanol induced a reproducible, significant 
increase in levels of intracellular triglyceride whereas the lower concentrations caused no 
significant increase. 500 pg/ml was therefore defined as the lowest tested concentration of 
ethanol which induced triglyceride accumulation in cultured hepatocytes.
9.2.2.3 Valproic Acid
A similar, but less pronounced effect on intracellular triglyceride levels was observed 
after monolayers were treated for 20h with 500-5000 pg/ml valproic acid (See Table 27). 
A significant increase was seen in each of the replicate experiments, although in most 
cases there was not a good concentration-response relationship. The magnitude of the 
response
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varied markedly between animals with the maximum increase in triglyceride levels 
ranging from 131.7-300.5% of concurrent control levels.
9.2.3 Optimisation of culture conditions
From the results obtained with the three steatogens described above, the two which 
induced triglyceride accumulation in cultured hepatocytes (ethanol and valproic acid) 
caused increases which were usually in the region of 200-300% of control levels. In an 
attempt to increase the magnitude of these responses, several changes in culture 
conditions were investigated. One concentration was chosen for both ethanol and valproic 
acid which had previously been shown to induce triglyceride accumulation. Culture 
conditions were then changed to investigate what the optimal culture conditions for 
studying triglyceride accumulation would be. A longer incubation period of 48h with the 
steatogen was investigated as well as manipulation of the constituents of the culture 
media. Two alterations were looked into which have been used previously in experiments 
to study lipid metabolism in cultured hepatocytes. Firstly, palmitic acid (0.4 mM) was 
added to the culture medium as suggested by Deboyser et al (1989). Fat accumulation 
may be limited in cultured hepatocytes as the in vitro system is isolated and unable to 
draw on supplies of fatty acids from fat depots as the liver can in vivo. Addition of fatty 
acids to the culture medium as fatty acid-albumin bound solutions presents the fatty acid 
to the cell in the same form as fatty acids arrive from the fat depots in vivo. Palmitic acid 
was used as this is the precursor fatty acid made in the liver from which all other fatty 
acids are synthesised.
The inclusion of hormonal additives to the treatment media was also investigated. The use 
of hormones and other media additives to help maintain hepatocytes at closer to “m v/vo” 
metabolic activities has recently been reviewed (Skett, 1994). However, most of this work 
has focused on maintenance of the hepatocyte cytochrome P450 levels. Insulin, glucagon 
and the glucocorticoid hormones can all affect the rate of triglyceride synthesis in times of 
stress in vivo. Pittner et al (1985) showed that addition of 100 nM dexamethasone and 10 
nM glucagon to culture media increased the activity of phosphatidide phosphohydrolase 
by a factor of eight in cultured rat hepatocytes. These additives were therefore used to 
investigate their effects on the levels of triglyceride in hepatocytes following treatment 
with ethanol or valproic acid.
144
E .E
8 o
I1
a
*o
I
2f
1f
1
f
«
t
I
!
*o
(D O )
ro T3
0  0
'O
§
(lOJlUOO %) S|0A0| 0pU0OA|6ui
Ei
i l
"a
D£
H
I
2
T 3
O
g*
2  .=
u 2  2
i l
cs
+
E
.2
T3
I
2  2
I I
t!
5 i
1 î
2  [ü
•c
“ j  5
Î î l
•C
.E
a CL(U
-O «
I
IT)Tj-
R
i §s
= » I
1 1
(U 3
Experimental details
Levels of intracellular triglyceride were measured in cultured female rat hepatocytes after 
treatment for 2 0 h with 1 0 0 0  pg/ml ethanol or 1 0 0 0  pg/ml valproic acid dissolved in 
Williams’ E medium (without serum). These results were then compared to treatment for 
48h, or treatment for 20h in Williams’ E medium containing 0.4 mM palmitic acid or 100 
nM dexamethasone +10 nM glucagon.
Results o f optimisation o f culture conditions
Fig 23 shows the increases in levels of intracellular triglyceride seen in hepatocytes after 
treatment with 1 0 0 0  pg/ml ethanol or 1 0 0 0  pg/ml valproic acid under different culture 
conditions. As seen in the initial experiments, 1000 pg/ml ethanol caused approximately a 
doubling in levels of triglyceride after 20h using standard culture conditions. The 
magnitude of this effect was not increased by extending the treatment period to 48h nor by 
the addition of dexamethasone and glucagon to the culture media. Addition of palmitic 
acid caused a reproducible decrease in the magnitude of the response. Likewise, none of 
the alterations in culture conditions caused any additional increase in valproic acid- 
induced triglyceride accumulation to that observed using standard culture conditions. 
When the treatment period was extended to 48h with valproic acid, no increase in 
triglyceride above control levels was seen.
These results indicated that manipulation of the culture conditions did not increase the 
magnitude of the response seen to either of the test steatogens. Therefore all subsequent 
work with the steatogens was carried out in simple Williams’ E media without additives.
9.2.4 ORO Staining of hepatocytes
The three reference steatogens were used to investigate whether a simple staining 
technique with ORO would be useful as a rapid marker for triglyceride accumulation in 
cultured hepatocytes. Results from ORO staining were compared to those obtained using 
the conventional biochemical measurements mentioned earlier. The major advantage of
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Fig 24a Photograph of ORO-stained cultured rat hepatocytes (control) after
20h in culture
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Fig 24 Photograph of ORO-stained cultured rat hepatocytes after treatment
for 20h with 500 pg/ml ethanol.
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such a technique would be that it could be performed on one day and would not involve 
complex lipid extraction techniques.
Experimental details
Cultures of female rat hepatocytes were treated for 20h with ethanol, valproic acid and 
ethionine using the optimal culture conditions described in Section 9.2.3. The 
concentrations used for treatment were based on those used in the original experiments. 
For additional information into use of this technique in cultures of hepatocytes from other 
species, ORO staining was also carried out on cultures of female dog hepatocytes after 
treatment for 20h with 100-5000 pg/ml ethanol.
Results o f ORO staining o f hepatocytes
Fig 24 is a representative photograph of rat hepatocytes stained with ORO after 20h 
treatment with 500 pg/ml ethanol. For initial investigations into quantification of ORO 
staining, control hepatocytes were compared to hepatocytes which had been treated with 
500 pg/ml ethanol for 20h. When cultures isolated from the same animal were assayed 
using either ORO measurement or conventional biochemical triglyceride measurement, a 
comparable increase in triglyceride levels was seen using both methods (207.2% and 
226.9% of concurrent control levels, respectively).
Three independent ORO staining experiments were then performed using the three 
reference steatogens. As with biochemical measurement of triglyceride levels, ORO 
staining in control cultured varied markedly between experiments. Therefore, results of 
individual experiments as well as pooled data are shown in Tables 28-29.
Treatment of monolayers of rat hepatocytes with 100-5000 pg/ml ethanol resulted in a 
significant increase in ORO staining in two of the three replicate experiments. In these 
initial rat experiments with ethanol, all results were expressed simply as the absorbance at 
520 nm/culture rather than as pg ORO/mg protein. The correction for protein was
* Fig 24a is a representative photograph of control rat hepatocytes stained with ORO 
after 2 0 h culture.
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introduced at a later date as it was realised that this would affect the results obtained for 
cytotoxic compounds which caused cells to detach from the monolayers. It was felt 
unnecessary to repeat the ethanol experiments with correction for protein as there was no 
evidence of cell detachment even after treatment with 5000 pg/ml ethanol. The magnitude 
of the response varied between experiments as was observed previously with biochemical 
measurements of triglyceride after ethanol treatment (Section 9.2.2.2). However, the fact 
that one of the replicate experiments with ORO staining after ethanol treatment did not 
result in a significant increase in staining may indicate that the ORO technique is less 
sensitive than biochemical measurement.
One experiment was also conducted with ethanol using monolayers of dog hepatocytes. 
The results of this experiment are also shown in Table 28. As with biochemical 
measurement of triglyceride content in rat hepatocytes after treatment with ethanol, the 
maximum increase seen in ORO staining in dog hepatocytes was an approximate 
doubling.
Treatment of cultured female rat hepatocytes for 20h with 100-5000 pg/ml valproic acid 
also induced an increase in ORO staining within the cultures (see Table 29) in each of the 
three replicate experiments (though statistical significance was only achieved in two of 
the experiments). Treatment for 20h with ethionine caused a small, statistically significant 
dose-related increase in ORO staining in only one of the three replicate experiments (see 
Table 29). The other two experiments with ethionine confirmed the results obtained in the 
triglyceride measurement experiments, i.e. that ethionine did not induce an accumulation 
of triglyceride within the hepatocellular cytoplasm.
These results with ORO staining of hepatocyte cultures indicate that the staining can 
clearly give a quick visual indication of increased triglyceride content following treatment 
with a test compound. This increase can be measured using simple spectrophotometric 
analysis, however, the results obtained are not as reproducible as those obtained using 
conventional biochemical analysis of triglyceride content. The technique of ORO staining 
may therefore be applicable as a rapid screen to identify possible compound-induced 
triglyceride accumulation. Positive results could then be further investigated using 
biochemical and radiolabelled techniques.
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9.3 DISCUSSION
Simple cytotoxicity tests carried out in cultured hepatocytes showed that ethanol was not 
cytotoxic as measured by MTT reduction or Neutral Red uptake when tested at 
concentrations of up to 5000 pg/ml (equivalent to approximately 0.6 % v/v). Ethanol has 
previously been shown to be non-toxic to rat hepatocytes in vitro up to concentrations of 
39,450 pg/ml (Fautrel et al, 1991), though when very high concentrations (up to 50% v/v 
(Tapani et al, 1996) are used, ethanol has been shown to kill hepatocytes. Unlike ethanol, 
valproic acid induced concentration-dependent cytotoxicity in cultured hepatocytes using 
both the MTT and Neutral Red uptake cytotoxicity assays, a similar degree of cytotoxicity 
was measured in both assays. Valproic acid (up to 320 pg/ml) and its metabolites have 
previously been shown to induce cell death in cultured hepatocytes as measured by 
leakage of lactate dehydrogenase (Kingsley et al, 1983; Jurima-Romet et al, 1996).
The difference in the response between ethanol and valproic acid in these two cytotoxicity 
assays may reflect the different types of lesion which these two compounds induce in vivo. 
Whilst the most common liver lesion induced by valproic acid in experimental rodents is 
steatosis (Kesterson et al, 1984; Tang et al, 1995), the liver biopsies taken from patients 
affected with valproate-induced steatosis sometimes reveal accompanying necrosis. This 
ability of valproic acid to cause occasional cell death in the liver of patients at therapeutic 
levels (80 pg/ml; Kingsley et al, 1983) may explain its cytotoxicity to cultured 
hepatocytes (IC50 approximately 3000 pg/ml). Ethanol, however is not cytotoxic to 
hepatocytes up to concentrations of 5000 pg/ml following 20h treatment. In vivo, the 
steatosis induced by ethanol after acute treatment is not associated with necrotic cell death 
(although chronic treatment will lead to alcoholic fibrosis and cirrhosis of the liver 
(Lieber, 1973a; 1973b; Weiner gr <3/, 1994).
Definite conclusions as to the mode of action of a compound cannot be made solely from 
the results of simple in vitro cytotoxicity tests, as shown by the results obtained in these 
studies with ethionine. Ethionine has not been reported to induce necrosis in the liver of 
rats after in vivo treatment (Plaa, 1986), yet caused concentration-dependent cytotoxicity 
in cultured hepatocytes when Neutral Red uptake was used as the indicator of toxicity. 
When MTT reduction was used as the indicator of toxicity however, no compound-
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induced cytotoxicity was measured confirming the results of Fry et al (1993) who found 
that treatment of hepatocytes with ethionine for 24h did not cause any decrease in MTT 
reduction. The reason for this discrepancy between Neutral Red and MTT results is not 
known, although it has previously been reported that Neutral Red is often a more sensitive 
toxicity indicator in in vitro hepatotoxicity studies than MTT reduction (Peloux et al, 
1992; George et al, 1994a). It is possible that the in vitro toxicity of ethionine may 
involve lysosomes as Neutral Red uptake is a marker of lysosomal function (Borenfreund 
and Puerner, 1985). It has been shown that radiolabelled ethionine binds to isolated cell 
membranes (Dr C Waterfield, personal communication). If such binding occurs to cellular 
membranes after treatment of hepatocytes with ethionine in vitro, it is possible that this 
may effect uptake of Neutral Red through the lysosomal membrane.
As mentioned in Section 9.1.5, an aim of the current experiments was to investigate the 
usefulness of measuring intracellular lipid accumulation when studying steatogens in 
vitro. The technique of lipid staining to study fat accumulation in vitro has previously 
been succesfully used for non-quantitative assessment. ORO staining has previously been 
used to study fat accumulation seen in mixed cultures of hepatocytes with RL19 cells (an 
established hepatic cell line) (Vajta et al, 1986). No toxic agents were examined in this 
test system, but fat accumulation was demonstrated by image analysis using different sera 
in the culture media. A similar, microscope-based assay was used by Moskowitz (1967) 
where Nile Blue and Sudan Red were used to stain fat in L cells (an established mouse 
cell line) after incubation with different culture media. Steimer (1989) used Sudan Black 
to stain monolayer cultures of Madin-Darby canine kidney cells after treatment with 
gentamicin and valproic acid. The current test results with ethanol, ethionine and valproic 
acid indicated that a useful quantitation of the amount of ORO taken up by hepatocyte 
cultures can be made by destaining cultures and spectophotometric measurement. The 
absorption of ORO at 520 nm was linear over a range of 0-50 pg/ml and values obtained 
in these experiments reflected the amount of stain seen visually in the cultures. Whilst no 
literature was found regarding the stoichiometry of ORO staining of triglycerides, from 
this limited evaluation of ORO staining and biochemical measurement of intracellular 
triglyceride, it appears that both measurements generally gave comparable results.
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The results of experiments to measure the lipid content of hepatocytes (either by 
biochemical triglyceride measurement or by ORO staining for lipid) after treatment with 
the three steatogens in vitro, give some support for the need to include markers of cellular 
parameters other than those associated with cell death in the in vitro assessment of test 
compounds. The results obtained with ethanol clearly show that a compound-related 
increase in cellular lipid content occurred after treatment for 2 0 h in the absence of any 
cytotoxicity. The low levels of ethanol needed to cause this increase in intracellular lipid 
are of particular interest as there are many examples in the literature where ethanol has 
been used as a solvent in in vitro systems. Whilst its use as a solvent at levels of 1% v/v 
and below does not cause frank cytotoxicity, the current results show that its use should 
be avoided when the lipid pathways of the hepatocyte are to be studied. The low levels of 
ethanol which caused fat accumulation in hepatocytes are also relevant to the plasma
levels of ethanol which can be [achieved | in humans. It was not possible to find any
literature relating to human plasma levels of ethanol in patients with |alcohol-induced| 
steatosis. However, in the UK it is illegal to drive a motor vehicle with blood levels of 
ethanol >800 pg/ml (HMSO, 1988). It can therefore be assumed that the plasma levels 
acheived in patients with alcohol-induced steatosis exceed these levels.
Valproic acid also induced lipid accumulation in treated cells which models its 
steatogenic properties in vivo. The results with valproic acid however, were not as 
reproducible as those obtained with ethanol. It is possible that hepatocytes may need to be 
treated for a longer period in vitro with valproic acid to obtain a maximal response. 
Rogiers et al (1995) reported that hepatocytes required treatment for 7 days in vitro to 
observe maximal levels of CYP2B1/2 induction. As discussed below, the current 
investigations did not show any increase in lipid accumulation when treatment was 
extended to 48h. However, as the toxicity of valproic acid is P450-mediated, monolayer 
culture of hepatocytes is not an appropriate culture model to study its long term toxicity 
due to the dedifferentiation of the model described in Section 7.3.1.1. Rogiers et al (1995) 
used a more sophisticated in vitro culture system which has been shown to preserve 
higher levels of P450 activity (co-culture of hepatocytes with liver epithelial cells) to 
study the long term action of valproic acid in vitro. It would be interesting to investigate 
the in vitro steatogenic properties of valproic acid in this model. The toxicity of valproic 
acid may also be more readily measured in vitro if hepatocytes were isolated from the
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livers of animals which had been treated with known inducers of P450. It has been 
demonstrated in vivo that treatment of rats with phenobarbitone and other P450 inducing 
agents prior to valproic acid treatment enhances its hepatotoxicity in these animals 
(Farrell, 1994).
The maximum increase in intracellular triglyceride content after treatment with both 
ethanol and valproic acid in vitro was approximately 200% of control levels. Biochemical 
data on the levels of triglyceride which accumulate in the liver in vivo following treatment 
with both ethanol and valproic acid are rare, since the majority of papers show 
histological sections to demonstrate fat accumulation. It may be possible that the doubling 
of control levels observed in vitro may refelect a similar magnitude to that which would 
be measured in vivo. Hirosue and Hosogai (1993) treated female rats in vivo with 10% 
ethanol as drinking water. Following treatment for 4 weeks the total fatty acid content in 
the livers of treated animals was 183% of control levels. In vivo experiments with other 
steatogens however, have shown much larger increases in liver triglyceride content (e.g. 
treatment of rats with hydrazine causes an increase from approx. 5 mg triglyceride/g liver 
to approx. 50 mg triglyceride/g liver [Timbrell et al, 1982]). It was therefore decided to 
investigate whether the magnitude of the in vitro responses with ethanol and valproic acid 
could be improved.
An increase in intracellular triglyceride levels after in vitro treatment of hepatocytes with 
ethanol has been reported previously (Dich et al, 1983; Grunnet et al, 1985). These 
authors reported that the magnitude of the response over time can be increased by 
manipulation of the culture media composition. Grunnet et al (1983) showed that 
treatment of hepatocytes with 2300 pg/ml ethanol for up to 12h induced a maximum 
increase of approximately 90% in triglyceride accumulation, depending on the culture 
conditions used. Several alterations in culture conditions were therefore used in the 
current, longer-term experiments to investigate whether a larger increase in intracellular 
triglyceride could be obtained with ethanol and valproic acid treatment. Neither addition 
of hormones or palmitic acid to the treatment media increased the magnitude of the 
response measured with ethanol or valproic acid. For initial, routine assessment of 
triglyceride accumulation alongside other measurements of compound-induced toxicity, it 
would therefore seem advisable not to include any specific media additives. Unnecessary
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variations in culture media composition can make interlaboratory comparison of in vitro 
toxicity data difficult to interpret (Skett, 1994). Lengthening of the treatment time in vitro 
(48h) with ethanol and valproic acid again did not increase the magnitude of lipid 
accumulation induced by these compounds, though as mentioned earlier valproic acid may 
require even longer treatment to achieve a maximum response. Interestingly, the little 
work which has been reported on fat accumulation in cultured hepatocytes has 
concentrated on short-term treatment (12h; Dich et al, 1983; Grunnet et al, 1985). Clearly, 
treatment time with steatogens in vitro may have a marked effect on the results obtained 
and, in any future work, a range of timepoints should be included.
The potent in vivo steatogen ethionine, did not induce any reproducible effects on levels 
of intracellular lipid even when the treatment time was extended up to 4 days. This was an 
unexpected finding. It is interesting to note that no decrease was seen in levels of 
intracellular ATP in previous work with ethionine after treatment for 20h with cultures of 
male rat hepatocytes (George et al, 1994b). This again was surprising as the postulated 
mode of action by which ethionine causes its effects in vivo is by reduction in levels of 
ATP in the liver, with a consequent reduction in levels of protein synthesis and production 
of the apoprotein complex which is necessary to transport lipid out of the liver (Timbrell, 
1986). However, experiments which have measured intracellular levels of ATP in rat 
hepatocyte suspensions which have been treated for l-3h with ethionine (Dr C Waterfield, 
personal communication) or in cultured rat hepatocytes which have been treated with 
ethionine for 4h (George et al, 1994b) have shown an ethionine-induced decrease in 
ATP levels. These shorter-term exposures have therefore been able to reproduce the initial 
biochemical lesion which ethionine is known to induce in the liver in vivo. Interestingly, 
these short-term treatments also showed a decrease in levels of intracellular GSH which is 
also seen in rat liver after in vivo treatment with ethionine (Glaser and Mager, 1974). 
Thus, the immediate short-term biochemical effects of ethionine in the liver can be 
modelled in vitro, however it would appear that these biochemical changes are not carried 
through to accumulation of triglyceride.
This discrepancy between the in vitro and in vivo findings with ethionine remains to be 
explained. The possibility that when ethionine is dissolved in culture media it cannot enter 
the hepatocytes m vitro seems unlikely due to the reproducible concentration-dependent
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cytotoxicity seen in the Neutral Red uptake tests at 20h and the early intracellular 
biochemical changes. As mentioned in Section 9.1.4.1, it has been proposed that 
oestrogen receptors in hepatocytes are involved in ethionine-induced steatosis (Katoh et 
al, 1991). If this is true, it could be possible that these receptors are damaged during 
collagenase isolation of hepatocytes so that the full toxic effects of ethionine in vivo 
cannot be measured in the in vitro system. It is also possible, as mentioned above, that the 
culture conditions used in the current investigations may be sub-optimal and that other 
factors may be needed in the culture medium to more closely mimic the in vivo situation.
One feature of both the ORO results and the biochemical measurement of triglyceride 
content was the large inter-experimental variability and the lack of a reproducible 
concentration-response curve in the results obtained. Whilst inter-culture variation in 
levels of lipid within a single experiment was usually relatively small, the levels of 
triglyceride in control cultures varied markedly between experiments. This is not 
surprising as the work was conducted with primary material and, as mentioned in Section 
9 .1 .2 , levels of liver lipids can vary from animal to animal depending on their hormonal 
status, time of last feeding etc. However, the inter-experimental variability was also 
noticeable in the magnitude of the response to the test compounds. For instance, the 
maximum increase in triglyceride levels after treatment with valproic acid in one 
experiment was 300.5% of control levels whereas in a replicate experiment with cultures 
derived from a different animal the maximum increase obtained was only 131.7% of 
control levels. Again, inter-animal variations in extrahepatic factors may go part way to 
explaining these differences and indeed, valproic acid only causes steatosis in a small 
proportion of the human patient population treated with the drug (Zimmerman and Ishak, 
1982). It is a common observation in in vivo toxicity studies that, at the same dose level of 
test compound, some animals may develop steatosis whereas others remain apparently 
unaffected. For instance, 48h after intraperitoneal administration of ethionine to male rats, 
the response (in terms of increased total liver lipid) was highly variable, with some 
animals showing a moderate response whilst others showed little or no increase. In this 
case, the inter-animal differences were shown to be due to the hormonal status of the 
animals (Farber, 1967). The status of the liver of the donor animal has also been shown to 
influence the cytotoxicity of valproic acid in cultured hepatocytes. Its toxicity can be 
increased if the animals are first pre-treated with inducers of cytochrome P450 (Jurima-
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Romet et al, 1996). This interanimal variability is an inevitable consequence of using 
primary cultures and highlights the need for more than one repeat experiment in in vitro 
toxicity studies.
The results of these initial investigations with ORO staining indicate that similar results 
were obtained after treatment with three test compounds regardless of the method of lipid 
measurement (with the exception of one positive test with ethionine seen only with ORO 
staining). The use of ORO staining is considerably quicker than measurement of 
intracellular triglycerides, and is therefore appropriate as an initial assessment of lipid 
accumulation in cultured hepatocytes. However, its use as a quantitative measurement of 
lipid content does not provide any additional information than the more conventional 
biochemical analysis of triglyceride content. The inclusion of a measurement of lipid 
accumulation provides additional information on the action of some hepatotoxins (e.g. 
ethanol and valproic acid) which cause steatosis in vivo which is not provided by 
conventional cytotoxicity markers. It therefore seems wise to recommend that ORO 
staining is used as rapid initial screen for steatogens in vitro and that any positive results 
are followed up with biochemical analysis of intracellular triglyceride content at several 
different timepoints.
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10 In vitro investigations into fibrinogen receptor antagonist-induced 
hepatotoxicity
159
10.1 Introduction
10.1.1 Hepatotoxicity with GR144053
GR144053 (see Fig 25 for structure) is a fibrinogen receptor antagonist (FRA) which was 
in development by GlaxoWellcome Research and Development for treatment of arterial 
thrombosis. During its preclinical toxicity assessment, it became apparent that GR144053 
caused hepatotoxicity in experimental animals.
Fig 25 Structure of GR144053.
(GR144053F is the number assigned to the hydrochloride salt of GR 144053)
O
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In order to register a pharmaceutical agent for use in man, its toxicity must be assessed in 
a rodent and a non-rodent (Scales and Mahoney, 1991). The concept of toxicity testing in 
two species is that it increases the likelihood of detecting adverse toxicity which may be 
relevant to human exposure (Parkinson, 1993). The non-rodent for which toxicologists 
have the most background information and which is routinely used for regulatory toxicity 
studies is the beagle dog (Parkinson and Grasso, 1993). A complete toxicological profile 
of GR 144053 in the dog was never completed due to the severe toxicity observed with 
this compound in initial studies.
One of the first repeat-dose toxicology studies which is routinely carried out at 
GlaxoWellcome is designed to define the maximum repeatable dose (MRD) which will be 
used in future chronic toxicology studies. The dose of compound administered to a small 
number of animals is increased incrementally until a maximum dose is reached, beyond 
which the toxicity of the compound would excessively distort the animal model (Wilson,
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1993). In the initial MRD study, GR144053 was administered intravenously (i.v.) to 2 
dogs. This MRD study was not completed due to unexpected severe clinical signs of 
toxicity which were noted in one dog following administration of 30 mg/kg GR 144053. 
These clinical signs were accompanied by a loss of appetite and bodyweight loss became 
apparent following cessation of dosing. Amongst the histological changes seen in these 
animals, the liver was affected with lesions comprising marked centrilobular lipid 
vacuolation and single cell necrosis.
As the initial MRD study with GR144053 showed marked hepatotoxicity, two further i.v. 
studies were performed in order to find a dose of GR144053 that did not produce any liver 
effects. However, similar effects were noted in both of these subsequent studies, notably a 
reduction in bodyweight or bodyweight gain following cessation of dosing. Marked liver 
changes were apparent at all dose levels tested (1 mg/kg GR144053 and above). These 
changes consisted of centrilobular lipid vacuolation, fibrosis, cellular necrosis and the 
presence of eosinophilic inclusions within the hepatocellular cytoplasm.
As a result of this hepatotoxicity associated with GR144053F which occurred at low 
doses thought to be relevant to potential human exposure, development of this compound 
as a potential treatment for arterial thrombosis was terminated.
10.1.2 Hepatotoxicity with subsequent FRAs
The development of subsequent FRAs by GlaxoWellcome Research and Development has 
also been affected by the occurrence of hepatotoxicity during toxicological evaluation in 
the dog. This hepatotoxicity however, is not associated with all FRAs. Of those examined 
in the dog to date, 5 (GR144053, GR135528, GR144358, GR160709 and GR177606) 
have caused hepatotoxicity in the dog, in each case this hepatotoxicity was characterised 
by the occurrence of cytoplasmic eosinophilic inclusions. When the work in this thesis 
commenced, the exact nature of these inclusions was unclear. Other FRAs (e.g. 
GR165500, GR188633 and GR199759) have not be associated with any hepatotoxicity in 
the dog.
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10.1.3 Aims of Current Research
If the occurrence of hepatotoxicity in the dog following treatment with FRAs could be 
predicted using in vitro models, the use of such a model would have considerable benefits 
over the detection of this toxicity in the whole animal in vivo. If hepatotoxic FRAs could 
be screened out using an in vitro model prior to in vivo investigations, this would prevent 
dogs from being exposed to compounds which severely affect their health. An in vitro 
model would use considerably less compound to detect FRA-induced hepatotoxicity than 
repeat dose administation to animals which is expensive and extremely compound­
consuming.
It was decided therefore to attempt to develop an in vitro model that could predict the in 
vivo hepatotoxicity observed with GR144053F and other FRAs in the dog.
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10.2 RESULTS
10.2.1 Initial in vitro investigations into GR144053F induced hepatotoxicity
Experimental details
InanimtiM study to identify suitable markers to study the toxicity of GR144053F in vitro, 
both dog liver slices and dog hepatocyte cultures were examined. Hepatocytes and liver 
slices were prepared from the same animal and were treated with only one, high 
concentration of GR144053F (5000 pg/ml). A number of toxicity markers were then 
measured to investigate whether any would be particularly suitable for studying 
GR144053F-induced toxicity. The markers used were: morphological assessment, 
reduced glutathione (GSH) content, adenosine triphosphate (ATP) content, total cellular 
protein (hepatocyte cultures only), albumin secretion and triglyceride content. Additional 
cultures were treated with ‘positive control’ solutions ( 1 0 0 0  pg/ml 2 ,6 -xylidine or 1 0 0 0  
pg/ml ethanol). 2,6-xylidine is hepatotoxic in dogs following in vivo treatment (Short et 
al, 1989) and has been shown previously to cause toxicity in cultured dog hepatocytes 
(George et al, 1994b). Ethanol treatment was included as a positive control for 
triglyceride measurement.
Hepatocyte cultures and liver slices were treated for 20h with GR144053F. In addition, 
hepatocyte cultures were treated continually for 3 days with GR144053F (media changed 
every day) to investigate any evidence of delayed toxicity. It was not possible to treat liver 
slices for any longer than 2 0 h due to the appearance of necrotic cells within the centre of 
slices. This necrotic band of cells was accompanied by a general loss of viability in the 
slices by 20h as indicated by a large decrease in intracellular levels of ATP and GSH.
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Results o f initial in vitro hepatotoxicity tests
10.2.1.1 Liver slices
The results of treating dog liver slices (initial weight 25.1 ±1.3 mg) for 20h with 5000 
pg/ml GR144053F and 1000 pg/ml 2,6-xylidine are shown in Table 30. GR144053F did 
not induce any large reduction in ATP or GSH content but did cause a decrease in levels 
of albumin secretion to 58.4% of the concurrent control level after treatment for 20h. 2,6- 
xylidine induced a decrease in levels of GSH, ATP and albumin secretion (22.8, 55.5 and 
56.7 % of concurrent control values respectively). Levels of triglyceride could not be 
measured in liver slices as the samples were resistant to homogenisation in 
chloroform: methanol.
When histological sections from slices at the end of treatment were examined, control 
slices showed generally good preservation of architecture and morphology. Hepatocytes in 
these slices however showed some cytoplasmic eosinophilia and loss of definition, and 
loss of nuclear chromatin definition. Necrotic cells were present around the periphery of 
slices and as a thin band through the centre of the slice (see Fig 26). However, after 
treatment with GR144053F the histology of treated slices was not discemibly different 
from that of control slices. After treatment for 20h with 2,6-xylidine, large areas of 
necrotic hepatocytes were seen throughout the slices and many degenerate cells showed 
vacuolation characteristic of lipid accumulation, though this was not confirmed with ORO 
staining.
10.2.1.2 Hepatocyte cultures
The results of treating dog hepatocyte cultures (initial viability 86.2%) for 20h and 3 days 
with 5000 pg/ml GR144053F, 1000 pg/ml 2,6-xylidine or 1000 pg/ml ethanol are shown 
in Table 31. GR144053F did not induce any large reduction in levels of ATP, GSH, total 
cellular protein or albumin secretion but did cause an increase in levels of intracellular 
triglyceride after treatment for both 20h and 3 days (204.7 and 266.9 % of concurrent 
control values respectively). This increase in intracellular triglyceride was of a similar
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Fig 26 Photograph of a section through a cultured liver slice, showing
necrotic band of cells (haematoxylin and eosin staining)
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magnitude to that seen with ethanol (260.2% after 20h and 257.2% after 3 days). 2,6- 
xylidine induced a decrease in levels of GSH, ATP and total cellular protein as expected 
(32.1, 7.1 and 12.7 % of concurrent control values respectively). However, a large 
increase (275.1% of the control value) was seen in the amount of albumin secreted by 
cultures during the 20h treatment period. Albumin secretion after treatment of dog 
hepatocytes with 2 ,6 -xylidine had not previously been measured and this effect would 
require further investigation before any conclusions about its relevance could be reached. 
Such an increase in albumin secretion after treatment with hepatotoxins has been 
observed previously after treatment of rat hepatocytes with ethionine and paracetamol 
(Westmoreland et al, 1995). It is possible that apparent increases in albumin secretion at 
very toxic levels of test compound may be an artefactual result due to greatly reduced total 
protein content within the cultures.
A marked effect on the morphology of cultured dog hepatocytes was seen during the 3 day 
treatment period with GR144053F. After treatment for 20h, control cultures were 
approximately 90% confluent with well flattened cells. Those treated with GR144053F 
appeared very similar to control cultures after 2 0 h treatment, but altered gradually over 
the 3 day treatment period. The cytoplasm of GR144053-treated cells appeared to round 
up slightly and cells became packed with spherical, opaque cytoplasmic inclusions. These 
inclusions were unlike anything previously seen after treatment of hepatocyte cultures 
with a variety of hepatotoxic and cytotoxic agents. In contrast, cultures treated with 2,6- 
xylidine showed classical signs of necrotic cell death after only 20h treatment. Cells 
detached from the monolayer and floated in the culture media; those which remained 
attached were very granular and rounded.
10.2.1.3 Summary of initial investigations
GR144053F (5000 pg/ml) did not appear to have a marked effect on dog liver slices after 
in vitro treatment for 20h in terms of morphological or biochemical changes. As it is not 
possible to culture slices for any longer period of time, it was decided to do no further 
work using this in vitro model.
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GR 144053F (5000 pg/ml) did however, cause marked morphological changes in cultured 
dog hepatocytes after treatment for 2 and 3 days in vitro. The only marked change in 
biochemical markers induced by GR144053F in this initial experiment was a doubling in 
levels of intracellular triglyceride. Further studies into the nature of GR144053F-induced 
hepatotoxicity therefore concentrated on these two changes which were seen in this initial 
study in cultured dog hepatocytes.
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10.2.2 Further investigations into GR144053F-induced toxicity in cultured
dog hepatocytes
10.2.2.1 GR144053F-induced increase in intracellular triglyceride
Experimental details
In order to further investigate the effects of GR144053F on the levels of intracellular 
triglyceride in cultured dog hepatocytes^ | three | experiments were performed which 
investigated the reproducibility of this effect together with any possible time and 
concentration-dependence in this phenomenon.
Results o f investigations into GR144053F-induced increase in intracellular triglyceride
The results of the experiments which investigated the effect of GR144053F on levels of 
intracellular triglyceride in cultured dog hepatocytes are shown in Table 32. The data 
obtained in these experiments was very variable between donor animals (control values 
ranged from 5.93 - 72.32 nmol triglyceride/mg protein). This inter-animal variation was 
also observed in studies with rat hepatocytes (see Section 9.2.2). The data obtained from 
cultured dog hepatocytes (unlike that shown previously with cultured rat hepatocytes) also 
showed considerable interculture variation within an experiment. The reason for this 
variation is not known. As a result of this large variation in the data obtained, the apparent 
increases in triglyceride shown in Table 32 (when expressed as % control) are not 
statistically significant. This lack of statistical significance together with the absence of 
any reproducible concentration- or time-dependence in the apparent increases led to the 
conclusion that measurement of intracellular triglyceride was not a suitable biochemical 
marker for monitoring GR144053F-induced hepatotoxicity in vitro.
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10.2.2.2 Morphological changes induced by GR144053F in cultured dog
hepatocytes
As mentioned in Section 10.2.1.2, the morphological changes seen in the initial 
experiment after treatment of dog hepatocytes with GR144053F were unlike any changes 
seen previously in cultured hepatocytes after treatment with several hepatotoxic and 
cytotoxic agents. It was therefore decided to examine these morphological changes in 
greater depth.
Experimental details
Several experiments were conducted in which monolayers of dog hepatocytes were treated 
for 3 days with 100, 1000 and 5000 pg/ml GR144053F. Living cultures were examined 
after 20, 48 and 72h by phase contrast microscopy and fixed stained specimens were 
examined by conventional light microscopy and TEM.
Results o f morphological analysis
10.2.2.2.1 Phase contrast microscopy
The most prominent change in dog hepatocytes after treatment with GR144053F in vitro 
was an induction of opaque, spherical white cytoplasmic inclusions as seen during the 
initial experiment with GR144053F. These were always present in the cytoplasm of cells 
treated with 1000 and 5000 pg/ml GR144053F after 2 days and occasionally in cells 
treated with 100 pg/ml. The appearance of inclusions in cells treated with 100 pg/ml 
GR144053F for two days appeared to vary from animal to animal, but inclusions were 
always present by 3 days after treatment with 100 pg/ml. Likewise, the morphological
appearance of cells after treatment for 3 days varied in severity from experiment to
experiment. On some occasions, cells would remain as they had looked after treatment for 
2 days, but would contain even more cytoplasmic inclusions. On other occasions 
(particularly after treatment with 5000 pg/ml GR144053F) cells would die and detach 
from the monolayer.
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Despite these inter-animal variations in the doses of GR144053F needed to cause the 
effects, the appearance of opaque, spherical, white cytoplasmic inclusions occurred in 
every experiment with GR144053F and has never been seen in control cultures of dog 
hepatocytes. Therefore these inclusions appear to represent a compound-specific alteration 
in morphology at concentrations where significant cell death has not occurred. Fig 27 is a 
representative photograph of a control culture of dog hepatocytes at day 2. Fig 28 is a 
photograph of dog hepatocytes after treatment for 2 days with 1000 pg/ml GR144053F, 
clearly showing many of the characteristic opaque, spherical white inclusions.
10.2.2.2.2 Light microscopy
In order to investigate the GR144053F-induced morphological changes in greater depth, a 
series of experiments were performed in which monolayer cultures of dog hepatocytes 
cultured on coverslips were treated with GR144053F and fixed in 10% NBF. The fixed 
cells were then stained with haemotoxylin and eosin and examined using conventional 
light microscopy. Slight variations were seen between experiments in the time of onset of 
morphological changes and the concentrations of test compound required to induce these 
changes. However, consistent concentration-related features were observed in all 
experiments at both 48 and 72h after the start of treatment. The major change, as observed 
with phase contrast microscopy, was the appearance of many small spherical inclusions 
within the cytoplasm accompanied by a reduction in cell size and sometimes followed by 
cell degeneration and cell death at the higher concentrations.
At 100 pg/ml GR144053F, the effects were variable and negligible, consisting of a slight 
increase in the number of vacuoles within the cells of some cultures compared to control 
cultures. After treatment with 1000 pg/ml GR144053F, the increase in cell vacuolation 
was pronounced when compared to control cultures. In some experiments, increased cell 
degeneration and loss were present with a consequent decrease in total area of confluence. 
At 5000 pg/ml GR144053F, some cells showed marked accumulation of many intra- 
cytoplasmic vacuoles. The effect on cell viability was generally pronounced with 
increased loss of cells from the cultures and evidence of cytoplasmic and nuclear 
degeneration in a significant proportion of the remaining attached cells. Fig 29 is a
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representative photograph of a control culture of dog hepatocytes stained with 
haematoxylin and eosin at day 2. Fig 30 is a photograph of dog hepatocytes after 
treatment for 2 days with 1000 pg/ml GR144053F, clearly showing many of the 
characteristic cytoplasmic inclusions.
Staining of these formalin-fixed monolayer cultures with ORO demonstrated that the 
vacuoles were not lipid (data not shown). |
10.2.2.2.3 TEM
All TEM examination was carried out by Mr John Bowles, Electron Microscopy, 
GlaxoWellcome, Ware.
In an initial examination of randomly selected hepatocytes from control cultures and 
cultures treated with 1000 pg/ml GR144053F for 2 days, an assessment was made of 
changes in all of the major cell organelles. This assessment revealed that there were no 
treatment-related abnormalities in nuclei, nucleoli, rough and smooth endoplasmic 
reticulum, glycogen content and Golgi apparatus. Numerous lysosomes were present in 
the cytoplasm of all cells and often these presented an appearance characteristic of 
teleolysosomes. Lipid droplets were almost invariably present in the cytoplasm and 
numerous peroxisomes were seen in both control and GR144053F-treated cells.
The only treatment-related abnormality observed was in the mitochondria. These were of 
varying size and often showed a bizarre appearance in treated cells. Although the variation 
in size and appearance of mitochondria initially appeared continuous, it was possible to 
identify 5 different forms:
1. Normal
2. Cup-shaped
3. Elongate
4. Light matrix
5. Dark matrix
Representative photographs of each of 
these types of mitochondria are shown 
on the page opposite
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Fig 27 Photograph of control dog hepatocyte culture (day 2; phase contrast
microscopy)
y  #  Æ
Fig 28 Photograph of dog hepatocyte culture after treatment with 1000 pg/ml
GR144053F (day 2; phase contrast microscopy)
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Fig 29
^  (ss -3
Photograph of control dog hepatocyte culture (day 2; haematoxylin
and eosin-stained cultures; light microscopy)
1%»
A/
Fig 30 Photograph of dog hepatocyte culture after treatment with 1000 pg/ml
GR144053F (day 2; haematoxylin and eosin-stained cultures; light 
microscopy)
100 pm
Fig 31 Photograph of control dog hepatocyte culture (day 2; transmission
electron microscopy)
Fig 32 Photograph of dog hepatocyte culture after treatment with 1000 pg/ml
GR144053F (day 2; transmission electron microscopy)
Mitochondria
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Fig 31 is a representative transmission electron micrograph of a control culture of dog 
hepatocytes at day 2. Fig 32 is a transmission electron micrograph of a dog hepatocyte 
after treatment for 2 days with 1000 pg/ml GR144053F.
10.2.2.3 Further investigations into GR144053F-induced mitochondrial 
changes
Experimental details
In order to make a semi-quantitative assessment of the morphological changes which 
were seen in the mitochondria after treatment of dog hepatocyte cultures with 
GR144053F, two independent experiments were performed. Coverslip cultures of dog 
hepatocytes were treated for 2 or 3 days with 100, 1000 or 5000 pg/ml GR144053F. 100 
hepatocytes were then randomly selected from each coverslip and the morphology of the 
mitochondria within that cell was assessed. Each cell contained more than one 
ultrastructural form of mitochondria. The cell was categorised based on the mitochondrial 
form which showed predominance within the cell. The categories of mitochondrial form 
used were those listed in Section 10.2.2.2.3.
In parallel to these samples for TEM assessment, 25 cm^ cultures of dog hepatocytes were 
also treated with GR144053F for concurrent assessment of morphology by phase contrast 
microscopy.
Results o f further investigations into GR144053F-induced mitochondrial changes
The results of TEM analysis of mitochondria in dog hepatocytes after treatment with 
GR144053F are shown in Tables 33 and 34 together with the results of phase contrast 
examinations during these experiments. As described earlier, the results of these two 
experiments further demonstrate the inter-animal variability seen in the toxicity of 
GR144053F. 5000 pg/ml GR144053F was overtly cytotoxic to the hepatocytes after 3 
days in one of the experiments (Table 33), whereas in a replicate experiment (Table 34) 
sufficient cells survived to allow assessment of mitochondrial ultrastructure.
177
IIt
T31
!
* o
I
ui
Î
«I
a
1
• Ë
I
o I
I f
m  
u
0
N  
k
c21 { Is 3
I Î
*©f
3
I
U
II
I III
o  <u 4= wf °
(D WII
Ü Ü
„ ë% 
| | 0
15 2
P Isz
o
ll
o
T3 -D11 
O «
^  Ü  
0)
Ü _
^  g
o  .£
0)
E
3
Cf t
S 3
0)Ü
c
oÜ
c
0)
EI
H
eg 8
m
cvi
O)
ins
o
o
CM
I
CM
I
I S.Ç 
0)tipfill
CO
CO
CO
c
Ü
Li.s
01 
E 
o
Oi
in
Oi
Oi 00
CD in
CD
■M-
8 8
i§
O
O
o
o
o
in
^  c
T J CD
I
CM
in
O)
m
d
in
fe
o
o
CM
I
CO
II
s.i
II
s
c
8 =^ 8
8 1  
CD O
1 1
C D C J
I!
< Q.
c  Çg •«
H i
Ô5 wO  U _3XJ U
II
CD
CM
CO CO
o
CO
CD
CO
a>
CO
"4"
CO
8 8 oo
8 11
c
o
Ü
8
M -
E
CD
§
0
'"Bc
1
a
0
e
1 J3
Ï
cd
&
-C
15
8
•oI
ii
00
I
0
d)
S1
ë
0  
%  
8
§
c11cd
1
. 1f
8
%I
e
3I
S '1t
tsx
' §
2  B1
* o
I
I
i
(V
Ia#
1■g
1■s
o
' o
1
2  
II
3
*©
I
I
I
m
k
0
a
1
r4gI 5
Tf
Z
H
s  I-I
llIJ
• ë l
I I
P I
II
p■D -D
P  Q .
>  - Co w
0) Q .
W Ü 
(Uo
JO
l lII
(D
I I
(DÜ
CoÜ
CM
o
o
I '
CM
coÜ
-  8 8o
S I I
III
1 1if
II
1— Oin CO
CD
CM
CO
o  o
CM CO
CD CM 
CM CO
O
O
O
O
8 8
II
IÎ
CD
CO
CO
o
o
Li.
I
EC
O
I I
CO Ü
f!
il II
§ §--i § S
0)
T3
ts illl i t ;
CD
CO
CO
CO
CM
CO
CM
O
O
O
O
O
O
O
O
O
" o
o
o
o
in
L LsI
E
( 0
iI
0  
c1
a13
d)
H
3
ë
O
8J2
I
1
Ï
I
8 -
13
- 8
- g
T3
C
. §
o \
r~
I
0
d>
■51
ë
0
8
rt
c11cd1
JZ
JZ
-S
ë
o
Ï
1 1 1
The results of ultrastructural analysis from both experiments clearly showed a time- and 
concentration-related decrease in the percentage of cells with predominantly normal 
mitochondria. The most striking change in both experiments was a concentration- and 
time-related increase in the percentage of cells where the dominant mitochondrial form 
was light matrix mitochondria. A change was also seen in both experiments in the 
percentage of cells where the dominant mitochondrial form was cup-shaped mitochondria. 
This form of morphological change was not as clearly time-related as the increase in light 
matrix mitochondria, but did appear to be most prominent after treatment for 2 days. Both 
cup-shaped and light matrix mitochondria had a very low (or zero) incidence in control 
cultures.
There is no direct evidence from these TEM results alone to show that the changes seen in 
mitochondrial ultrastructure after GR144053F-treatment are sequential. The possibility 
does exist however, that the mitochondria may change after treatment from normal to cup­
shaped mitochondria and then into mitochondria with a light matrix. The obvious 
correlation between the appearance of the opaque, spherical, white cytoplasmic inclusions 
seen using phase contrast microscopy and the appearance of mitochondria with light 
matrices indicates that these may both be the same structures.
10.2.2.4 MTT tests with GR144053F
Experimental details
In order to get a quantitative measurement of GR144053F-induced cytotoxicity in 
cultured dog hepatocytes, the MTT test was used. This endpoint has traditionally been 
used in in vitro toxicology testing as a measure of the mitochondrial activity in cultured 
cells (Supino, 1995). Dog hepatocytes in 96 well plates were treated for 1, 2 or 3 days 
with 100, 1000 or 5000 pg/ml GR144053F (see Section 8 .6 ). Five replicate experiments 
were performed.
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Table 35 Summary of MTT tests with GR144053F in monolayer cultures of dog
hepatocytes
Treatment Concentration Level of MTT reduction (expressed as % control) ± SE
Day 1 Day 2 Day 3
Control 100.0 ±0.0 100.0 ±0.0 100.0 ±0.0
2,6-xylidine® 1000 47.8 ± 6.6 * 25.7 ±9.8 * 14.3 ±2.8 *
GR144053F 100 90.7 ± 2.7 * 86.5 ±7.2 64.7 ± 5.6 *
1000 85.8 ± 3.5 * 85.2 ± 9.4 50.1 ±7.1 *
5000 80.6 ± 7.3 59.7 ±7.5 * 31.7 ±3.4*
ICgo^ >5000 >5000 1022
Monolayer cultures of dog hepatocytes were treated for 1, 2 or 3 days with GR144053F (100-5000 pg/ml). 
MTT tests were carried out following treatment as described in section 8.6. 16 wells of a 96 well plate were 
measured per data point. The results presented are the mean results (expressed as % control) of 5 
independent experiments. Mean responses were compared to control values using Student’s t-test; 
^  significantly different from control (p<0.05)
a 2,6-xylidine, the positive control, gave the expected decrease in levels of MTT reduction,
b Calculated concentration of GR144053F which would decrease levels of MTT reduction to 50%
of concurrent control levels.
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Results o f MTT tests with GR144053F
The results of MTT tests in dog hepatocytes after treatment with GR144053F are shown 
in Table 35. A concentration- and time-related decrease was observed in the levels of 
MTT reduction after treatment with GR144053F. In general however, significant 
decreases in MTT reduction were not measured until the day after the appearance of the 
characteristic morphological changes in the treated cells, e.g. 1000 pg/ml GR144053F 
did not induce a significant decrease in levels of MTT reduction until 3 days after the start 
of treatment, whereas the appearance of the opaque, spherical, white cytoplasmic 
inclusions generally occurred after treatment for 2  days.
10.2.2.5 Treatment of cultured dog hepatocytes for 14 days with GR144053F
As mentioned previously, it is usual to conduct in vitro hepatotoxicity investigations with
monolayer hepatocyte cultures over a period of 24h or less, due to the loss of metabolising
capability associated with de-differentiation of cultured hepatocytes over time. Although
little work was done into the metabolism of GR144053F, an initial in vitro investigation
carried out during the development of GR144053F in cultured dog liver slices indicated
:X-
that no major metabolites were formed. The current investigations, indicate that the 
toxicity of GR144053F in hepatocytes was expressed only after treatment for 2-3 days in 
vitro. However, the concentrations of GR144053F that were used in these in vitro 
experiments (up to 5000 pg/ml) were far in excess of the plasma levels of the compound 
that would be expected in vivo after i.v. administration of GR144053F to dogs.
The in vivo toxicological evaluation of GR144053 in the dog indicated that a daily i.v. 
dose of 1 mg/kg for 14 days was sufficient to induce liver damage in vivo. Whilst there is 
no data available for the plasma concentration of GR144053 during these toxicology 
studies, it can be assumed that levels would have been considerably lower than the 
concentrations used in the in vitro studies (100-5000 pg/ml). In a safety pharmacology 
study in the dog, pharmacokinetic data showed that a plasma concentration of only 1.56 
pg/ml GR144053 was reached Ih after after i.v. administration of 30 mg/kg GR144053C 
(the trihydrochloride dihydrate salt of GR144053). Even if the entire i.v. dose of 1 mg/kg 
were to have remained in the bloodstream of the treated dog, a theoretical maximum
^  work carried out by Mr P Mutch, BioMet Division, GlaxoWellcome Research and 
Development.; j g ] ------------------------ -----------^
concentration of only 1 1 .1  pg/ml could have been been reached (assuming a 1 0  kg animal 
with a total blood volume of approximately 900 ml [Jain, 1986]).
Clearly, the concentrations used in the in vitro investigation into GR144053F-induced 
hepatotoxicity (100, 1000 and 5000 pg/ml) are several orders of magnitude greater than 
those which would have been reached in the animals in the MRD studies where 
hepatotoxicity was observed.
To investigate the difference in concentrations between the in vitro and in vivo tests, 
further experiments in cultured dog hepatocytes were performed using a 2  week exposure 
period (the same time period used in the in vivo MRD studies).
Experimental details
Monolayers of dog hepatocytes were treated for 14 days with 1, 10, 100, 1000 and 5000 
pg/ml GR144053F. Fresh media was added to the cultures every 2-3 days. The toxicity 
endpoints previously mentioned (induction of cytoplasmic inclusions and levels of MTT 
reduction) were measured after treatment for 1, 2, 3, 5, 6 , 7 and 14 days. The experiment 
was repeated three times.
Results o f treatment o f monolayers o f dog hepatocytes for 14 days with GR144053F
As with previous experiments with GR144053F in cultured dog hepatocytes, cytoplasmic 
inclusions were observed after treatment for 2 or 3 days at concentrations of 100 pg/ml 
and above. However, after treatment for 5-7 days with 10 pg/ml GR144053F, the 
characteristic inclusions were clearly visible in a proportion of the cells.
In one of the experiments, an attempt was made to quantify the number of cells which 
contained the inclusions after treatment for 6  and 7 days with 10 pg/ml GR144053F. The 
number of affected and non-affected cells seen in flasks using phase contrast microscopy 
were counted in three randomly chosen fields of view. After treatment for 6  days, 6.0% of 
hepatocytes contained cytoplasmic inclusions. This percentage was increased to 12.1% 
after treatment for 7 days. No inclusions were observed in concurrent control cultures.
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The morphology of cultures which were kept for longer than 7 days began to deteriorate in 
both control and treated flasks. Cells became elongated (more fibroblastic) and occasional 
cells began to develop cytoplasmic outgrowths. Such de-differentiation with time is a 
usual feature of monolayer cultures of hepatocytes. Despite this de-differentiation, cells 
containing the characteristic inclusions could still be easily identified.
The induction of inclusions by 10 pg/ml GR144053F after 5-7 days is reflected in the 
results of the MTT tests over this period (eee Table 36). No decrease in MTT reduction 
was seen after treatment for 1-3 days, however from days 5-14 of treatment a decrease 
was seen in levels of MTT reduction (49.2% of control levels at day 14).
Summary o f 14 day treatment with GR144053F
GR144053F became increasingly toxic to the cultured dog hepatocytes when the 
treatment period was extended beyond the usual 3 days. At 1 pg/ml (where no 
cytoplasmic inclusions were seen throughout the experiment) there was no evidence of 
drug-induced cytotoxicity. However, after treatment with 10 pg/ml, toxicity was seen 
from day 5 of treatment onwards, again following the appearance of the round 
cytoplasmic inclusions. This resulted in IC50 values which were much closer to the 
expected plasma levels which would cause hepatotoxicity in the dog in vivo.
10.2.3 Limited ‘validation’ of in vitro screen with other FRAs
As mentioned in Section 10.1.3, the ultimate aim of the in vitro work with GR 144053 was 
to establish an in vitro model which could be used to screen FRAs for hepatotoxicity prior 
to their administration to animals. The work described above established that specific 
morphological changes in cultured dog hepatocytes (i.e. characteristic cytoplasmic 
inclusions visible with phase contrast microscopy) were associated with treatment with 
the hepatotoxic FRA GR144053F. In order to establish whether the appearance of these 
inclusions could be used as a specific marker for FRA-induced toxicity a limited 
‘validation’ experiment was carried out.
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Five FRAs (GR135528, GR144358, GR144053, GR160709 and GR177606) have all 
been demonstrated to cause hepatotoxicity after i.v. administration to the dog (14 days, 5  
mg/kg). Of these compounds, sufficient drug substance remained of only three 
(GR135528, GR144053 and GR160709; see Fig 33 for structures) to allow in vitro 
testing. It was therefore decided to test these three compounds alongside three FRAs 
which had shown no evidence of hepatotoxicity after i.v. administration to the dog 
(GR199759, GR 165500 and GR233548; see Fig 33 for structures; 14 days, 5 mg/kg). The 
liver pathology for each of these compounds is summarised in Table 37.
Table 37 Summary of liver pathology seen after in vivo treatment of dogs with 5 
FRAs (light microscopy)
Compound Number Dose ( mg/kg i.v.) Liver Pathology
GR144053
GR135528
GR160709
1, 2.5 and 5 for 14 days Centrilobular degeneration with eosinophilic
inclusions, single cell necrosis, fibrosis and 
inflammatory cells at all doses.
5 for 14 days
5 for 14 days
Centrilobular cytoplasmic rarefaction, 
eosinophilic inclusions, basophilic particles 
and hepatocyte degeneration.
As for GR135528, but less severe.
GR165500 5 for 14 days N.A.D.
GR199759 5 for 14 days N.A.D.
GR233548 5 for 14 days N.A.D.
N.A.D. = No abnormalities detected.
Experimental details
Each compound was tested in cultures of dog hepatocytes at concentrations of 100, 1000
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and 5000 |iig/ml with the exception of GR 165500 which was tested at concentrations of 
100, 500 and 1000 pg/ml due to limiting solubility (the top concentration of 1000 pg/ml 
GR165500 showed evidence of precipitation during the treatment period). Appearance of 
cytoplasmic inclusions and MTT reduction were assessed after treatment for 1, 2 and 3 
days. Due to the small amount of material available, this experiment was performed only 
once.
Results o f limited ‘validation’ o f in vitro screen with other FRAs
10.2.3.1 Morphological changes
For simplicity, the description of the morphological changes seen in vitro with the test 
compounds will be limited to the presence/absence of the characteristic opaque, round 
white cytoplasmic inclusions (termed ‘inclusions’ from now on) and any obvious signs of 
compound-induced cell death (observed as rounding up of cells, increased granularity and 
detachment from the monolayer).
In vivo hepatotoxins
GR 144053 and GR 160709 both induced inclusions after treatment for 2 days in vitro. The 
lowest concentration at which this effect was seen was 1 0 0  pg/ml for both compounds. 
After 3 days, both compounds induced a dose-related increase in cell death. GR135528 
did not induce inclusions over the 3 day treatment period, but did induce some cell death 
after treatment for 3 days.
In vivo non-hepatotoxins.
GR165500, GR199759 and GR233548 did not induce inclusions over the 3 day treatment 
period in vitro. GR 165500 did not induce cell death over the three day treatment period. 
GR 199759 did not affect cell morphology when examined using phase contrast 
microscopy, but appeared to cause a concentration-related increase in cell death when 
fixed H&E stained cultures were examined. GR233548 caused concentration-related cell 
death over the three days at all concentrations tested. No inclusions were observed at any
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of the concentrations tested, however, it was felt necessary to repeat the experiment using 
lower concentrations of 1, 10, 50 and 100 pg/ml GR233548 where accurate observations 
could be made on cell morphology. Again, cell death was observed after treatment with 
100 pg/ml GR233548, however, no toxicity was observed at the lower concentrations and 
no evidence of cytoplasmic inclusions was seen at any of the concentrations tested. In 
order to further demonstrate the negative result with GR233548, TEM was performed on 
the samples which showed no evidence of alterations in mitochondria ultrastructure (see 
Table 39).
10.2.3.2 MTT Tests
The results of MTT tests with the six test compounds are shown in Table 40.
In vivo hepatotoxins
The two fibrinogen receptor antagonists which induced inclusions (GR144053 and 
GR160709) also induced cytotoxicity in vitro as measured by MTT reduction on the day 
after the initial appearance of the inclusions. From this data it appears that cells cannot 
remain viable once they contain inclusions. G R l35228 also caused a decrease in MTT 
reduction, but this was not associated with the appearance of inclusions.
In vivo non-hepatotoxins
Of the three non-hepatotoxic compounds tested, two (GR199759 and GR233548) caused 
a concentration-related decrease in levels of MTT reduction in vitro. This cytotoxicity 
increased in severity over the three day treatment period but was not associated with the 
prior induction of inclusions.
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Table 40 Summary of MTT tests with 6 FRAs in monolayer cultures of dog
hepatocytes
T reatment
Control
2,6-xylidine^
Hepatotoxic Compounds
GR144053
Concentration Level of MTT reduction (expressed as % control)® 
(pg/ml)___________ Day 1________ Day 2________ Day 3
GRl 35528
GR160709
Non-Hepatotoxic Compounds
GR199759
GRl 65500
GR233548^ (test 1)
GR233548 (test 2)
1000
100
1000
5000
1 0 0
1000
5000
1^ 50
100
1000
5000
1^ 50
1 0 0
1000
5000
1^ 50
100
1000
5000
1^ 50
100
1000
5000
1^ 50
1
5
50
1 0 0
1^ 50
100.0
65.8
87.6
88.3
79.9 
>5000
90.7
87.6
65.9 
>5000
78.7
61.9
56.4 
>5000
90.9
94.5
39.8
4254
91.7
85.1
74.1 
>1000
60.2
40.7
31.7 
571
94.0 
100.2
86.2
82.1 
>100
100.0
54.6
81.4
74.5
64.5 
>5000
97.6 
105.7
56.2
>5000
69.9
58.7
26.8 
2091
92.3
97.2
14.4 
3280
85.8
82.9
77.2 
>1000
31.7
19.7
21.3 
73
100.0
91.6
79.5 
61.1 
>100
100.0
20.6
59.1
44.3
34.7 
653
85.2
70.7
26.4 
2869
37.8
26.9
12.3 
80
109.0
116.9
12.9 
3573
94.5
93.9
82.3 
>1000
16.2
8.4
24.5 
60
93.4 
90.2 
65.8
47.4 
94
a Results from only one experiment (see Section 10.2.3).
b 2,6-xylidine, the positive control, gave the expected decrease in levels of MTT reduction,
c Calculated concentration of test compound (pg/ml) which would decrease levels of MTT
reduction to 50% of concurrent control values, 
d GR233548 was tested twice using two different concentration ranges (see Section 10.2.3.1).
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10.2.3.3 Summary of limited ‘validation’ of in vitro screen with other FRAs
The results obtained with the 6  FRAs used in this limited ‘validation’ exercise can be 
summarised as follows:
Compound Hepatotoxic in vivo Induces inclusions in vitro
GR144053 ✓ ✓
GR160709 ✓ ✓
GR135528 ✓ /
GR165500 / X
GR197759 / X
GR135528 / X
These results indicate that the proposed in vitro pre-screen was able to detect 2 out of the 
3 hepatotoxins tested and that no false positives were found. This indicates that the in 
vivo test for hepatotoxic FRAs has given similar results to in vitro experiments with dog 
hepatocytes, but that a follow-up in vivo test would be necessary to confirm negative 
results as some compounds (e.g. GR135528) may be hepatotoxic in vivo, but not in vitro. 
This may be due to metabolic activation of compounds in vivo, a characteristic of the in 
vitro system which is lost over the long culture periods used in this protocol.
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10.3 DISCUSSION
In the current in vitro investigations with monolayer cultures of dog hepatocytes, 
GR144053 induced spherical cytoplasmic inclusions (observed by phase contrast 
microscopy of living cells and light microscopy of fixed, stained cultures) after treatment 
for 2 or 3 days. These inclusions were seen on the same days of treatment as abnormal 
mitochondria were observed in the cultures using TEM. GR144053 induced both cup­
shaped mitochondria and mitochondria with a light matrix. It seems likely that the 
mitochondria with light matrices are the same structures observed as cytoplasmic 
inclusions by phase contrast and light microscopy. Reports of ultrastructural changes in 
the mitochondria of cultured hepatocytes following treatment in vitro with toxins are 
scarce. The antiarrhythmic drug, amiodarone, causes the swelling of mitochondria in 
cultured rat hepatocytes (Gross et al, 1989). Amiodarone-induced mitochondrial toxicity 
is however quite distinct from that seen with GRl44053 in the current investigations. The 
primary ultrastructural change seen initially with GRl44053 is the induction of altered 
mitochondria (cup-shaped, elongate, altered matrix). These cells then appear to undergo 
cell death with subsequent culture. In the case of amiodarone treatment (Gross et al, 1989) 
the primary ultrastructural change is the appearance of myelinoid incIusionJbodies.JThe____
1 the mitochondrial changes are
mitochondria of the cell are not affected until later in the toxic process and] L__
accompanied by disruption of cell membranes and aggregation of subcellular structures 
prior to cell death. Mitochondrial swelling as a late toxic response has also been reported 
after in vitro treatment of rat hepatocytes with phalloidin (Russo et al, 1982).
GR144053 caused severe hepatotoxicity in dogs in vivo following i.v. administration for 
14 days. The hepatotoxicity of this, and other FRAs, was characterised by the appearance 
of eosinophilic inclusions within the hepatocellular cytoplasm when histological 
specimens were examined using light microscopy. Subsequent to these initial findings, 
liver tissue was further examined from GRl44053-treated animals using TEM. The 
findings of the TEM work, which became available during the course of the in vitro work 
described here, revealed that the eosinophilic inclusions may in fact be giant mitochondria 
(see Fig 34). The occurrence of giant mitochondria (also termed ‘megamitochondria’) in 
the liver under both physiological and pathological conditions has been widely reported
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Fig 34 Photographs of dog liver after treatment with GR144053F in vivo
Haematoxylin and Eosin stained section showing eosinophilic inclusions (-►)
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(Munn, 1974; Ghadially, 1988; Tander and Hoppel, 1986). Examples of compounds 
which have been demonstrated to induce giant mitochondria in rodent liver include 
chloramphenicol (Matsuhashi et al, 1996), propylthiouracil (Aguas et al, 1981) cuprizone, 
semi-carbazide and hydrazine (Wakabyashi et al, 1983; Asano et al, 1978).
In the case of hydrazine-induced giant mitochondria in the livers of mice (which was 
accompanied by marked accumulation of fat droplets), biochemical studies on isolated 
mitochondria indicated that functional integrity (coupling efficiency measured using an 
oxygen electrode) was not greatly affected by the increase in organelle size indicating that 
the giant mitochondria had an intact electron transfer system. The authors (Wakabyashi et 
al, 1983) proposed that the giant mitochondria may form by the fusion of outer 
membranes of adjacent mitochondria. It has since been suggested (Antosiewicz et al, 
1994) that hydrazine-treatment may alter the unsaturated:saturated fatty acid composition 
of the phospholipid domain of mitochondrial membranes and that this may be a key event 
in the membrane fusion process. The administration of free radical scavenging agents 
(either a-tocopherol [Antosiewicz et al, 1994] or coenzyme QIO [Adachi et al, 1994]) to 
hydrazine-treated animals prevents the formation of megamitochondria. This data 
suggests that free radicals generated by hydrazine and its metabolites may be involved in 
the induction of megamitochondria.
Wakabyashi et al (1984) extended their work on hydrazine to study a series of related 
ammonia derivatives (general structure NH2-R). When R was an electron-releasing group 
(hydrazine, phenylhydrazine, hydroxylamine and aniline) all compounds were capable of 
inducing giant mitochondria in the livers of rats and mice following oral administration. 
Conversely those containing an R group which was electron-withdrawing (formamide, 
sulphamic acid and acetamide) were ineffective in inducing giant mitochondria. 
Interestingly G Rl44053 contains a NH2 group in the form of a benzamidine moiety (as do 
several of the other hepatotoxic FRAs; See Fig 34). However, this is clearly not the sole 
explanation for the hepatotoxicity of these compounds as the presence of the benzamidine 
moiety in some FRAs is not associated with hepatotoxicity.
From the results of morphological analysis of the in vitro experiments, it appears that 
G Rl44053 causes concentration- and time-related mitochondrial toxicity in cultured dog
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hépatocytes. Whilst the morphological changes seen in dog hepatocytes in vitro were not 
identical to those seen in the dog liver in vivo (e.g. cytoplasmic inclusions were 
eosinophilic in vivo, but not in vitro) there are clear similarities between the effects of 
GR144053 in vivo and its effects in vitro. Both in vivo and in vitro, the mitochondrion 
was the target organelle for GR144053-induced toxicity.
The use of an in vitro system to screen for mitochondrial toxicity in cultured dog 
hepatocytes was therefore suggested as a possible in vitro pre-screen prior to 
commencement of in vivo toxicology studies with future FRAs. A limited ‘validation’ 
exercise was carried out with the proposed screen as described in Section 10.2.3. This was 
by no means an extensive validation of the proposed screen and was limited to only six 
compounds due to the availability of test substance. However, the results indicated that no 
‘false positives’ were obtained and that two of the three in vivo hepatotoxins tested were 
correctly identified by the in vitro pre-screen. Since this work was completed, several 
other FRAs have also been tested in this in vitro pre-screen, and a database on its 
predictive ability is growing.
The area of validation of in vitro methods in toxicology testing as alternative tests to 
conventional in vivo toxicology assays is a complex subject. The type of pre-screen 
described here for use with fibrinogen receptor antagonists is an example of the most 
common type of in vitro toxicity assay (Walum et al, 1994), i.e. it is designed for 
toxicological pre-screening in the development of test compounds and is not aimed at 
forming the basis of documentation for regulatory authorities. Such pre-screens are used 
to model a specific type of toxicity with test compounds from a well-defined chemical 
group. Similar examples of ‘in-house’ in vitro pre-screens are used widely within the 
cosmetics industry in the areas of skin and eye irritation testing (e.g. Coltin, 1996). A 
small validation exercise is needed for these assays as described above to ensure that the 
method provides adequate information which can be of value to make decisions on the 
further development of test compounds. As all FRAs which do not show in vitro 
mitochondrial toxicity in the pre-screen will be progressed for in vivo assessment, a larger 
database on the usefulness of the pre-screen will become established. However, with the 
use of in vitro toxicity tests as complete alternatives to currently accepted in vivo 
regulatory toxicity tests, the validation required is necessarily much more complex
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(Walum et al, 1994, Balls and Clothier, 1991). In these cases the tests must be shown to 
be reproducible, reliable and transferable between laboratories. It is therefore necessary to 
test a large number of compounds in several laboratories to ensure that they are predictive 
of in vivo tests. Many factors can influence the success of such an approach to validation, 
not least of which is the fact that some accepted regulatory in vivo assays are themselves 
not easily reproducible and difficult to transfer between laboratories. A recent large 
validation trial on in vitro alternatives to the Draize eye irritation assay tested 60 
chemicals in 37 separate laboratories (Balls et al, 1995b). It was concluded from this 
study that, with the possible exception of predicting the irritancy of surfactants, none of 
the 9 in vitro tests met the performance criteria required of an in vitro ‘alternative’ to the 
Draize eye irritation test.
Many biochemical parameters were originally used to investigate GR144053-induced 
toxicity in vitro. The results obtained from many of these assays were variable both 
between experiments and between cultures within a single experiment (See Section 
10.2.2.1). The most reproducible results were obtained with a simple cytotoxicity assay, 
MTT reduction. Results from MTT tests showed that GR 144053 induced a time- and 
concentration-related toxicity in cultured dog hepatocytes. It has been widely quoted that 
MTT reduction is the result of succinate dehydrogenase activity within mitochondria (e.g. 
Supino, 1995; Mosmann, 1983). Indeed, some authors have used the results of MTT tests 
as evidence of mitochondrial involvement in toxicity (e.g. Bonnefoi, 1992). However, 
tétrazolium dyes are widely used in biochemistry and histochemistry to detect a variety of 
dehydrogenase activities (both mitochondrial and non-mitochondrial). Therefore it has 
recently been suggested (Fry et al, 1995; Dhanjal and Fry, 1997) that the results of MTT 
tests may reflect the general NADH/NADPH status of the cell and may therefore best be 
regarded as an indicator of general metabolic activity. Dhanjal and Fry (1997) state 
“Caution should be exercised in ascribing an alteration in the level of cellular MTT 
reduction to a change in mitochondrial performance in the absence of corroborating 
evidence”. It is interesting that the MTT test was the most consistent marker of 
GR144053-induced toxicity in cultured hepatocytes and that the morphological lesion 
involved in its toxicity was the mitochondrion. However, its use in the current 
investigations into GR144053-induced toxicity jwas j  as a result of its sensitivity and 
reproducibility rather than its putative mode of action.
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The use of the MTT assay during experiments with GR144053 in vitro provided useful 
information on cell viability throughout the three days of culture. In particular, the MTT 
test showed that regardless of the day on which GR 144053 induced the morphological 
changes in the cultured hepatocytes, overall viability of the culture was greatly decreased 
the following day. This simple cytotoxicity test however was used primarily to provide 
supporting data on culture viability. It is not suggested that a decrease in MTT reduction 
alone could be a useful marker for detection of hepatotoxic fibrinogen receptor 
antagonists. This is clear from the results of the limited ‘validation’ experiment which 
was carried out with 6 fibrinogen receptor antagonists which included cytotoxic 
compounds (as measured by MTT reduction) which were both hepatotoxic and non- 
hepatotoxic in vitro. As with the previous work with steatogens in vitro (see Section 9), 
the most reliable in vitro toxicity parameter (i.e. the parameter which showed greatest 
predictivity of in vivo toxic responses) was one which closely matched the toxicity 
parameter in vivo - in this case ultrastructural alterations of the mitochondria.
One unusual aspect of the toxicity observed with GR144053 in vitro was the length of 
treatment needed before any significant toxicity was seen in the cultures. No significant 
changes (either in morphology or in MTT test results) were seen after treatment of 
hepatocytes for 1 day. Many published protocols for in vitro hepatotoxicity testing suggest 
treatment times of 24h or less for cultured hepatocytes (e.g. Fautrel et al, 1991; Fry et al, 
1993, Blaauboer et al 1994, Peloux et al, 1992). The rationale for the use of this relatively 
short treatment time compared with many in vivo toxicity studies is the dedifferentiation 
of monolayers with time in culture (see Section 7.3.1.1). Although hepatocytes initially 
survive in monolayer culture, they show a rapid decline in differentiated function. A 
particular problem is the rapid loss of cytochrome P450-mediated metabolic capability. 
Limiting treatment to 24h or less in in vitro hepatotoxicity tests therefore ensures that the 
test cells have at least some metabolic capability and that the test agent may undergo 
liver-specific metabolic modification. As mentioned previously, initial studies into the 
metabolism of GR144053 indicated that no major metabolites were formed in the dog. If 
the mitochondrial toxicity seen in the current experiments with GR 144053 was due to the 
parent compound rather than a metabolite, this may explain why the use of hepatocyte 
monolayers cultured for up to fourteen days in vitro produced useful results.
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It is possible that the lack of metabolic capacity in the longer term monolayer cultures 
used in these experiments may be responsible for the negative result obtained with 
GR135528. GR135528 caused eosinophilic inclusions in the livers of dogs after in vivo 
treatment for 14 days, but did not cause mitochondrial toxicity in cultured dog hepatocytes 
after treatment for 3 days in vitro. No data is available on either the in vivo or the in vitro 
metabolism of GR 135528. However, if the in vivo toxicity of this compound was as a 
result of the generation of a reactive metabolite in the liver, the de-differentiating 
monolayer cultures used in the in vitro experiments may have had insufficient metabolic 
capability to produce this metabolite after 2-3 days in culture.
The results of these experiments with longer term cultures of hepatocytes further 
emphasise the need for robust models of liver which can be maintained for longer than the 
currently available models (Roberts and Soames, 1993; Rogiers et al, 1995). As 
mentioned in Section 7.3.3.1 many investigators have attempted to slow the rapid 
differentiation of monolayer cultures by alterations of the culture medium used and by 
addition of other soluble factors to the medium. The tissue culture medium used in the 
current investigations (Williams’ E medium) has been traditionally used for the culture of 
hepatocytes and can successfully maintain both constitutive and inducible cytochrome 
P450 expression to a greater extent than more basic culture media (Turner and Pitot, 
1989; LeCluyse et al, 1996). When individual liver-specific functions are examined, the 
type of culture medium used can greatly affect the results obtained. Ghee’s medium, 
Leibovitz L I5 medium, Waymouth’s medium and Williams’ E medium each have 
specific advantages depending on the parameter under study (LeCluyse et al, 1996), 
though recent papers (e.g. Zurlo and Arterbum, 1996) indicate that a larger range of 
functions may be maintained with the use of Ghee’s medium.
The investigations into a longer-term model to study the liver in vitro have recently 
started to consider not only the constituents of the culture medium used, but also the 
microenvironment in which the hepatocytes are cultured (LeCluyse et al, 1996). Cell-cell 
interactions, cell-matrix interactions, extracellular matrix components, cell shape and 
polarity are thought to play a role in the maintenance of differentiated liver function. 
Several of the models now available for longer-term culture of hepatocytes exploit one or
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more of these features. Co-culture of hepatocytes with a non-parenchymal cell-type (liver 
epithelial cells or sinusoidal endothelial cells) has been shown to retain many liver- 
specific functions (including P450 content, albumin secretion and urea synthesis) for up to 
two months in vitro (Guguen-Guillouzo et al, 1983; Begue et al, 1984). It is thought that 
the cell-cell contacts established in this model more accurately reflect the combination of 
cell adhesion molecules and receptors which the hepatocytes are exposed to in vivo than is 
seen with traditional monolayer culture of hepatocytes alone. Most of these long-term 
models for hepatocyte culture have not been used extensively for toxicology studies and 
are in the process of being characterised biochemically to assess their potential usefulness.
Other models available for the long term culture of hepatocytes concentrate on 
maintenance of a more in v/vo-like cell morphology. In conventional monolayer cultures 
as used in the current investigations, hepatocytes flatten out. However, in the liver in vivo, 
hepatocytes have a cuboidal cell shape. It is thought that maintenance of this cuboidal cell 
shape by providing appropriate cell-cell and cell-matrix interactions in culture is 
important in the maintenance of differentiated function. The organisation of cytoskeletal 
elements within the hepatocyte as well as regulation of cell-cell contact and 
communication (gap and tight junctions) and cell polarity are all closely linked to cell 
shape. Culture systems which maintain this cuboidal cell shape include culture of 
hepatocytes on Matrigel® (Bissell et al, 1987); with an overlay of extracellular matrix 
(“sandwich” configuration; Dunn et al, 1989) or as floating multicellular “spheroids” 
(Roberts and Soames, 1993).
The requirement for long-term treatment of in vitro models with FRAs to observe toxicity 
also highlighted the limitations of liver slices for toxicological investigations. As 
mentioned in Section 7.3.1.2, liver slices have several potential advantages over 
hepatocyte cultures for studying toxins in vitro. Whilst some authors have successfully 
cultured liver slices for periods of >24h (e.g. Vickers, 1994; Fisher et al, 1995, Gokhale et 
al, 1997), the current investigations were limited to shorter timepoints due to the 
development of a necrotic band of cells within the centre of the slice. Whilst such 
degeneration of a slice may be acceptable when measuring levels of metabolites within 
the culture medium, it is obviously unacceptable when intracellular levels of biochemical 
parameters such as ATP and GSH are to be measured. The probable reason for the
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degeneration seen in the current studies was poor permeability of the centre of the slice to 
nutrients and oxygen. More sophisticated methods of slice culture are available which 
may help to overcome these oxygenation problems (e.g. j gassinglof cultures within the 
incubator; rotating inserts in 6  well plates). Indeed, a recent workshop at the European 
Centre for the Validation of Alternative Methods (Bach et al, 1996) highlighted the 
optimisation of culture conditions for long-term (beyond 5 days) liver slices as an issue 
which needs addressing.
One aspect of in vitro toxicity tests that longer-term hepatocyte cultures may help to 
address is that of the high concentrations of test compound which are often needed to 
elicit toxic responses in vitro. It is a common finding in in vitro toxicity tests that very 
high concentrations of test compound are often required (Timbrell, 1994; Timbrell et al, 
1996). Ponsoda et al (1995) compared the lethal blood concentrations of a number of test 
compounds with the IC50 values of the same test compounds in vitro and concluded that 
the in vitro toxicity data underestimated the in vivo toxicity (in some cases by two orders 
of magnitude). The current investigations with GR144053 indicated that very high levels 
of test compound ( > 1 0 0 0  pg/ml) were required to demonstrate toxicity over the short 
treatment period of 2-3 days. However, when the treatment period was extended to a 
period more analogous to the treatment period used during in vivo investigations, lower 
concentrations ( 1 0  pg/ml, closer to those obtained in the plasma of treated animals) could 
be shown to cause the same toxic response.
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11 Summary of the use of in vitro models to study hepatotoxicity
The current investigations have used cultured hepatocytes to investigate two areas of 
hepatotoxicity: steatogen-induced hepatotoxicity and hepatotoxicity induced by FRAs. 
During the in vitro investigations into the toxicity induced by both classes of 
hepatotoxins, several common features in the in vitro models were highlighted.
Simple cytotoxicity tests (Neutral Red uptake and MTT tests) were included in the assays 
used to characterise the action of both classes of hepatotoxin in vitro. Whilst some of the 
hepatotoxins tested (valproic acid and ethionine) did induce concentration-dependent 
cytotoxicity after treatment for 2 0 h in vitro, others did not induce cytotoxicity (ethanol) or 
required extended treatment times (FRAs) to demonstrate cytotoxicity. It has been 
suggested (e.g. Peloux et al, 1992) that cytotoxicity testing in cultured hepatocytes may 
provide an in vitro alternative to acute in vivo toxicity studies designed to determine the 
lethal dose of test compounds in rodents. Flint (1996) has recently reviewed a large 
database comparing in vitro cytotoxicity tests with in vivo LDgg test results (the LD50 test 
determines the lethal dose of a test compound in 50% of treated animals). In vitro 
cytotoxicity assays could predict, with some degree of accuracy, the in vivo lethal doses of 
test compounds following i.v. administration, but a poor correlation was obtained between 
in vitro cytotoxicity and LD50 values obtained after oral administration of test compounds. 
For the test compounds examined in the current studies, information was not sought on 
their acute lethality, but on the mode of action by which they caused specific forms of 
hepatotoxicity. It therefore seems most appropriate that cytotoxicity markers are included 
in in vitro tests with hepatotoxins for comparative purposes with other, more sensitive, 
biochemical markers.
The results of the current investigations have given some further evidence for the need to 
include endpoints in in vitro hepatotoxicity assays which are relevant to the type of in vivo 
hepatotoxicity which is under investigation as described in Section 7.3.3. The need for 
refinement of the endpoints used in vitro reflects the fact that the term ‘hepatotoxicity’ 
encompasses a wide range of distinct pathological changes within the liver. For the 
investigation of ethanol-induced hepatotoxicity, measurement of lipid accumulation 
proved to be a more sensitive marker in vitro than measurement of general cytotoxicity. 
However, this was not true for all the steatogens tested. Indeed, the potent in vivo
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steatogen ethionine which has a different mode of action in vivo from ethanol, did not 
induce lipid accumulation in vitro. These results indicate that, just as hepatotoxins cannot 
be regarded as a single category of chemicals, likewise steatogens can be subdivided by 
their mode of action and that this must not be ignored when studying these compounds in 
vitro.
Within the chemical class of FRAs which were investigated, the in vivo hepatotoxicity of 
these compounds was characterised by morphological changes in mitochondria. 
Mitochondrial toxicity was also modelled in vitro using cultured hepatocytes which 
allowed the initial development of an in vitro screen for hepatotoxic FRAs. As with the in 
vitro assays for steatogens, the in vitro screen for FRAs was not 100% accurate in its 
prediction of potential in vivo hepatotoxicity. One compound (GR135528) which was 
hepatotoxic to the dog in vivo did not induce mitochondrial changes in dog hepatocytes in 
vitro.
The differences observed with some compounds between in vivo and in vitro results 
emphasise the need for in vitro results to be considered alongside available in vivo 
information and not be judged in isolation. In the case of FRAs, a follow-up in vivo test 
will still be necessary to confirm negative in vitro findings. With certain classes of in vivo 
steatogens, it is clear that measurement of lipid accumulation in vitro will not be a 
suitable marker, whereas with other classes lipid accumulation may provide a useful tool 
for screening purposes.
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12 Overall Discussion
As mentioned earlier, the use of in vitro toxicology is unlikely to universally replace the 
use of whole animals in toxicity testing of new chemical entities. However, the work 
presented in this thesis has demonstrated that in vitro models can add valuable 
information in the toxicity assessment of chemicals when they are used to address specific 
problems.
To study carcinogen-induced nuclear enlargement in vitro, it was first necessary to define 
an in vitro model (i.e. cell types, exposure conditions) which produced reproducible 
nuclear enlargement following carcinogen treatment. This in vitro model was then used as 
a tool to examine possible mechanisms for the carcinogen-induced nuclear enlargement. 
The techniques used (flow cytometry, chromosome preparation) were particularly suited 
to in vitro examinations and provided some evidence for the mechanisms underlying 
nuclear enlargement. The use of similar techniques in vivo for mechanistic studies (for 
instance from mouse skin after in vivo NEST assays) would be complicated by 
disaggregation of tissues into single cell suspensions and interanimal variability in 
responsiveness to carcinogens. A large number of animals would also have been 
necessary to examine multiple timepoints. It is not anticipated that the in vitro system 
used here should be used as an ‘alternative’ to whole animal nuclear enlargement tests as 
its predicitivity for carcinogens has previously been shown to be low (see section 2.2). To 
date, the in vivo NEST has had an empirical base (i.e. its use has been based on 
correlation with carcinogenicity rather than having any mechanistic base). The results of 
the current in vitro investigations have given some insight into potential mechanisms by 
which carcinogen-induced nuclear enlargement may occur.
The term ‘hepatotoxicity’ encompasses many different biochemical and histological 
changes within the liver following toxic insult. The results of the experiments presented 
here have shown that if in vitro liver models are treated with hepatotoxins, the endpoints 
used for measurement of compound-induced toxicity should be tailored to fit the type of 
hepatotoxicity under investigation. Under such circumstances, if appropriate in vitro 
models for specific, well-defined types of hepatotoxicity can be established, they can be 
used for toxicity screening of related compounds prior to in vivo investigations.
205
When used in the ways described above, although in vitro tests do not offer ‘alternatives’ 
to whole animal experiments, when they are used in combination with in vivo data, they 
can in fact lead to a reduction in the total numbers of animals used in toxicology 
experiments.
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